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1.0 Abstract  
 
Prostate cancer (PCa) is the most prevalent adenocarcinoma and the second highest 
cause of cancer-related deaths in men. Early diagnosis is required to identify the 
development of PCa to reduce the risk of the disease metastasising to different regions 
of the body. Multiple biomarkers in serum have been identified for the diagnosis of 
PCa. However, prostate-specific antigen (PSA) and its isoforms remain the gold 
standard test for PCa detection. Many antibodies have been generated for the detection 
of PSA with good sensitivities and limits of detection. To ensure reliable assay 
performance a number of biomarkers for PCa are required to increase specificity and 
sensitivity thus reducing the number of false positive results upon initial examination. 
The overall aims of the work presented in this thesis were to generate, select and 
characterise antibodies to PSA, an important biomarker in PCa. 
 
The generation and selection of murine and avian recombinant antibody fragments to 
free PSA (fPSA) was performed. Animals were immunised, RNA extracted and cDNA 
synthesised. The antibody variable genes were amplified by PCR, gel-purified and 
cloned into a phagemid vector. Electrocompetent cells were transformed and library 
sizes of 2.02 x 10
6
 cfu/mL and 3.10 x 10
8
 cfu/mL were obtained for the murine and 
avian clones, respectively. Specific clones were isolated by ‗biopanning‘ which 
involved a selection process on fPSA-coated immunotubes, enrichment and affinity 
maturation. Five and three rounds of selection were performed on the murine and avian 
anti-fPSA single chain variable fragments (scFv) recombinant antibody libraries, 
respectively. Preliminary analysis by ELISA indicated a large panel of positive binding 
clones for both screened libraries with approximately 60% of the analysed clones 
binding to fPSA. The murine recombinant antibody fragments were reformatted and 
expressed as single chain antibodies (scAb). This construct greatly enhanced soluble 
protein expression and stability while also facilitating the rapid kinetic analysis of 
candidate antibodies by Biacore. A differential expression profile of an anti-fPSA scFv 
and reformatted scAb was performed by ELISA.  
 
Individual antibodies isolated from the ‗biopanning‘ process were then characterised. 
The murine anti-fPSA antibodies were further analysed using the Biacore 3000 in a 
xvii 
 
capture assay format. This facilitates correct affinity ranking of the selected antibodies 
where the antibody fragment was captured using the appropriate secondary tag antibody 
(anti-human constant kappa Ab) and a fixed concentration of fPSA (1 g/mL) passed 
over the captured antibody fragment. Ninety four antibody fragments were evaluated 
and ranked on their percentage complex stability values after a 5 minute dissociation 
period.  Eleven of the ninety four were subjected to further analysis and their affinities 
ranged from 3.99 x 10
-9
 M to 3.62 x 10
-10
 M. They were then expressed in host 
Escherichia coli (E. coli) cells on a large scale and purified by immobilised metal 
affinity chromatography (IMAC). The cell lysates were characterised by ELISA, SDS-
PAGE and Western blotting. The antibodies were sequenced and analysed for 
variability and similarities between the coding regions of the variable domains. 
Inhibition ELISA-based assays with inter and intra-day analysis were performed on the 
purified antibodies and a reproducible and accurate assay format was demonstrated with 
a limit of detection of 2.6 ng/mL. The avian clones were analysed, ranked and affinities 
evaluated by Dr. Paul Leonard using the Biacore A100 employing the same assay 
format used for analysis of the murine antibody fragments. Imperative to assay design is 
the selection of optimal antibody candidates for improved performance. For assay 
development antibody pairs which bind different regions of the fPSA molecule were 
determined using the capture assay format on the Biacore 3000. One murine scAb, two 
avian Fabs and one avian scFv were shown to bind different epitopes of the fPSA 
molecule with no non-specific binding evident. Following the successful purification of 
the murine and avian antibody fragments immunohistochemistry studies were 
performed on PCa tissue samples. These antibodies were shown to bind to different 
zones of the prostate gland (epithelial and stromal regions) confirming that the 
antibodies were binding to different epitopes of the fPSA molecule.   
 
The purified murine anti-fPSA scAb was biotinylated and this was employed in a 
sandwich ELISA assay whereby the murine anti-fPSA biotinylated scAb was captured 
on a neutravidin-coated ELISA plate and fPSA sandwiched using the avian antibody 
fragments as the detection antibodies. The assay sensitivity was improved using this 
format with a limit of detection of 1.8 ng/mL in PBST solution. Female serum was 
spiked with fPSA and inter-day studies performed by sandwich ELISA. Patient serum 
samples with diagnosed PCa were evaluated by sandwich ELISA to determine levels of 
xviii 
 
fPSA in the sample and data were compared to documented tPSA levels which were 
comparable to the levels obtained from a commercially available sandwich assay. 
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1.1 Section overview 
 
The aim of this thesis was to develop a sensitive immunoassay for the detection of 
prostate cancer (PCa). This chapter describes the importance of early detection of PCa 
and the impact of the disease on individuals. Potentially useful biomarkers for early 
detection of PCa and current immunoassay tests available for their detection are 
critically reviewed. A comprehensive description of antibody production and the 
methods used for selecting antigen-specific antibodies is given. Sensitive detection 
methods such as surface-plasmon resonance (SPR) and real-time polymerase chain 
reaction (PCR) are also reviewed.  
 
1.2 History of PCa 
 
PCa was first discovered in 1853 (Lytton, 2001) and was initially regarded as a very 
rare cancer. However, in the last 30 years an increase in our knowledge of cancer in 
general and PCa in particular has occurred. Today 85% of new PCa cases are diagnosed 
at local and regional stages and the 5 year relative PCa survival rate has increased by 
20% since 1985 (Denmeade et al., 2004). The most widely used indicator to detect PCa 
in the general population is a measurement of serum levels of prostate-specific antigen 
(PSA), a serine protease produced by the prostate epithelium (Nadler et al., 1995). PSA, 
the most widely used marker in clinical use for detection of PCa (Klotz and Teahan, 
2006) became an FDA approved biomarker in 1987. Subsequent data demonstrating 
that elevated levels of PSA could be used to detect PCa earlier than rectal examination 
led to widespread PSA testing for early disease detection (Özena and Sözen, 2006). 
Although raised levels of serum PSA are suggestive of PCa, diagnostic confirmation 
requires a transrectal prostatic needle biopsy, a costly and invasive procedure requiring 
prophylactic antibiotics (Roddam et al., 2005). Overall, survival rates have improved 
when PCa is detected at an early stage but it can metastasize and spread to other regions 
of the body. PCa is an indolent disease and many more men die with the disease than 
die from the disease but its diagnosis severely impacts the patient‘s life and contributes 
to anxiety and stress. 
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1.2.1 Background to PCa 
 
Adenocarcinoma of the prostate is now the most frequently diagnosed male malignancy 
with 1 in every 11 men developing the disease (Hayward, 2000). Each year in the UK 
more than 25,000 men are diagnosed with PCa and approximately 10,000 die from the 
disease (Zhu et al., 2006). Excluding skin cancers, PCa is the most common cancer in 
men in the United States and the leading cause of cancer deaths in American men who 
do not smoke (Özena and Sözen, 2006). In Europe, an estimated 2.6 million new cases 
of cancer are diagnosed each year. Prostate cancer constitutes about 11% of all cancers 
in Europe and accounts for 9% of all cancer deaths among the male population within 
the EU (Aus et al., 2005). The incidence and mortality numbers world-wide are 
approximately 679,000 and 221,000, respectively (Aus et al., 2005; Zhu et al., 2006).  
 
PCa is classified as an adenocarcinoma, or glandular cancer of the prostate gland. The 
prostate gland a walnut sized organ located in the front of the rectum and below the 
bladder (http://www.psa-rising.com/prostatecancer/prostate.htm). Its principle function 
is the production of seminal fluid that carries sperm. The majority of the seminal fluid is 
produced by the seminal vesicles which are located directly behind the prostate gland 
(http://www.mamashealth.com/organs/prostate.asp). The prostate encompasses part of 
the urethra, the tube that expels urine from the bladder and semen through the penis. 
Cancer occurs when the prostate cells mutate and start to multiply out of control. These 
cells may metastasize from the prostate to other parts of the body, especially the bones 
and lymph nodes causing pain, difficulty in urinating and other symptoms. Early PCa 
usually produces no symptoms. Sometimes, however, PCa does cause symptoms, often 
similar to those of non-malignant diseases such as benign prostatic hyperplasia (BPH). 
These include frequent urination, increased urination at night, difficulty starting and 
maintaining a steady stream of urine, blood in urine, and painful urination. PCa may 
also cause problems with sexual function, such as difficulty achieving erection or 
painful ejaculation (Miller et al., 2003).  
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1.2.2 Environmental factors 
 
The specific causes of PCa remain unknown, yet several key factors have been 
associated with an increasing risk of PCa. Age, diet, lifestyle, medications, race and 
genetic makeup have long been recognised as contributors to PCa. The primary risk 
factor is age. Prostate cancer is uncommon in men under 45, but becomes more 
common with advancing age. The average age at the time of diagnosis is 70 (Hsing and 
Chokkalingam, 2006). One of the most striking characteristics of PCa is the degree of 
geographic variation in its patterns of occurrence and progression (Klassen and Platz, 
2006). Higher rates are seen in the United States and Western Europe, with peak rates 
among black men in the United States, while the lowest rates are observed in Asia 
(Hsing et al., 2000). An interesting observation is the increase risk of PCa among 
Asians when they emigrate to North America. Thus, the connection between 
environmental and lifestyle-related factors is further strengthened (Whittemore et al., 
1995). The enhanced incidence of PCa is often linked with the high fat intake of 
Western nations over those of Asia. In the U.S. the diet is rich in animal fats and meats 
and poor in fruit and vegetables. Previous studies involving 51,529 men have shown 
that increased total fat intake, animal fat intake, and consumption of red meat are linked 
with an increased risk of PCa (Giovannucci et al., 1993). Dietary amounts of certain 
foods such as vitamins and minerals can also contribute to PCa risk. Men with higher 
serum levels of the short-chain -3 fatty acid linolenic acid have higher rates of PCa 
(Gann and Giovannucci, 2005).  
 
Other dietary factors that may increase PCa risk include low intake of vitamin E, 
lycopene, omega-3 fatty acids, the mineral selenium and low blood levels of vitamin D 
(Schulman et al., 2001). Clinical trials have provided evidence that men given tomato 
sauce-based pasta dishes for three weeks before radical prostatectomy had increased 
lycopene levels in the blood and the prostate resulting in decreased oxidative genomic 
damage in leukocytes and prostate cells (Chen et al., 2001). Similar results were 
observed where high plasma levels of the antioxidant carotenoid lycopene, resulting 
from high tomato intake, were associated with a reduced risk of PCa (Gann et al., 
1999).  
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There are also some links between PCa and medications and medical conditions. Use of 
anti-inflammatory medicines such as aspirin and chlolesterol-lowering drugs known as 
the statins may also decrease PCa risk (Jacobs et al., 2005; Shannon et al., 2005).  
However, recent conflicting studies have shown there may be an increased risk of PCa 
development with statin use in obese men (Charnow, 2008). The use of statins in 
patients with high cholesterol levels can mask subclinical PCa by lowering serum PSA 
levels. Infection or inflammation of the prostate (prostatitis) may increase the chance for 
developing PCa. In particular, infections with sexually transmitted infections syphilis, 
chlamydia, and gonorrhea seem to increase PCa risk (Dennis et al., 2002).  
 
Increased incidence of PCa found in certain racial groups, in identical twins with PCa 
and in men with certain genes indicates genetic background contributes to the risk of 
developing PCa. In the US, PCa affects black men more than white or Hispanic men 
and is also more deadly in black men (Hoffman et al., 2001). Studies of twins in 
Scandinavia suggest that forty percent of cancer risk can be explained by inherited 
factors (Lichtenstein et al., 2000). While no single gene is responsible for PCa, two 
genes (BRCA1 and BRCA2) are important risk factors for ovarian cancer and breast 
cancer in women and have also been implicated in PCa (Struewing et al., 1997).  
 
1.2.3 PSA  
 
PSA (Figure 1.1) is produced mainly by the prostate gland and its function is thought to 
be liquefaction of seminal fluid through enzymatic action. The active site of PSA is 
closely related to that of chymotrypsin (Vihinen, 1994). PSA is not a cancer-specific 
protein. Its presence is not unique to cancerous cells, as it is present in normal prostate 
tissue (Jung et al., 2000a). Its use as a marker for PCa is due to the elevated levels 
detectable in the serum of PCa patients.  
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Under normal conditions, i.e. in non-cancerous tissue, PSA synthesised by the epithelial 
cells of the prostate gland is secreted into the seminal fluid. PSA can only enter the 
bloodstream by leaking into the extracellular fluid and diffusing into veins and 
capillaries. However, in cancerous prostatic tissue, tumour growth disrupts the basal cell 
layer and cell polarity is altered (Figure 1.2). The direction of PSA secretion is 
disturbed and PSA is released freely into the circulatory system.  
 
Figure 1.1: The structure of horse prostate kallikrein (HPK) isolated from stallion 
plasma as an example of a homologue of Human PSA (PDB accession codes 1PFA). 
HPK was the first structure of a serine protease purified from seminal plasma and shares 
extensive sequence homology with human PSA, including the predicted chymotrypsin-like 
specificity (Carvalho et al., 2002). Image accessed using Protein Data Bank website 
(http://www.rcsb.org/pdb/home/home.do). The catalytic triad residues (His57, Asp102 
and Ser195) within the active site are shown. 
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Figure 1.2: The prostate is a walnut-sized gland located in front of the rectum and below the 
bladder. PCa occurs when the cells mutate and begin to multiply out of control and the 
structure orientation of the gland is breached. This diagram was obtained from 
http://www.fitness-health.co.uk/prostate-cancer.htm. 
 
This explains the elevated PSA levels in the serum of PCa patients (Stenman et al., 
1999). Even though PCa cells produce less PSA than non-cancerous cells, more leaks 
into the serum and, therefore, elevated serum PSA is detected (Jung et al., 2000b). At 
present, PSA remains one of the best studied PCa-associated markers. The discovery of 
different forms of PSA and the differences in their relative ratios in PCa patients has 
refocused research on PSA. However, the practical application of PSA in cancer 
detection has proved problematic. One major factor contributing to this stems from the 
fact that PSA is not a truly cancer-specific marker (Levesque et al., 1995).  
 
Various other benign disorders have been shown to increase serum PSA levels, and the 
potential for false positive results has diminished the reliability of PSA assays. One 
major disorder capable of increasing the level of PSA in serum is benign prostatic 
hyperplasia (BPH Anderson, 2002). BPH is a non-malignant growth of the prostate 
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gland, characterised by similar distortion of the basal cell layer of the prostate gland and 
free release of PSA into blood circulation, as previously described for PCa. Current 
commercially available assays can often fail to distinguish PCa from such benign 
disorders and, as a result, much research is underway to enhance specificity of PSA 
assays so as to eliminate the high percentage of false positives. The discovery of various 
forms of PSA in serum, including the presence of complexes, has provided a new angle 
on the protein‘s role and significance as a disease marker.  
 
In forensics PSA is an acceptable marker in suspected rape criminal cases even in 
individuals with vasectomises. The marker can be detected in vaginal swabs or 
extracted from clothing fabric of cadavers. The presence of PSA in the sample can 
implicate an individual in a specific crime and this may be confirmed by DNA analysis. 
PSA is a 34 kilo Daltons (kDa) glycoprotein that consists of 237 amino acids, and is 
found in the serum in several isoforms (Table 1.1). It is a member of the kallikrein 
(KLK) family which can be divided into 2 groups, plasma and tissue kallikreins. The 
role of plasma kallikrein in the body includes activation of blood clotting, kinin 
generation and inflammation. The tissue kallikreins, otherwise known as glandular 
kallikreins, were discovered initially in urine in 1928 by Frey and Kraut (Garatinni and 
Shore, 1966). The gene family, located on chromosome 19q13.2-q13.4 (Mahabeer and 
Bhoola, 2000), are a subgroup of the serine protease family of proteolytic enzymes. 
Fifteen human tissue kallikrein members have been identified and these proteins are 
intensely studied because of their association with cancers.  
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Table 1.1: Forms of PSA found in serum 
PSA form Description Relevance to PSA 
detection 
Reference 
Free PSA Complete PSA protein 
that has no 
modifications 
Levels of PSA increase 
in the serum of prostate 
cancer patients 
Kuriyama et al. 
(1980); 
Stowell et al. 
(1991); 
Khosravi et al. 
(1995); Gregorakis 
et al. (2005). 
Complexed PSA PSA that has formed 
complexes with various 
serum proteins e.g. 1-
chymotrypsin and 2-
macroglobulin and is 
inactive 
Levels of complexed 
PSA decrease in the 
serum of prostate cancer 
patients, and the ratio of 
free to complexed forms 
of PSA can discriminate 
prostate cancer from 
benign disorders 
Matsumoto et al. 
(1999); Matsumoto 
et al. (2000); 
Stephan et al. 
(2007). 
ProPSA Precursor forms of PSA 
that contains 7, 5, 4 and 
2 extra amino acids at 
the start of the protein 
In serum studies of men 
with PCa, proPSA was 
shown to improve 
specificity for PCa 
detection. 
Peter et al. (2001); 
Catalona et al. 
(2003); 
Kumar et al. 
(1997); 
Mikolajczyk et al. 
(2001). 
Benign PSA 
(BPSA) 
BPSA contains 2 
internal peptide bond 
cleavages at lysines 145 
and 182 
BPSA concentrations 
are elevated in benign 
prostatic disease 
Linton et al. 
(2003); 
Stangelberger et al. 
(2007). 
Intact non-native 
PSA 
A non-native form of 
PSA that is not cleaved 
at lysines 145 
Serum inPSA levels 
decrease in PCa 
Nurmikko et al. 
(2000); 
Nurmikko et al. 
(2001); 
Djavan et al 
(2004). 
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Kallikrein proteins are useful serum biomarkers for diagnosis and prognosis of cancer 
(Yousef et al., 2003) and a number of these biomarkers have been linked with ovarian, 
breast, prostate, testicular, cervical, pancreatic, colon cancers (Obiezu and Diamandis, 
2005) and lymphoblastic leukemia. Many of the KLK genes are frequently expressed in 
certain tissue samples and are secreted into the serum or seminal plasma. The kallikreins 
share similar homology (40–80%) with the greatest degree of similarity noted between 
KLK2 and PSA (Pakioures et al., 2007). 
 
1.2.4 PSA and its isoforms 
 
Pro PSA is released into the lumen of the prostate and, since it contains a 7 amino acid 
pro-leader sequence, is also termed (-7)pPSA. (-7)pPSA is converted to mature PSA by 
human kallikrein 2 (hk2) and human kallikrein 4 (hk4). Partial degradation of (-7)pPSA, 
leading to truncation of the pro-leader sequence, gives rise to other forms of pPSA 
including (-2), (-4) and (-5)pPSA. The predominant form of tPSA is an1-
chymotrypsin PSA complex (PSA-ACT), which appears to form 65 – 95% of the total 
PSA content of human serum (Zhang et al., 1999; Özena and Sözen, 2006). Other PSA-
protein complexes have been found in trace amounts, such as PSA 1-protease inhibitor 
(PSA-API) and PSA 2-macroglobulin (PSA-AMG) which is inactive. Uncomplexed or 
‗free‘ PSA (fPSA) accounts for most of the remaining PSA in serum which is 5–35% of 
the total PSA content. Free PSA is composed of 3 distinct isoforms, pro PSA (pPSA) 
isoforms, benign PSA (BPSA) and intact PSA (inPSA) – all of these forms are 
significant in the diagnosis of patients with PCa (Mikolajczyk et al., 2004) (Figure 1.3). 
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Figure 1.3: ProPSA is activated to PSA by hK2 through cleavage of the 7 amino acid pro-
leader sequence. PSA is mainly secreted directly in the lumen of the prostate gland where it 
liquefies the seminal plasma, provides nutrients and protects the sperm from the acidic 
environment of the vaginal secretions. However, gland abnormalities such as BPH and PCa 
cause an elevation in the levels of detectable PSA in the circulatory system. PSA isoforms such 
as fPSA and cPSA can be detected to determine for early diagnosis of the disease and the focus 
has moved towards these isoforms for early detection of PCa. This diagram was  obtained from 
Lilja et al. (2008) 
 
PSA testing has revolutionised survival rates among men over the past 20 years (Djavan 
et al., 2004). According to Surveillance, Epidemiology and End Results (SEER) data, 
the relative 5 year survival rates in PCa had reached almost 100% by 2000, compared to 
67% and 75% during 1973–1976 and 1983–1985, respectively (Weir et al., 2003). A 
serum total PSA (tPSA) measurement of 4 ng/mL is generally regarded as the threshold 
above which a prostate biopsy is required. The specificity of this PSA cut-off level is 
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poor, however, especially below 10 ng/mL, and is associated with significant false 
positive and negative results. It has been estimated that between 60–75% of men in the 
4–10 ng/mL range (also termed the diagnostic grey zone) undergo unnecessary biopsy 
(Catalona et al., 1991, 1994; Brawer et al., 2000; Finne et al., 2000; Andriole et al., 
2005) while a PSA threshold of 4 ng/mL misses between 20–40% of PCa positive 
individuals (Mistry and Cable, 2003; Thompson et al., 2004). A PSA threshold of 2.5 or 
3 ng/mL is being adopted by a number of urology clinics and screening studies (Labrie 
et al., 1999; Krumholtz et al., 2002) as an indication for biopsy in order to maintain 
high levels of PCa detection, but incurs the cost of a potentially higher proportion of 
unnecessary biopsies. Despite its importance in significantly decreasing the number of 
individuals diagnosed with clinically inoperative, non-organ confined disease, 
alternative biomarkers are required to increase the specificity and reliability of testing, 
especially at low tPSA serum concentrations (2–10 ng/mL). Increased tPSA levels have 
been reported in both benign prostatic hyperplasia and prostatitis (Hessels et al., 2004), 
and as such an increased serum tPSA level is, therefore, only a sensitive marker for 
prostate gland irregularities (Stephen et al., 2003). Current research is focusing on the 
use of different PSA isoforms to improve the discrimination between a non-malignant 
and malignant tumour.  
 
Although the majority of tPSA found in serum is PSA-ACT (65-95%), the use of this 
protein complex as a diagnostic tool may be valuable in early detection of PCa, 
especially in the 2.5–4.0 ng/mL tPSA range (Naya et al., 2005). However, it still 
remains unclear whether this marker alone will be sufficient in the diagnosis of PCa. 
PSA-ACT levels are higher in men with PCa than in healthy normal men. Since its 
approval by the FDA as a test for monitoring PCa, almost every study performed on 
PSA-ACT as a specific test marker has shown better diagnosis capabilities than tPSA at 
tPSA serum levels above 4 ng/mL (Brawer et al., 2000; Jung et al., 2000; Mitchell et 
al., 2001; Sozen et al., 2005). Investigations into the measurement of percentage (5-
35%) fPSA as an improved and useful diagnostic tool in differentiating PCa from BPH 
have also been performed, since it is known that a higher percentage of fPSA in serum 
correlates with a lower risk of PCa. Improved discrimination between PCa and BPH in 
the 2–10 ng/mL tPSA range can be achieved by measuring f/tPSA ratio (Catalona et al., 
1998; Woodrum et al., 1998). It has been reported that by measuring the f/tPSA ratio or 
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PSA-ACT levels, up to 50% and 35% of unnecessary biopsies could be avoided in the 
tPSA ranges of 4–10 ng/mL and 2–4 ng/mL, respectively, while maintaining PCa 
detection rates at about 80% (Roddam et al., 2005).  
 
Evidence exists that the measurement of proenzyme forms of PSA may improve the 
detection of PCa (Mikolaczyk et al., 2004). As mentioned earlier, Pro PSA (pPSA), 
which is converted to active PSA through a cleavage process involving removal of  a 7 
amino acid sequence from the pro-leader sequence between arginine and isoleucine 
(Peyromaure et al., 2005), may have an important role to play in PCa detection. 
Truncated forms of pPSA including (-2) pPSA and (-4) pPSA are of particular interest 
as they are more resistant to conversion to mature PSA. Scientific data using mass 
spectrometry investigated levels of intact (-7) pPSA and truncated pPSA in cancer 
serum and found the combined levels to be more than half of fPSA in the sample (Peter 
et al., 2001). (-7) pPSA was the major form detected with (-5) pPSA, (-4) pPSA and (-
2) pPSA present to a lesser extent. In serum studies of men with PCa, pPSA has been 
shown to improve specificity for PCa detection (Sokoll et al., 2003; Khan et al., 2003). 
Immunostaining studies in cancerous and benign tissues showed that (-2) pPSA stained 
stronger in the cancerous tissue extracts than in the benign tissue extracts, indicating its 
link with cancer. (-2) pPSA represents 25–95% of fPSA in the serum of PCa patients 
and only 6–19% of fPSA in patients without PCa. The percentage of fPSA that is 
comprised of the pPSA forms increase in aggressive type cancers and this %pPSA could 
considerably enhance the specificity for PCa detection in men with tPSA levels of 2 – 
10 ng/mL, especially in low tPSA levels (< 4 ng/mL Mikolaczyk et al., 2004; 
Peyromaure et al., 2005). Catalona and co-workers (Catalona et al., 2003) reported that 
in the analysis of 1091 serum samples from patients enrolled in PCa screening studies, 
measurement of %pPSA (ratio pPSA/fPSA) would have spared 19% of unnecessary 
biopsies for patients with tPSA levels of 2-4 ng/mL, compared to 10% and 11% 
biopsies spared by measurement of fPSA and PSA-ACT, respectively. At higher tPSA 
levels (4-10 ng/mL), measurement of % pPSA would have spared 31% of unnecessary 
biopsies compared to 20% for fPSA and 19% for PSA-ACT.  
 
Other PSA isoforms may also have a role to play in the generation of more specific tests 
that can discriminate between PCa and benign conditions, thereby leading to fewer 
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unnecessary biopsies. A distinct enzymatically-inactive form of PSA containing two 
internal bond cleavages at Lys145 and Lys182 has been identified in BPH tissue (Zhang 
et al., 1995; Chen et al., 1997) and is termed BPSA. BPSA has been shown to be 
significantly higher in the serum of non-cancerous men with elevated PSA (Linton et 
al., 2003) and relatively lower in cancerous prostate tissue (Mikolajczyk and 
Rittenhouse, 2003). BPSA analysis in serum in conjunction with pPSA immunoassays 
may provide additional discrimination between PCa and BPH (Mikolajczyk and 
Rittenhouse, 2003). In addition to the different proPSA isoforms and BPSA, the 
remaining fPSA serum appears to be composed of intact PSA, termed inPSA (Noldus et 
al., 1997; Hilz et al., 1999). It appears that an increase in inPSA is most likely to be 
associated with benign disease as inPSA levels seem to decrease in cancer (Mikolaczyk 
et al., 2004). This form of fPSA has shown some promise as a marker for distinguishing 
PCa from benign disease (Nurmikko et al., 2001).   
 
1.2.5 Other potential markers of PCa 
 
PSA and its derivatives are recognised as the best current indicators for the presence of 
PCa. However, alternative markers that could be used to detect prostate cancer with 
increased specificity and sensitivity are being investigated, including other members of 
the human tissue kallikrein family of proteins. The expression of human glandular 
kallikrein 2 (hk2), which is 78–80% identical to PSA, increases during the change from 
benign to primary prostate cancer (Darson et al., 1999). It has been reported that hk2 
can improve the discrimination of PCa from benign disease when measured in 
combination with tPSA and fPSA (Kwiatkowski et al., 1998; Partin et al., 1999). Hk2 
may also be an important marker for PCa aggressiveness (Haese et al., 2001) and for 
predicting and staging organ-confined tumours (Hessels et al., 2004). Other kallikrein 
family members have also been identified as promising new candidate markers for PCa 
diagnosis (Yousef and Diamandis, 2001), including human kallikreins 4 (hk4) (Obiezu 
et al., 2002), 11 (hk11) (Diamandis et al., 2002), 14 (hk14) (Yousef and Diamandis, 
2001), and 15 (hk15) (Diamandis and Yousef, 2002). For example, a study by 
Nakamura and co-workers showed that a combination of hk11-to-tPSA ratio with 
%fPSA values gave a PCa detection specificity of 51.5%, compared with detection 
specificities of 10–31% and 10–45% using tPSA and %fPSA measurements alone, 
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respectively (Nakamura et al., 2003). The future use of panels of these kallikreins in 
combination with PSA and other markers may thus provide more specific assays for 
PCa that reduce the prevalence of unnecessary biopsies.  
 
The potential of several other possible prostate cancer markers to improve disease 
detection have been investigated, and markers reported to be associated with aggressive 
cancers include E-cadherin (ECAD Rubin et al., 2001), enhancer of Zeste homologue 2 
(EZH2 Varambally et al., 2002), hepsin (Magee et al., 2001), -methylacyl-coenzyme 
A racemase (AMACR Rubin et al., 2002) among others. For example, Rhodes and co-
workers have demonstrated that the ratio of E-cadherin (ECAD) to enhancer of Zeste 
homologue 2 (EZH2) was associated with prostate cancer recurrence after radical 
prostatectomy in a statistically significantly manner and may be useful in defining a 
cohort of high-risk patients (Rhodes et al., 2003). High levels of circulating insulin-like 
growth factor (IGF)-1 and low IGF binding protein-3 (IGFBP-3) have been identified as 
being associated with increased risk of prostate cancer, although the reliability of these 
serum markers for use in the detection of prostate cancer has been questioned (Ismail et 
al., 2003). Serum IGF-11 levels are lower in PCa patients than men with BPH, and it 
has been suggested that IGF-11 may serve as a useful marker for detecting PCa in men 
with high PSA values (Trojan et al., 2006). 
 
Reports on the usefulness of urinary biomarkers for the detection of PCa have also been 
published. For example, it has been reported that the ratio of urinary PSA to serum PSA 
(U/S PSA), when combined with the free to total serum PSA ratio, may be of benefit in 
detection of PCa (Irani et al., 2005). In addition, the urinary biomarker thymosin 15 
has been linked to PCa malignancy and its future recurrence. It has been reported that 
the specificity of PCa detection using a tPSA cut-off of 2.5 ng/mL can be improved 
from 55.4% to 70.8% by incorporating thymosin 15 measurements (Hutchinson et al., 
2005a). Attempts have been made to increase the value of thymosin 15 as a potential 
biomarker in PCa detection by developing a quantitative assay to detect this protein in 
bodily fluids (Hutchinson et al., 2005b).   
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1.3 Introduction to antibodies and immunity 
 
1.3.1 Antibodies and their structure 
 
Antibodies are glycoproteins produced when a foreign entity elicits an immune response 
in the body. The body‘s defence system generates antibodies upon exposure to 
potentially hazardous pathogens which eliminate and destroy them. The basic structure 
of an antibody is shown in Figure 1.4. 
 
 
Figure 1.4: (A) Ribbon structure of the immunoglobulin G (IgG) molecule. The molecule 
consists of two identical heavy (H) chains (approximately 50 kDa) and two identical copies of 
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a light chain (25 kDa). Each light chain is attached to a corresponding heavy chain by a 
disulphide bond. Both heavy chains are covalently linked by interchain disulphide bridges 
located at the hinge axis. The heavy chain is divided into 4 domains (1 x VH and 3 x CH 
domains) and the light chain is divided into 2 domains (1 x VL and 1 x CL). The VH and VL 
domains confer antigenic binding specificity. (B) The complementary determining regions 
(CDR) regions which form the antigen binding site, antigen binding fragment (Fab), variable 
fragment (Fv) and constant fragments (Fc) are highlighted. 
 
Polyclonal antibodies are a mixture of immunoglobulins (Ig) that recognise different 
epitopes of the antigen, while monoclonal antibodies bind a single epitope of the 
antigen. Monoclonal antibodies (Figure 1.4) were first reported by Georges Kohler and 
Cesar Milstein in 1975. Since then many advancements in this scientific field have 
generated recombinant antibody fragments namely, the single chain variable fragments 
(scFv), the fragment antigen binding (Fab) and the single chain antibody fragment 
(scAb). These fragments retain antigenic specificity due to the complementary 
determining region (CDR) of the antibody without comprising binding affinity. 
 
1.3.2 Antibody classes 
 
There are 5 major classes of antibodies, IgM, IgG, IgA, IgD and IgE. These 
immunoglobulins differ in both their structure and immune function. IgMs are 
pentameric in structure and are clinically significant because they are predominant in 
early immune responses to most antigens. IgAs are polymeric and are the predominant 
immunoglobulin in saliva, tears, nasal mucosa, prostatic fluid and many other bodily 
fluids. IgD antibodies are monomeric and trace amounts are present in serum and are 
found on the surface of human B lymphocytes. IgE antibodies are present in serum in a 
monomeric form and represent only a small fraction of total antibodies in blood. They 
are involved in the production and release of vasoactive mediators e.g. histamine and 
other chemicals that cause an inflammatory reaction. In healthy adults, the four-
polypeptide chain IgG monomer constitutes approximately 75% of the total serum 
immunoglobulins (Mayer, 2006). The basic structure of an antibody consists of four 
polypeptide chains with two identical heavy (H) chains and two identical light (L) 
chains connected by disulphide bonds. The structure varies depending on the isotype. 
The amino sequence in the variable region of the antibody varies greatly among 
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different antibodies. It is composed of 110-130 amino acids which give the antibody its 
specificity for binding to the antigen. The variable region is subdivided into 
hypervariable (HV) and framework (FR) regions. Within the variable heavy (VH) and 
variable light (VL) chains three HV regions exist (HV 1, 2 and 3). These HV regions are 
collectively known as complementary determining regions (CDRs). The CDRs are 
interspersed by Framework (FR) regions. The FRs provide a backbone structure for the 
antibody, and can also have an influence on antigenic specificity (Maher, 2006). The 
conformation of the VH and VL chain CDRs result in six HV loop structures which 
structurally form antigen-binding surfaces or pockets (Figure 1.4). 
 
 1.3.3 Innate and acquired Immunity 
 
Immunity is the protection of the body from infectious diseases which may cause harm 
and sickness. The innate immune system is a non-specific genetically derived system 
passed on from mother to offspring. The natural body defence system encompasses 
surfaces barriers e.g. skin, which cannot be penetrated by most organisms unless an 
opening is present. It also consists of mucosal immunity e.g. saliva, tears, nasal 
secretions and lysozyme, an enzyme in perspiration that cause cell lysis in Gram 
positive bacteria. Acquired immunity involves a cascade of events involving B and T 
lymphocytes (Roitt et al., 2006). B cells lymphocytes (generically referred as B cells) 
are derived from the stem cells of the bone marrow and produce antibodies. T 
lymphocytes (also known as T cells) are produced in the bone marrow but processed in 
the thymus and constitute the basis of cell-mediated immunity. In cell-mediated 
immunity, macrophages engulf the antigens, process them internally and display part of 
the antigens on their surface along with their own proteins. This stimulates T cells to 
recognise the presented antigens. Helper T cells (CD4+) are involved in directing the 
immune response. They secrete lymphokines that encourage cytotoxic T cells and B 
cells to grow and divide, attract neutrophils and boost the ability of macrophages to 
engulf and destroy microbes. Suppressor T cells inhibit the production of cytotoxic T 
cells and memory T cells recognise and respond to a further infection of the same 
pathogen. Immature B-lymphocytes are stimulated to maturity when an antigen binds to 
their surface receptors and T helper cells are in close proximity.  
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Figure 1.5: Somatic recombination of the separate gene segments for the construction of the 
variable genes. Light chain genes are constructed whereby a variable (V) and joining (J) gene 
segment are combined to form a complete light-chain V-region gene. The constant (C) is 
encoded on a separated gene locus and is attached to the variable region exon through splicing 
of the light-chain RNA to remove the J and C introns. Heavy chain genes are constructed using 
three gene segments, diversity (D), J and C. Firstly the D and J gene segments are joined 
followed by the combination of the V gene segment to form a complete heavy-chain exon. The 
heavy chain C-region genes are encoded by numerous exons which are spliced to the heavy 
chain C-region during processing of the heavy-chain transcript. The light and heavy chain 
genes are translated into large polypeptide chains that associate to form the antibody molecule. 
The diagram was adapted from Janeway et al., (1999). 
 
The capability of the body to generate an enormous diversity of antibodies accounts for 
the remarkable adaptive nature of the immune system. It is because of the unique 
genetic mechanisms governing antibody synthesis that the body is capable of producing 
these highly specific molecules to foreign entities. This diversity is mainly confined to 
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the VH and VL chains. VL chain genes are composed of two loci, the variable (V) and 
joining (J) loci, while the VH genes are composed of three loci, the V and J loci with an 
additional diversity (D) locus. During B-cell maturation, these different regions 
combine randomly to produce a huge range of diverse antibodies. Recombination of the 
various VDJ sequences in the VH chain and VJ sequences in the VL chain results in the 
formation of different conformations in the binding sites of the antibody (Storb et al., 
2001; Janeway et al., 1999; Figure 1.5). 
 
1.4 Antibody Production 
 
1.4.1 Hybridoma technology 
 
Over a century ago Paul Ehrlich (19
th
 Century) coined the phrase ‗magic bullets‘ to 
explain how antibodies might target and interact with their respective antigens. Seventy 
five years later, Georges Kohler and Cesar Milstein invented the technology for cloning 
individual antibodies (Bartal and Hirshaut, 1987). Monoclonal antibodies specifically 
recognize one epitope of the cognate antigen. They can be generated using hybridoma 
technology which involves fusing lymphocytes from the spleen of an immunised mouse 
with an immortal cancer cell line (myeloma). The myeloma cell lines are selected so 
that they do not possess the capability to produce immunoglobulins unless fused to 
lymphocytes. This fusion is performed using polyethylene glycol (PEG) which is a 
polywax solution that enhance adjacent cell fusions and the exchange of nuclei (Little et 
al., 2000). A mixed population of fused cells, unfused myelomas and lymphocytes 
results and these are incubated for 7 days before screening. The fused hybridoma cells 
are selected using HAT (Hypoxanthine, Aminopterin and Thymidine)-containing 
medium. Myeloma cells lack the HGPRT (hypoxanthine-guanine 
phosphoribosyltransfer)  are enzyme and when the de novo synthesis of purine and 
pyrimidines is blocked by HAT addition the cells die, while lymphocytes which do not 
grow in this culture media eventually die. Therefore, in the presence of HAT-
supplemented media only the hybridoma cells will proliferate. Secreted antibodies in 
conditioned media from each hybridoma are tested against the immunised antigen by 
ELISA. Positive hybridomas are scaled up and subsequently cloned (by limiting 
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dilution) to select for a single monoclonal antibody-producing hybridoma cell. The 
hybridoma cells can be stored indefinitely in liquid nitrogen.  
 
1.4.2 Recombinant antibodies 
 
The development of recombinant techniques has facilitated the generation of 
specifically engineered antibody fragments that have been successfully employed in 
immunoassays (Dillon et al., 2003). Recombinant antibody fragments are becoming 
essential tools in research due to their intrinsic properties such as greater penetrability, 
ability to maintain antigen recognition, small size and ease of production when 
compared to the complete antibody. In medicine, biotechnology and therapeutics use of 
recombinant antibody fragments expressed in E. coli cells is becoming increasingly 
popular.  
 
Recombinant antibody fragments can be generated by directly cloning the heavy and 
light chain variable domains from a monoclonal antibody-producing hybridoma cell or 
amplifying the variable genes from cDNA derived from mRNA from lymphocytes of an 
immunised source. The single-chain variable fragment (scFv) consists of heavy and 
light chain variable domains of the full immunoglobulin antibody joined using a flexible 
glycine-serine linker (Figure 1.6). The small fragment (30 kDa) retains the specificity 
and affinity of the parental antibody (150 kDa) despite the exclusion of the constant 
domains. The antigen-binding fragment (Fab) has generally been seen as a more 
functional and stable version of recombinant antibodies than the scFv. The Fab consists 
of the variable heavy and light chain genes joined with the constant heavy and light 
chain genes developing a more stable antibody construct. Functional stability studies by 
Hernandez et al., (2006) demonstrated the overall improved stability of a Fab over scFv 
in guanidinium hydrochloride. In 1 M guanidinium hydrochloride 80% activity for Fab 
was observed compared to 50% activity for an scFv. The affinity of the Fab and scFv 
was not drastically affected by the antibody format but the functional stability was 
significantly improved using the Fab format suggesting that the constant regions of the 
Fab greatly enhance stability. Disadvantages of using murine scFvs include poor 
expression levels with low product solubility, cell culture arrest and lysis, misfolding of 
expressed antibody and protein aggregation (Hayhurst, 2000). Hayhurst and co-workers 
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partially addressed these problems by generating a single chain antibody fragment 
(scAb) by fusing a human constant kappa light chain constant domain to the scFv and, 
in addition, significantly improved expression levels were achieved by incorporating a 
downstream periplasmic Skp chaperone gene. The elevated expression levels of scAb 
were observed to be 10-fold better than the scFv. 
 
Figure 1.6: Genetically-derived recombinant antibodies which retain antigen specificity are 
shown. The smallest of these recombinant antibody fragments is a scFv fragment consisting of 
the VH and VL chain of the full IgG molecule bound by a glycine-serine linker. The Fab fragment 
is similar in structure to the scFv fragment but is a more stable construct. A scAb fragment 
consists of linking a human constant kappa domain to the scFv fragment. The CDR regions of 
the antibody fragment are responsible for binding to the epitope on the antigen. 
 
1.4.3 Phage display 
 
The selection of antigen-specific recombinant antibody fragments involves a process 
known phage display technology. This technology was first reported in 1985 by Smith 
and since then phage display has been extensively and exhaustively implemented in 
many fields of research, in particular for antibody generation. Five years later 
McCafferty et al., (1990) demonstrated that an antibody scFv gene could be directly 
incorporated into the phage genome. The selection of antigen-specific antibodies from 
recombinant antibody libraries is the most successful use of phage display (Bradbury 
and Marks, 2004). Phage display involves using a filamentous bacteriophage which is a 
circular singly stranded DNA genome encapsulated within surface coat proteins. 
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Foreign DNA can be inserted into regions of the genome and expressed on the surface 
as fusion coat proteins. Thus, there is a direct link between the genotype and phenotype.  
 
 
Figure 1.7: The recombinant scFv is expressed on the surface of a bacteriophage and the 
gene encoding the fusion protein within the virion. Each pIII protein can display 2 – 3 copies 
of the recombinant antibody fragment. Each phage infects E. coli cells and multiple copies 
are propagated and selected using ‘biopanning’. Antigen-specific recombinant antibody 
fragments are selected from large recombinant antibody libraries. 
 
Phage display libraries can be successfully generated using an immunised source or 
developed synthetically. Naive libraries are generated from unimmunised human V 
genes, shuffled human V genes or synthetic human V genes while immune libraries are 
derived from V genes from an immunised source. Normally, cDNA is generated from 
the mRNA extracted from the spleen or bone marrow of an immunised animal. The 
heavy and light chain genes are amplified by polymerase chain reaction (PCR) and the 
antibody fragment inserted into one of the encoding genes for surface coat proteins. The 
phagemid DNA is transformed into competent E. coli cells and after expression the coat 
protein fusions are integrated into new phage particles assembled in the bacterium. This 
enables phage particles to be replicated as ssDNA in the presence of helper phage 
(NEB). Helper phages provide the necessary viral tools for the initiation and packaging 
of phagemid DNA into phage particles. Helper phages contain a defective origin of 
replication thus limiting their own packaging ability to produce more helper phage 
molecules. This characteristic is important as it reduces the ability of helper phage to 
replicate resulting in dominant phagemid DNA production. The advantages of 
recombinant technology for antibody production include the fact that a highly 
comprehensive library of antibody fragments can be generated from which an antibody 
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with high specificity for the antigen can be selected (Hoogenboom et al., 1998). Phage 
particles are harvested from the infected cells and positive clones with desired affinities 
selected by a process known as ‗biopanning‘ (Figure 1.8). The selection process can be 
achieved by immobilising the antigen on a solid surface, incubating the antibody-
containing phage particles, removing non-specific phage by washing, eluting bound 
phage with a high salt or low pH solution and re-infection into bacteria for replication, 
enrichment and further rounds of panning with more stringent selection conditions. The 
support for antigen immobilisation must possess a low phage binding capacity. The 
target antigen-coating concentration must be sufficient for selection of specific phage 
for further rounds of enrichment (Smith, 1985). 
 
 
Figure 1.8: Individual phage particles displaying the scFv – pIII fusion proteins are selected 
by ‘biopanning’. This process involves incubating the phage-scFv particle in an immunotube 
coated with the antigen and washing away non-specific phage particles. The antigen-specific 
phage particles are eluted and re-infected into E. coli cells for propagation and analysis in 
subsequent rounds of selection. The stringency is increased by decreasing the antigen 
concentration and increasing the washing steps to select high affinity recombinant antibody 
fragments. 
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The phage pools from each round of selection are analysed by ELISA to confirm 
antigen-specific antibody fragment enrichment. Individual clones are analysed, 
screened, sequenced and affinities determined. Methods for the selection of antigen-
specific recombinant antibodies have evolved, of which phage display has emerged as 
one of the most valuable. The key aspect of phage display is that the genotype of a 
particular antibody is linked through packaging inside a virion particle to the phenotype 
of a display antibody fused to a coat protein of the phage particle.  
 
Although phage display libraries have been generated using the pVIII major coat phage 
protein, the pIII minor coat protein of filamentous phage is more widely acceptable 
(Barbas et al., 2001, Figure 1.7). The clear advantage of pIII over the other coat proteins 
is its ability to package large insertions, its capability to display monovalent copies of 
the phage-antibody particle and the availability of suitable vectors. The filamentous 
bacteriophages are a group of viruses capable of infecting Gram negative bacteria. The 
most widely used are the Ff class (f1, fd and M13) which have shown to be 98% 
homologous. The Ff phages infect E. coli cells with the F conjugative pilus and do not 
kill the host cells during infection. The phage is 6.5 nm in diameter and 930 nm in 
length with a covalently closed single stranded genome of 6400 nucleotides coding for 
11 different proteins (pI-pXI) present within the coat proteins. Five of the 11 proteins 
(pIII, pVI, pVII, pVIII and pIX) make up the flexible protein cylinder, 2 (pII and pX) 
are involved in single stranded DNA (ssDNA) replication and 3 are required for phage 
particle assembly. The length of the cylinder is composed of 2700 molecules of the 
major coat protein (pVIII) while the minor coat proteins (pVII and pIX) are found at 
one end of the phage particle with 5 molecules of both gene products. There are 
approximately 5 copies of the other minor coat proteins (pIII and pVI) at the other end 
of the phage particle. The package signal is located at the pVII and pIX end of the phage 
particle and this is the first region to be assembled (Figure 1.7). 
 
The infection process is a multistep process involving the F pilus on the surface of the 
E. coli cell. When the phage comes in contact with the pilus, it retracts drawing the 
phage particle into the cell. Pilus formation is at its most abundance at mid-exponential 
phase of growth and decreases with increasing growth profile. The outer membrane 
bacterial proteins (TolQ, R and A) are needed for translocation of the filamentous phage 
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DNA into the cytoplasm and the translocation of the phage coat proteins into the 
cytoplasmic membrane. The initiation of infection occurs upon binding of the tip of the 
F pilus to the pIII phage protein. The pIII phage protein consists of 3 domains (N1, N2 
and CT) separated by glycine-rich regions. Each domain is essential for bacterial 
infection. The N1 and N2 domains are in close proximity and N2 is responsible for 
binding to the F pilus. The N1 domain interacts with the bacterial membrane protein 
(TolA-D3) and the phage is retracted towards the bacterium surface where the major 
and minor phage capsid proteins are disassembled and the phage DNA is translocated 
into the cytoplasm. The viral (+) phage ssDNA strand enters the cytoplasm and the 
complementary (-) DNA strand is synthesised by bacterial enzymes. This replicative 
form (RF) is the template for transcription and phage protein translation. The pII protein 
cleaves the intergenic region of the positive strand of the RF which acts as a primer for 
synthesis of a new viral strand via a ‗rolling-circle‘ replication method continuing until 
200 copies are within the cell. This continues until pV approaches a crucial level where 
it binds to newly synthesised viral ssDNA. The newly synthesised ssDNA-pV (800 nm 
in length and 8 nm in diameter) is assembled in the cytoplasm of the bacterium and the 
phage particle is subsequently secreted from the cell. This is then cleaved and used as a 
template for further phage propagation. Approximately 1000 phage per cell are 
produced in the first hour with 100 – 200 phage particles in subsequent cycles.   
 
Consideration of a vector for the display of proteins or peptides as coat protein fusions 
to pVIII or pIII is important. In phage vectors the gene is inserted directly into the 
genome and expressed with multiple copies of displayed protein leading to polyvalent 
display. This causes the selection of lower affinity variants during the biopanning 
process. To avoid an avidity affect a monovalent phage display process was developed 
using a phage-plasmid vector (phagemid). This is a plasmid with a plasmid origin of 
replication and a phage-derived origin of replication. The vector is capable of producing 
large quantities of pIII-fusion proteins but cannot make phage. This is aided by the 
addition of helper phage (i.e. M13K07 and VCSM13) that supply all the phage enzymes 
and proteins needed for phage replication (Barbas et al., 2001). As mentioned 
previously the phagemid genomes can be packaged in the phage coat preferentially 
rather than in helper phage as these contain a defective origin of replication, which thus 
ensure an abundance of pIII fusion protein. In phage assembly only 10% of the 
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packaged phage display the pIII fusion protein with 1–2 fusion proteins displayed on the 
phage. The low percentage is due to the preferential assembling and packaging of wild 
type pIII into phage. In contrast to phage vectors, phagemid vectors offer both a plasmid 
origin of replication and a phage-derived origin of replication with a selectable 
antibiotic resistance gene for facile selection and propagation of pIII fusion proteins. 
The emergence of tetracycline resistance in cells not infected with phage was observed. 
Thus, cultures for phage display should be grown fresh from a reliable frozen stock. The 
phagemid vector also contains a lac promoter which controls expression levels with 
ompA and pelB leader sequences directing the protein expression to the bacterial 
periplasm.   
 
Soluble expression of recombinant antibody fragments can be achieved by changing the 
bacterial strain. An amber stop codon (TAG) is present between the protein gene and 
the phage gene. During the selection process the phagemid is expressed in a suppressor 
E. coli strain (XL1-Blue, TG1) which allows for transcription of the pIII fusion protein. 
By incorporating the phage into a non-suppressor E. coli strain (TOP10F) the amber 
stop codon is read with soluble expression of the recombinant antibody fragment in the 
periplasmic space without the pIII gene product. Recombinant antibodies can be 
expressed with fusion tags (hemagglutinin and His) for downstream detection and 
purification. 
 
Recombinant antibodies can be genetically manipulated by techniques such as affinity 
maturation (Schier et al., 1996), chain shuffling, error-prone PCR and site-directed 
mutagenesis (Gram et al., 1992) to further increase affinity and sensitivity. In light 
chain shuffling the VH gene of the parental antibody is joined with the random VL gene 
of the generated library stock and the newly generated library screened by phage 
display. This has been shown to be successful with low affinity antibody fragments 
(Low et al., 1996) with 20-fold improvements (Marks et al., 1992). Error prone PCR 
involves introducing random nucleotides in the gene sequence and biopanning against 
the immunised antigen. It is important not to alter too many nucleotides as it may 
influence the binding capabilities of the translated antibody fragment. Site-directed 
mutagenesis involves changing specific amino acid sequences within the known 
antibody sequence to allow selection of an antibody fragment with improved binding. 
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Tyrosine is an important amino acid in protein recognition and is a common amino acid 
in the CDR binding region of the antibody variable heavy chain. It has been shown to 
increase antibody binding to protein molecules and is therefore seen as a favourable 
amino acid residue. The binding pocket of the antigen should be known prior to site-
directed mutagenesis as key amino acids may be required for antibody/antigen 
interaction. These amino acids should not be deleted or substituted as they may hinder 
the binding ability of the antibody fragment. A problem arising with mutagenesis 
strategies are the library size requirements which may restrict the selection of improved 
higher affinity antibodies (Irving et al., 1996). Large library sizes are required to ensure 
the retrieval of antibody fragments with improved binding affinity over the parental 
clone. By incubating less antigen on the immunotubes the parental antibody fragment 
should not be selected or propagated in sequential rounds of biopanning (Smith, 1985). 
This approach should ensure the selection of recombinant antibody fragment with 
improved binding characteristics towards the antigen.  
 
1.5 Immunoassays for PCa detection 
 
The application of antibodies for the detection of a variety of analytes in medicine, 
agriculture and food industries is an area of major significance. It is possible to produce 
antibodies against a very broad range of antigens, including conformationally intact or 
denatured proteins, short peptides, carbohydrates, drugs, hormones and small chemicals 
(Delves et al., 1997). Indeed, immunological detection with antibodies is perhaps the 
only technology that has been successfully employed for such a range of analytes. 
While the versatility of such assays is widely recognised, advancement in their quality 
and usefulness arises from the more recent availability of antibodies with higher 
specificity. This achievement can largely be attributed to several key discoveries 
involving novel methods of antibody production (Kohler and Milstein, 1975; Krebber et 
al., 1997). Today, three main types of antibody are used for immunodiagnostic 
applications i.e. polyclonal, monoclonal and recombinant antibodies.  
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1.5.1 Current immunoassays for PSA detection 
 
Advances in immunoassay technology have facilitated the development of sensitive 
immunoassays for the measurement of PSA in blood samples to detect the presence of 
PCa. PSA is currently the best available marker for PCa detection and is an FDA 
approved marker as previously described in Section 1.2.3. The major application of 
PSA measurement is for screening men of 45 years and older for the presence of PCa. A 
tPSA measurement above a cut-off value of 4.0 ng/mL is generally regarded as positive 
and indicates the need for biopsy. PSA testing is also used to monitor the response of 
PCa patients to ablative therapy such as radical prostatectomy. In this situation tPSA 
should be undetectable, and subsequent detectable levels of tPSA is a sign of disease 
recurrence. For this reason, more sensitive PSA assays have been developed to facilitate 
earlier detection of recurrence.  
 
Although there are different ways to assemble immunoassays, the most common format 
is a solid phase, two-site sandwich immunoenzymatic assay for use on high throughput 
immunoassay analysers. The capture antibody is immobilised onto coated paramagnetic 
beads, and an enzyme-labelled secondary antibody directed against a distinct antigenic 
site allows colorimetric determination of tPSA concentration. The use of paramagnetic 
beads as the solid phase allows efficient washing steps, since the beads can be captured 
from a solution upon application of a magnetic field, but at they do not themselves 
become magnetised they are resuspended upon removal of the magnetic source.  
 
1.5.2 History of PSA immunoassay development for clinical use 
 
Before the distinction of the various forms of tPSA (i.e. free and bound forms) was 
established as an important factor in PCa detection, the available antibodies did not 
distinguish between such forms, and assays detected tPSA levels only.  The first 
immunoassay for the measurement of tPSA was reported in 1980 (Kuriyama et al., 
1980), and the first commercial immunoassays for tPSA used clinically were available 
in the late 1980s, namely the Hybritech Tandem-R

 and the Yang Pros-Check

 
radioimmunometric assays. These assays were manually performed and had analytical 
sensitivities (i.e. the lowest concentration of measured PSA that could be distinguished 
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from zero samples) of the order of 0.5 ng/mL. These ‗first generation‘ assays were 
sensitive enough to distinguish elevated PSA from normal levels, but not adequate for 
the early detection of disease recurrence following, for example, radical prostatectomy. 
 
During the early to mid 1990s a large body of research both by clinical researchers and 
diagnostic immunoassay manufacturers led to the development of numerous 
immunoassays with improved limits of detection.  
 
Table 1.2: Commercially available tests commonly used for PSA determinations in 
serum 
Manufacturer Assay PSA isoform 
detected 
Claimed 
sensitivity 
(ng/mL) 
Claimed 
range 
(ng/mL) 
Abbott 
Diagnostics 
Architect 
 
AxSYM 
 
IMx 
Free PSA 
Total PSA 
Free PSA 
Total PSA 
Total PSA 
< 0.008 
< 0.008 
< 0.02 
< 0.04 
< 0.04 
0–30 
0–100 
0–10 
0–50 
0–50 
Diagnostic 
Products 
Corporation 
Immunlite Total PSA 
Free PSA 
3
rd
 Generation PSA 
< 0.04 
< 0.02 
< 0.003 
0–150 
0–25 
0–20 
Roche Elecsys Total PSA 
Free PSA 
< 0.002 
< 0.01 
0–100 
0–50 
Beckman Coulter Access-
Hybritech 
Total PSA 
Free PSA 
< 0.008 
< 0.005 
0–150 
0–20 
Bayer 
Diagnostics 
ADVIA PSA-ACT 
 
< 0.03 
 
0–100 
 
These ‗second generation‘ assays, also termed hypersensitive or ultrasensitive, provided 
detection limits in the region of 0.05 ng/mL, i.e. roughly a 10–fold improvement in 
analytical sensitivity compared to first-generation assays. At the same time, automated 
immunoassay analysers were developed, providing a platform for the processing of 
hundreds of samples per day with reduced inherent error compared to earlier manual 
31 
 
tests. The first ‗third generation‘ PSA immunoassay was available to the U.S. market in 
1997, with the subsequent introduction of numerous other PSA tests in the following 
years. Third generation assays offer analytical sensitivities in the region of 0.005 
ng/mL, and are generally performed on high throughput analysers allowing the 
processing of hundreds or thousands of samples per day if required. Today, there are 
numerous PSA assays available in the marketplace (Table 1.2), although it should be 
noted that only a limited number have attained FDA approval for clinical use, for 
example the Tandem E and Tandem R assays (Formerly Hybritech, now Beckman 
Coulter), IMx assay (Abbott), and Immunlite assay (Diagnostic Products Corporation). 
 
Measurement of tPSA using a cut-off level of 4 ng/mL, is associated with a significant 
rate of false-positive and false-negative results and is unable to distinguish PCa from 
BPH. Therefore, at the same time as assay sensitivity was being improved, more 
specific assays were also being developed. The increased assay specificity was based on 
the detection of different molecular forms of PSA, including PSA complexed to α1-
antichymotrypsin (PSA-ACT) and free (uncomplexed) PSA (fPSA), discovered in the 
early 1990s (Lilja et al., 1991). In a landmark paper, Catalona et al. demonstrated that 
measurement of % fPSA within the so-called diagnostic grey zone of 4–10 ng/mL 
significantly improved the specificity of cancer detection compared to tPSA 
measurement, such that 20% of unnecessary biopsies could be avoided (Catalona et al., 
1995). By 1998, assays specific for the complexed form of PSA were reported with 
sensitivities as low as 0.05 ng/mL (Allard et al., 1998; Wu et al., 1998). A year later an 
ELISA capable of detecting the levels of uncomplexed, fPSA in serum was first 
reported by Matsumoto and co-workers (Matsumoto et al., 1999). The detection limit 
for fPSA established for this assay was 0.008 ng/mL.  Today many commercial assays 
are available that discriminate between different PSA isoforms, allowing better 
discrimination between benign and malignant conditions than by measurement of tPSA 
alone. However, studies have shown significant differences in the sensitivities of these 
assays, indicating a lack of reliability (Oberpenning et al., 2002). It is for this reason 
that current research is still intensely focused on the development of more reliable and 
accurate assays for the presence of PCa. 
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One aspect of such research is the development of immunoassays that can demonstrate 
higher specificities for the various forms of PSA. Assays able to specifically detect 
these isoforms could provide further accuracy in discriminating PCa from benign 
disorders (Steuber et al., 2002). In 2000, Nurmikko et al. produced a PSA-specific 
monoclonal antibody that did not detect the internally cleaved form of PSA (Nurmikko 
et al., 2000).  A year later, the same group reported the development of an 
immunofluorometric sandwich assay for the measurement of intact, fPSA, but not 
internally cleaved forms (Nurmikko et al., 2001). The detection limit of this assay was 
determined to be 0.035 ng/mL. To date as mentioned in Section 1.2.4, limited research 
seems to indicate that measurement of the ratio of internally cleaved to normal forms of 
PSA may be useful to discriminate benign from malignant prostatic disease (Steuber et 
al., 2002). Hence, an immunoassay capable of quantifying these forms could potentially 
increase the accuracy of detection of PCa. 
 
1.6 PSA assays for forensic applications 
 
In addition to its use in the diagnosis of PCa, detection of PSA has also become the 
method of choice for determining the presence of semen in the absence of sperm and 
when sperm count is low, in forensic sexual assault cases. Measurement of PSA in such 
samples is associated with many variables not applicable to normal serum samples. 
Problems encountered with forensic samples include contamination with other body 
fluids or dirt, scarcity of sample, the need for extraction from different types of fabric 
leading often to low extraction efficiencies and sample decomposition in burnt cadavers 
or following laundry of fabrics. Other problems associated with the detection of PSA 
include specificity, false positive/negative results, sensitivity to pH/temperature, 
interference from matrix components and PSA stability. In sexual assaults, PSA may be 
exposed to harsh environmental conditions for prolonged periods of time that will alter 
the protein. This can happen before analysis is carried out and can lead to 
conformational changes, reduction of enzymatic activity, and degradation of the 
molecule. Furthermore, this can result in non-detection of the molecule by the antibody 
used in the test, giving false negative results. The vaginal environment and secretions 
are also acidic, which may also contribute to denaturation of PSA. Methods for the 
detection of PSA in semen include Ouchterlony double diffusion, crossover 
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electrophoresis, rocket immunoelectrophoresis, radial immunodiffusion and ELISA 
(Graves et al., 1985).  
 
PSA immunoassays involving an ELISA format commonly used in tests for clinical 
measurement of serum PSA have been studied for their potential use in the forensic 
identification of semen (Johnson and Kotowski, 1993; Jimenez-Verdego et al., 1994; 
Simich et al., 1999). These high sensitivity assays are relatively time consuming and 
expensive for the analysis of small numbers of samples, and unsuitable for forensic 
applications because of the aforementioned difficulties associated with forensic 
samples. It has been reported that the specificity and sensitivity of ELISA-based PSA 
tests becomes compromised for forensic semen samples that have been subjected to 
laundry treatment or exposed to contaminants including dishwashing detergents, 
shampoo, toothpaste and cleansers (Johnson and Kotowski, 1993).  Also, PSA is 
expressed in female tissue at very low levels and, therefore, antibodies which are too 
sensitive would not be desired candidates for assay purposes. The possibility of 
antibody cross-reactivity with female PSA was investigated by Laux and Custis (2004) 
as potential cross-reactivity would lead to false results. This study demonstrated that the 
level of PSA in female tissue varies with the tissue type. Current PSA tests used in 
detection of semen are generally immunochromatographic membrane tests 
(Hochmeister et al., 1999; Yokota et al., 2001; Maher et al., 2002; Sato et al., 2002; 
Khaldi et al., 2004). The sensitivity issues of a commercial immunochromatographic 
test were addressed in the study by Laux and Custis (2004) with respect to the presence 
of PSA in female body fluids. Levels of PSA reported prior to extraction were 3.7 
ng/mL in female urine and 0.53 ng/mL in female serum. Post-extraction, levels were 
0.558 ng/mL and 0.08 ng/mL, for urine and serum, respectively. These results indicated 
that female PSA levels are negligible in comparison to male PSA (820 000 ng/mL in 
semen and 123 000 ng/mL in semen post-extraction).  
 
Validated immunochromatographic membrane tests include the OneStep ABAcard p30 
test (Abacus Diagnostics, California, USA), Seratec PSA Semiquant Kit (Seratec, 
Gottigen, Germany), BioSign PSA membrane test (Biosign), SMITEST PSA card 
(manufacturer) and Onestep PSA test Strip (FF Diagnostics, Cologne, Germany). These 
assays are simple in nature, suitable for use on small numbers of samples, give rapid 
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results, and have been reported to be as sensitive and specific as ELISA tests 
(Hochmeister et al., 1999). The membrane tests work on the basis that PSA binds to a 
mobile monoclonal anti-PSA antibody in the membrane, forming a mobile antigen-
antibody complex that migrates through the test area due to the capillary effect of the 
membrane. A second labelled anti-PSA antibody that is immobilised in the test area 
binds the migrating antibody-PSA complex and leads to the formation of a coloured 
band in the presence of sufficient PSA (generally 1–4 ng/mL).  
 
Although membrane tests are far less sensitive than the clinically used second or third 
generation PSA assays, the nature of forensic PSA detection is such that an assay that is 
too sensitive may yield false positive results, because PSA has been detected in many 
female tissues and fluids, including breast tissue and milk (Papotti et al., 1989; Yu and 
Diamandis, 1995), amniotic fluid (Yu and Diamandis, 1995) and urine (Breul et al., 
1994).  Although more suitable than current ELISA tests for use with forensic samples, 
membrane tests still suffer from a number of problems related to specificity, false 
positives, interference from matrix components and PSA instability (Hochmeister et al., 
1999; Yokota et al., 2001; Khaldi et al., 2004). We envisage that future PSA tests for 
use in forensic work will contain antibodies capable of detecting multiple epitopes on 
the PSA antigen: for example, a combination of antibodies directed against pH-stable, 
temperature stable and detergent stable PSA elements may improve the detection of 
PSA in difficult forensic samples. These tests are likely to be delivered in the form of 
handheld portable devices, and similar to future PSA tests for clinical use, may 
incorporate new assay formats and detection technologies such as those discussed below 
in Section 1.7. 
 
1.7 Novel immunoassay formats reported in the literature 
 
Over the past few years many novel-format PSA measurement assays have been 
reported in the literature that aim to facilitate more sensitive and specific measurement 
of PSA in serum and semen samples (Table 1.3). Research is now focused on more 
mechanised, rapid and reliable assays.  Biosensor technology has emerged as a useful 
tool in immunodetection strategies for a variety of analytes. Biosensors use a 
combination of biological receptor compounds (antibody, enzyme, nucleic acid, etc.) 
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and a physical or physico-chemical transducer directing, in most cases, ―real-time‖ 
observation of a specific biological event e.g. antibody–antigen interaction.   In recent 
years, new immunoassay readout strategies have been devised that have potential to 
provide greater sensitivity than more conventional approaches. Strategies including 
surface plasmon resonance (SPR), immuno-PCR, microcantilevers, quantum dots, 
surface-enhanced Raman scattering (SERS), and atomic force microscopy (AFM) have 
shown promise in PSA assay formats. Although this section does not document every 
assay reported, selected assays of particular interest are included. 
 
Table 1.3: Novel PSA assay formats recently reported in the literature 
Detection 
method 
Assay format PSA 
isoform 
detected 
Reported 
sensitivity 
Reference 
Surface 
plasmon 
resonance 
Self-assembled 
monolayer on 
commercial SPR 
biochip with signal 
enhancement using a 
sandwich assay 
format 
PSA-ACT 
 
Total PSA 
18.1 ng/mL 
 
1 ng/mL 
 
0.15 ng/mL 
Cao et al. 
(2006); 
Huang et al. 
(2005); 
Besselink et 
al. (2004). 
Surface 
plasmon 
fluorescence 
spectroscopy 
Sandwich 
immunoassay format 
on commercial CM5 
(Biacore) chip 
Free PSA 80 fM Yu et al. 
(2004). 
Surface-
enhanced 
Raman 
scattering 
Sandwich assay using 
gold nanoparticles 
coated with a Raman 
scatterer 
Free PSA 1 pg/mL Grubisha et 
al. (2003). 
 
Time-
resolved 
fluorescence 
Fluorescently-labelled 
nanoparticles 
Total PSA 
 
 
 
Free PSA 
7.0 pg/mL 
 
0.4 ng/mL 
 
0.83 pg/mL 
Ye et al. 
(2004); 
Ye et al. 
(2005); 
Huhtinen et 
36 
 
 
0.04 pg/mL 
al. (2004); 
Soukka et al. 
(2001). 
Electrical 
sensing 
Resonance frequency 
shift in a 
nanomechanical 
microcantilever 
 
Conductance change 
in silicon nanowire 
sensor chip array 
Total PSA 
 
 
Free PSA 
 
Free PSA 
 
PSA-ACT 
10 pg/mL 
 
 
0.2 ng/mL 
 
100 fg/mL 
 
100 fg/mL 
Lee et al. 
(2005). 
 
Hwang et al. 
(2004); 
Wu et al. 
(2001); 
Zheng et al. 
(2005). 
Real-time 
PCR 
Sandwich assay with 
DNA label on 
detection antibody 
Total PSA 4.8 x 10
5
 
molecules 
Lind et al. 
(2005). 
Multi-photon 
detection 
Sandwich assay with 
I-streptavidin on 
detection antibody 
Total PSA 100 fg/mL Drukier et al. 
(2005). 
Disposable 
assay 
Strip format one-step 
lateral flow assay 
Free and 
total PSA 
1 ng/mL Fernandez-
Sanchez et al. 
(2005). 
 
1.8 Biosensor devices  
 
This approach has many advantages over traditional methods for the detection of minute 
amounts of target analyte. It allows label-free, rapid monitoring of biomolecular 
reactions in ‗real-time‘, and requires only a small amount of sample. The SPR device 
consists of a sensor chip containing flow cells, a light source, a prism and a detector 
(Figure 1.10). SPR sensor chips are usually composed of a carboxymethyl dextran 
matrix linked to a thin layer (~50 nm) of gold substrate on the sensor surface (Wilson, 
2002). SPR measures changes in refractive index and thus in the resonance angle at 
which polarised light is reflected from a surface, which is in turn related to a change in 
layer thickness or mass (Wilson, 2002). Thus, if polarised light strikes a gold layer at 
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the interface between media (e.g. glass and buffer) of differing refractive indices at a 
fixed wavelength above a critical angle, the photons are absorbed into surface plasmons 
(electron density waves) resulting in resonance and no reflection of light. If the 
refractive index changes at one side of the surface due to immobilisation of, for 
example, a ligand to its receptor, the resonance angle is changed and the intensity of the 
reflected light is increased (Figure 1.10).    
 
 
 
B 
A 
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Figure 1.10: Schematic of the typical set-up for a surface plasmon resonance (SPR) biosensor. 
SPR detects changes in the refractive index in the immediate vicinity of the surface layer of a 
sensor chip. SPR is observed as a shadow in the reflected light from the surface at an angle 
dependent on the mass of material at the surface. (A) When antigen is passed over the flow cell 
it binds to the receptor resulting in a change in the mass of the surface layer, leading to a shift 
in the resonance angle (from I to II in the diagram). This change in signal is proportional to the 
amount of ligand bound to the receptor, which enables detection of a ligand and determination 
of the ligand–receptor interaction affinities and kinetics. (B) The change in resonance angle can 
be monitored non-invasively in ‘real-time’ as a plot of resonance signal (proportional to mass 
change) versus time. 
 
Huang and co-workers reported an immunosensor based on the use of a commercial 
SPR biosensor (Biacore 2000) for the detection of PSA concentrations as low as 1 
ng/mL (Huang et al., 2005). Biacore SPR chips are generally composed of a 
carboxymethyl dextran matrix linked to a gold substrate on the sensor surface. 
However, self-assembled monolayers (SAMs) have been used as the immobilisation 
substrate and have been shown to give better sensitivities than dextran layers (Frederix 
et al., 2003). The PSA sandwich assay reported by Huang et al. (2005) used a camel 
anti-PSA antibody fragment attached to a mixed SAM of thiols for PSA capture, and a 
biotinylated mouse monoclonal anti-PSA antibody and streptavidin-modified gold 
nanoparticles for amplification of the detection signal. Cao and co-workers 
subsequently reported a SPR-based immunoassay specific for PSA-ACT, in which the 
limit of detection was enhanced simply by using a sandwich strategy in which an intact 
PSA monoclonal antibody was used as an amplifying agent (Cao et al., 2006). Yu and 
co-workers reported the use of a CM5 Biacore chip as a dextran surface on which a 
sandwich assay for free PSA was conducted (Yu et al., 2004). The assay combined SPR 
and fluorescent labelling, i.e. surface plasmon field-enhanced fluorescence spectroscopy 
(SPFS). This technology used surface plasmons to excite the fluorescent label and 
produce the signal. The limit of detection observed was 80 fM for a 40 minute contact 
time, which is many orders of magnitude lower than detection limits of third generation 
PSA assays commercially available today. Related to SPR, surface-enhanced Raman 
scattering (SERS) has also been used in the detection of minute amounts of target 
molecules. In Raman spectroscopy the light scattered inelastically from a molecule 
provides information about the molecule's vibrational quantum states. The Raman effect 
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can be greatly strengthened if the molecules are attached to nm–sized metal structures, 
similar to the gold sheets on SPR biosensor chips. SERS has also been used in a 
sandwich assay format immunoassay for the detection of PSA (Grubisha et al., 2003). 
The assay used tracer nanoparticles created by the physisorption of antibodies and 
Raman reporter molecules (RRMs) on gold colloids. It has been speculated that SERS 
could be used for the sensitive detection of multiple analytes by immobilising a mixture 
of different capture antibodies and using nanoparticles coated with different sets of 
tracer antibodies and RRMs (Ni et al., 1999). Such an approach is possible because 
Raman bands are sufficiently narrow to reduce the likelihood of spectral overlap when 
multiple labels are used.  
 
There has been considerable interest in harnessing the very high sensitivity of ‗real-
time‘ PCR for use in diagnostic applications. As early as 1992, Sano and co-workers 
described a new technique using PCR for the analysis of protein analytes, which they 
called immuno-PCR (Sano et al., 1992). This technique was based on a sandwich assay 
format, in which the detection antibody was coupled to a DNA molecule, which was 
then amplified after washing steps. The amount of product formed during the 
exponential phase of DNA amplification, assessed by gel electrophoresis or PCR-
ELISA, reflected the amount of target protein bound by the capture antibody. However, 
the use of real-time PCR for DNA quantification, first demonstrated by Sims and co-
workers, led to a significant improvement in sensitivity and accuracy over a wide 
concentration range (Sims et al., 2000). Recently, the development of real-time 
immuno-PCR systems for the specific detection of PSA was reported (Lind et al., 
2005). The most sensitive assay could detect 4.8 x 10
5
 PSA molecules in a 5 µl sample, 
equivalent to a sensitivity of approximately 0.2 pg/mL. ‗Real-time‘ immuno-PCR 
assays could be applied to simultaneous multi-analyte detection, since primers binding 
specific DNA sequences could be used for each of a number of different detection 
antibodies.  
 
Much research into immunoassay development is currently focused on the 
miniaturisation of assays for future use in disposable format tests. Some disposable 
format PSA tests have recently been reported. A disposable immunosensor based on a 
lateral flow format has been successfully designed for the detection of free and total 
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forms of PSA (Fernandez-Sanchez et al., 2005). The lateral flow system was based on a 
non-competitive sandwich assay format. The membrane was coated with anti-free-PSA 
or anti-total-PSA antibodies with a monoclonal anti-PSA urease conjugate as the 
probing molecule. The system consisted of a polymer-coated electrode system to which 
each immunostrip was placed in contact. Upon completion of the immunoassay on the 
strip, hydrolysis of urea by the urease label generated ammonia and an increase in pH, 
which resulted in degradation of the polymer and subsequent determination of the 
amount of analyte in the sample, PSA could therefore be quantified. A lower detection 
limit of 10 ng/mL of both free and complexed PSA species was observed with this 
method.  
 
Considerable interest exists in biosensors that use microelectromechanical system 
(MEMS) and nanoelectromechanical system (NEMS) detection technologies (Cherian 
et al., 2003). Most nanomechanical sensors use silicon-based cantilevers that bend due 
to increased surface stress when the target molecule binds to specific receptors on the 
cantilever surface. Lee et al., (2005) reported the development of an immunoassay for 
PSA using a piezoresistive nanomechanical microcantelever. Electrical detection, via 
surface stress changes, of antigen-antibody binding was achieved through micro-
fabricated self-sensing micro-cantilevers. When binding occurred on a functionalised 
gold surface, surface stress was induced resulting in cantilever bending and resistance 
change of the piezoresistive layer. The authors reported that the novel electrical 
measurement system facilitated label-free detection of PSA with a reported achievable 
sensitivity of 10 pg/mL.  
 
The last 30 years have seen a significant improvement in PCa diagnosis, general welfare 
and life expectancy of the PCa patient. This has coincided with the discovery of PSA, 
the most widely used cancer-associated marker for the disease. Despite its 
achievements, some researchers have questioned its value in PCa diagnosis, since 
increased serum levels are also associated with non-malignant conditions such as BPH. 
Immunoassay development is currently focusing on the detection of the various 
isoforms of PSA to increase assay specificity and reduce the rate of false positives and 
unnecessary biopsies. While numerous reports of assays for the detection of various 
forms have been reported, it is still unclear whether these assays will improve the 
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detection of PCa in the presence of non-malignant disease, and therefore further 
research is required. It is likely that the specific detection of PCa will require a panel of 
antibodies against multiple markers for PCa including other members of the kallikrein 
family of proteases, and even non-protein markers such as genes upregulated in PCa 
progression. The advent of proteomics and microarray technology will likely involve 
the amalgamation of current antibody-based assays with antibodies against novel 
biomarkers monitoring the change in levels of numerous factors thus giving a more 
accurate assessment of the disease state and facilitating earlier diagnosis.  
 
1.9 Thesis Outline 
 
The aim of the work presented in this thesis was focused on the generation, selection, 
characterisation and application of novel recombinant antibody fragments for the 
detection of fPSA. The work involved generating 3 recombinant antibody libraries from 
immunised sources and selecting antigen-specific antibody fragments using phage-
display technology (Chapter 3). Recombinant murine antibody fragments selected from 
‗biopanning‘ were reformatted and expressed as scAb for enhanced protein expression 
and stability due to problems incurred with poor expression levels of murine scFvs. 
Individual clones (murine and avian clones) were ranked using a capture assay approach 
on the Biacore system and kinetic analysis performed on the most suitable candidate 
clones displaying the greatest percentage stability (Chapter 4). All antibodies were 
purified and characterised by ELISA, Biacore analysis, SDS-PAGE and Western 
blotting. Epitope mapping using a sandwich assay on the Biacore system revealed 
potential clones for immunoassay development.  
 
ELISA and Biacore inhibition-based assays were evaluated. However, low sensitivity 
proved to be an issue. A sandwich assay approach was investigated using a biotinylated 
murine anti-fPSA scAb and an avian anti-fPSA scFv as a detection antibody. This 
approach improved assay sensitivity; female serum samples spiked with fPSA were 
assessed to evaluate assay sensitivity in the serum matrix. Serum samples from patients 
presenting with PCa were analysed to determine levels of fPSA in the serum sample. 
PCa tissue samples were analysed by immunohistochemistry using purified murine and 
avian anti-fPSA recombinant antibodies and positive staining was observed (Chapter 5). 
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Chapter 2 
 
Materials & Methods 
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2.1 Materials & Methods 
2.1.1 Materials 
 
All reagents were purchased from Sigma-Aldrich, Airton Road, Tallaght, Dublin 24, 
Ireland except where otherwise stated below. 
 
Reagent Supplier 
Bacteriological Agar 
Yeast 
Tryptone 
Cruinn Diagnostics Ltd., Hume Centre, 
Parkwest Business Park, Nanogor Road, 
Dublin 12, Ireland. 
DNA ligase 
Helper phage 
Restriction enzymes 
ISIS Ltd., Unit 1 & 2, Ballywaltrim 
Business Centre, Boghall Road, Bray, Co. 
Wicklow, Ireland. 
EZ-Link Biotinylation Kit Fischer Scientific Ireland, Suite 3, Plaza 
212, Blanchardstown Corporate Park 2, 
Ballycoolin, Dublin 15, Ireland. 
fPSA Lee Biosolutions Inc., 2924 Mary Avenue, 
St. Louis, Missouri, (63144-2730) USA. 
Methanol Lennox, John F. Kennedy Drive, Naas 
Road, Dublin 12, Ireland. 
PCR primers Eurofins MWG Operon, 318 Worple 
Road, Raynes Park, London, SW20 8QU, 
UK. 
Perfect Prep gel cleanup kit Unitech, Unitech House, Magna Drive, 
Magna Business Park, City West, Dublin 
24, Ireland. 
Prestain full range rainbow marker GE Healthcare Life Sciences, Amersham 
Place, Little Chalfont, Buckinghamshire, 
HP7 9NA, UK. 
Superscript system Bio-sciences, 3 Charlemont Terrace, 
Crofton Road, Dun Laoghaire, Dublin, 
Ireland. 
Trypsin AGB Scientific Ltd., Dublin Industrial 
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Estate, Dublin 11, Ireland. 
Wizard Plus Mini-prep kit 
Promega cDNA synthesis kit 
Promega gel clean up kit 
Medical Supply Co Ltd., Damastown, 
Mulhuddart, Dublin 15, Ireland. 
 
2.1.2 Culture media formulation 
 
Media Ingredients 
2x Tryptone Yeast extract medium (2xTY) Tryptone 16 g/L 
Yeast Extract  10 g/L 
NaCl  5 g/L 
Super Broth Medium (SB) Tryptone 30 g/L 
Yeast  20 g/L 
MOPS  10 g/L 
Super Optimal Catabolite Medium (SOC) Tryptone 20 g/L 
Yeast Extract 5 g/L 
NaCl  0.5 g/L 
KCl  2.5 mM 
MgCl2  20 mM 
Glucose 20 mM 
 
2.1.3 Buffer compositions 
 
2.1.3.1 Phosphate buffered saline (PBS) (150 mM, pH 7.4)  
0.15 M NaCl 
2.5 mM KCl 
10 mM Na2HPO4 
18 mM KH2PO4 
 
All the listed reagents were dissolved in 800 mL of ultra pure H2O, adjusted to pH 7.4 
and made up to 1 litre with ultra pure H2O.  
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2.1.3.2 PBS-Tween (PBST)  
 
Tween 20 detergent (Sigma) was added to PBS to give a final concentration of 0.05 % 
(v/v). 
  
2.1.3.3 HEPES buffered saline (HBS) (240 mM, pH 7.4)  
2.38 g HEPES 
     8.77 g NaCl 
     1.27 g EDTA 
     0.5 mL Tween 
 
HEPES, NaCl and EDTA were dissolved in 800 mL of ultra-pure water. The pH was 
adjusted to pH 7.4 by the addition of NaOH. The solution was filtered through a 0.2 µm 
filter. The Tween 20 was added to the solution and the solution was degassed. 
 
2.1.3.4 Tris buffered saline (TBS) (150 mM, pH 7.6) 
0.05 M Trizma base 
0.15 M NaCl 
 
The Trizma base and NaCl were dissolved in 800 mL ultra-pure water. The pH was 
adjusted to pH 7.6 using NaOH and made up to 1 litre with ultra pure H2O. 
 
2.1.3.5 Tris-acetic acid-EDTA buffer (TAE) (400 mM, pH 8.3) 
 
A 10X stock solution of TAE buffer, supplied as a proprietary reagent by Sigma, was 
diluted to 1 litre with distilled water. All agarose gels for DNA visualisation were 
prepared and resolved in 1X TAE buffer. 
 
2.1.3.6 Tris-EDTA buffer (TE) (10 mM, pH 8.0) 
0.01 M Trizma hydrochloric acid 
0.001 M EDTA 
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2.1.4 Equipment list 
 
Equipment Supplier 
Balances (Chyo JK-180, Mettler PJ300) Medical Supply Company Ltd, 
Damastown, Mulhuddart, Dublin 15, 
Ireland. 
Biacore 3000
TM 
CM5 chips 
Pharmacia Biosensor AB, Uppsala, 
Sweden. 
Biometra TGRADIENT PCR machine 
Orbital shaker 
Millipore Ultrapure H2O Milli-Q academic 
Sanyo Orbital Incubator 
AGB Scientific Ltd., Dublin Industrial 
Estate, Glasnevin, Dublin 9, Ireland. 
Bio Rad Gene Pulser Xcell 
SDS Bio-Rad Min-Protean
®
 3 Cell 
Trans-Blot
®
SD Semi-Dry Transfer cell 
Bio-Rad Powerpac Basic 
Bio-Rad DNA gel apparatus (Wide-Mini-
Sub
®
 CellGT) 
Alpha Technologies, The Leinster 
Technology Centre, Blessington Industrial 
Estate, Blessington, Co. Wicklow, Ireland. 
Blood tube rotator SB1 Stuart Scientific, Beacon Road, Stone, 
Staffordshire, ST15 0SA, UK. 
Gelaire BSB4 laminar unit Gelman Ltd, 71 Broomhill road, Tallaght 
Industrial Estate, Tallaght, Dublin 24, 
Ireland. 
HermLe Z233MK-2 refrigerated 
centrifuge 
HermLe Labortechnik GmbH, 25 
Siemensstrasse, Wehingen, 78564, 
Germany. 
Homogeniser (Ultra-Turrax) Janke & Kunkel IKA-Werk Ultra-Turrax, 
Staufen, 79129, Germany. 
Camag Linomat 5 (Lateral Flow 
Instrument) 
New Brunswick Scientific-Excella E24 
Incubator Shaker Series (plate shaker) 
ND-1000 Spectrophotometer (Nanodrop) 
Mason Technologies, Greenville Hall, 228 
South Circular Road, Dublin 8, Ireland. 
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Tomy Autoclave SX-700E High Pressure 
Steam Sterilizer) 
pH meter (Orion 3 star) Medical Supply Company Ltd, 
Damastown, Mulhuddart, Dublin 15, 
Ireland. 
Plate incubator shaking IKA
®
 MTS 2/4 
digital 
Platform shaker STR6 
Lennox, John F. Kennedy Drive, Naas 
Road, Dublin 12, Ireland. 
Tecan Saffire2 Plate reader Tecan Austria GmbH, Untersbergstrasse, 
5082 Grödig, Austria. 
Water bath (Y6 model) Grant instruments (Cambridge) Ltd, 29 
Station Road, Shepreth, Royston, Herts., 
SG8 6PZ, UK. 
 
2.1.5 Bacterial strains used  
 
All bacterial strains cultured and expressed in different nutrient broth solutions are 
listed below. 
 
Bacterial Strain Product details Suppliers 
E.coli XL-1 Blue cells Stratagene RecA endA1 
gyrA96 thi-1 hsdR17supE44 
relA1 lac (F proAB lacI
q
 Z 
M15 Tn10 (Tet
r
)) 
Techno-path Ltd., 
Holland Road, National 
Technology Park, 
Plassey, Limerick, 
Ireland. 
E.coli TOP10F' cells Invitrogen F'[lacI
q
 Tn10(tet
R
)] 
mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 deoR 
nupG recA1 araD139 Δ(ara-
leu)7697 galU galK rpsL(Str
R
) 
endA1 λ- 
Techno-path Ltd., 
Holland Road, National 
Technology Park, 
Plassey, Limerick, 
Ireland. 
E.coli Tuner cells Novagen – Merck F– ompT 
hsdSB (rB
–
 mB
–
) gal dcm lacY1 
Techno-path Ltd., 
Holland Road, National 
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Technology Park, 
Plassey, Limerick, 
Ireland. 
 
2.2 Production of murine recombinant antibody fragments 
 
2.2.1 Preparation of bacterial stocks 
 
All bacterial stocks were streaked on 2xTY agar plates overnight at 37
o
C for individual 
colony isolation. Individual colonies were picked and cultured in 2xTY media overnight 
at 37
o
C with shaking at 200 rpm. The overnight cultures were subcultured into fresh 
2xTY medium (Section 2.1.2) and grown until reaching the desired cell density (OD600 
nm ~ 0.8). The cultures were centrifuged at 4,000 rpm (3,220 x g) for 10 minutes and 
resuspended in sterile glycerol (20% v/v final concentration)-supplemented media. The 
cell suspension was transferred aseptically to sterile 1.5 mL centrifugation tubes and 
flash frozen using liquid nitrogen. Bacterial strains were stored at -80
o
C. 
 
 2.2.2 Immunisation of Balb/c mice with fPSA and antibody titre determination 
 
The Laboratory Animal Science and Training (LAST) Ireland Animal handling training 
course was attended and the associated examination passed. The proposed work was 
passed by the ethics committees of the School of Biotechnology and the University and 
the licence subsequently granted by the Department of Health and Children. Extreme 
care was taken to minimise stress levels to the animals. Balb/c mice aged between 5–8 
weeks were used for production of recombinant antibodies to fPSA. These were initially 
immunised in the peritoneal cavity with a final concentration of 50 g/mL fPSA in 200 
µl PBS, mixed in a 1:1 ratio with Freund‘s complete adjuvant. The mixture was 
vigorously shaken to ensure a complete homogenous solution. Freund‘s Complete 
Adjuvant (FCA) is an emulsified mineral oil antigen solution used as an 
immunopotentiator. Subsequent ‗booster‘ injections (4, 8 and 12 weeks) were 
performed with 25 g/mL fPSA mixed in a 1:1 ratio with Freund‘s Incomplete 
Adjuvant (FICA). A tail bleed was taken from the mice 7 days after the second booster 
administration to confirm the animals were responding to the immunisations and 
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antigen-specific antibodies were being produced. Once the titre reached an appropriate 
level (1:100,000 dilution) as determined by ELISA, the mice were boosted 7 days prior 
to sacrifice (Krebber et al., 1997). 
 
2.2.3 Extraction and isolation of total RNA from the spleen of an immunised Balb/c 
mouse 
 
All work was performed in the Bioresource facility in DCU, Dublin, Ireland. Prior to 
use the laminar unit (Gelaire BSB 4) was cleaned with Industrial Methylated Spirits 
(IMS) and ‗RNase-free‘ wash solution thus ensuring an uncontaminated environment. 
The mouse was sacrificed by cervical dislocation and transfer to the laminar unit. Its 
spleen was removed and homogenised in TRI reagent (2 mL) using a pre-baked (180
o
C, 
overnight) sterile homogeniser. The mixture was incubated for 5 min at room 
temperature to permit the total dissociation of nucleoprotein complexes. Chloroform 
(400 L) was added and the solution shaken vigorously for 15 seconds. The resulting 
mixture was stored for 15 min at room temperature and after incubation centrifuged at 
12,000 rpm (Eppendorf centrifuge 5810R) for 15 min at 4
o
C. Three layers were 
observed, a lower red phenol/chloroform phase, a protein interphase and a colourless 
liquid upper phase containing the RNA. The aqueous upper phase was precipitated 
using isopropanol (1 mL) in a fresh ‗RNase-free‘ tube. This mixture was stored for 10 
min at room temperature and centrifuged at 12,000 rpm for 8 min at 4
o
C. RNA forms a 
white pellet at the bottom of the tube. The supernatant was removed, the pellet washed 
with 75% (v/v) ethanol (2 mL) and centrifuged at 7,500 rpm for 5 min at 4
o
C 
(Eppendorf centrifuge, 5810R). The pellet was allowed to dry and resuspended in 
molecular grade water (140 L).  
 
2.2.4 Reverse transcription of total RNA to cDNA 
 
A PCR was performed for 1 hour at 42
o
C to transcribe total RNA to cDNA. The 
synthesis of cDNA was performed using a Promega cDNA synthesis kit containing 
oligo (dT) primers. The PCR reaction contained the following components 
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Components  Stock Concentration Final Conc.       Volume (20L) 
 MgCl2   25 mM   5 mM   4 L 
 10X Buffer  10 X   1 X   2 L 
 dNTP mix  10 mM  1 mM   2 L 
 RNase   40 U/L  1 U/L             0.5L 
 Oligo (dT) Primer 0.5 g/L  0.2 g/rxn  0.4 L 
 AMV RT*  25 U/L  10 U/rxn  0.4 L 
 RNA   1.5 g/L  11.25 g/rxn  7.5 L 
 Molecular Grade H20       3.2 L  
 
* Avian myeloblastosis virus reverse transcriptase  
 
All the components, excluding the enzymes, were placed on ice and slowly thawed. The 
enzymes were removed from the -20
o
C freezer immediately before use to minimise loss 
of activity. The components were added to sterile PCR tubes and the PCR programme 
initiated.  
Steps   Temperature (
o
C)        Time (min) 
  1    42    15 
  2    95    5 
  3    4    pause 
 
2.2.5 PCR Primers 
 
The primers listed below were obtained from Sigma-Genosys Ltd and are compatible 
with the primers set described by Krebber for the pAK vector system (Krebber et al., 
1997). The FLAG tag (gactacaaaGAY) and Bam H1 restriction site (ggatcc) were 
incorporated into the designed primers for amplifying the antibody variable domains. 
 
Variable light chain reverse primers 
LB1 5gccatggcggactacaaaGAYATCCAGCTGACTCAGCC3 
LB2 5gccatggcggactacaaaGAYATTGTTCTCWCCCAGTC3 
LB3 5gccatggcggactacaaaGAYATTGTGMTMACTCAGTC3 
LB4 5gccatggcggactacaaaGAYATTGTGYTRACACAGTC3 
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LB5 5gccatggcggactacaaaGAYATTGTRATGACMCAGTC3 
LB6 5gccatggcggactacaaaGAYATTMAGATRAMCCAGTC3 
LB7 5gccatggcggactacaaaGAYATTCAGATGAYDCAGTC3 
LB8 5gccatggcggactacaaaGAYATYCAGATGACACAGAC3 
LB9 5gccatggcggactacaaaGAYATTGTTCTCAWCCAGTC3 
LB10 5gccatggcggactacaaaGAYATTGWGCTSACCCAATC3 
LB11 5gccatggcggactacaaaGAYATTSTRATGACCCARTC3 
LB12 5gccatggcggactacaaaGAYRTTKTGATGACCCARAC3 
LB13 5gccatggcggactacaaaGAYATTGTGATGACBCAGKC3 
LB14 5gccatggcggactacaaaGAYATTGTGATAACYCAGGA3 
LB15 5gccatggcggactacaaaGAYATTGTGATGACCCAGWT3 
LB16 5gccatggcggactacaaaGAYATTGTGATGACACAACC3 
LB17 5gccatggcggactacaaaGAYATTTTGCTGACTCAGTC3 
LB 5gccatggcggactacaaaGATGCTGTTGTGACTCAGGAATC3 
 
Variable light chain forward primers 
LF1 5ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTGATTTCCAGCTTGG3  
LF2 5ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTTATTTCCAGCTTGG3 
LF4 5ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTTATTTCCAACTTTG3 
LF5 5ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTCAGCTCCAGCTTGG3  
LF 5ggagccgccgccgcc(agaaccaccaccacc)2ACCTAGGACAGTCAGTTTGG3 
 
Variable heavy chain reverse primers 
HB1 5ggcggcggcggctccggtggtggtggatccGAKGTRMAGCTTCAGGAGTTC3   
HB2 5ggcggcggcggctccggtggtggtggatccGAGGTBCAGCTBCAGCAGTC3 
HB3 5ggcggcggcggctccggtggtggtggatccCAGGTGCAGCTGAAGSASTC3 
HB4 5ggcggcggcggctccggtggtggtggatccGAGGTCCARCTGCAACARTC3 
HB5 5ggcggcggcggctccggtggtggtggatccCAGGTYCAGCTBCAGCARTC3 
HB6 5ggcggcggcggctccggtggtggtggatccCAGGTYCARCTGCAGCAGTC3 
HB7 5ggcggcggcggctccggtggtggtggatccCAGGTCCACGTGAAGCAGTC3 
HB8 5ggcggcggcggctccggtggtggtggatccGAGGTGAASSTGGTGGAATC3 
HB9 5ggcggcggcggctccggtggtggtggatccGAVGTGAWGYTGGTGGAGTC3 
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HB10 5ggcggcggcggctccggtggtggtggatccGAGGTGCAGSKGGTGGAGTC3 
HB11 5ggcggcggcggctccggtggtggtggatccGAKGTGCAMCTGGTGGAGTC3 
HB12 5ggcggcggcggctccggtggtggtggatccGAGGTGAAGCTGATGGARTC3 
HB13 5ggcggcggcggctccggtggtggtggatccGAGGTGCARCTTGTTGAGTC3 
HB14 5ggcggcggcggctccggtggtggtggatccGARGTRAAGCTTCTCGAGTC3 
HB15 5ggcggcggcggctccggtggtggtggatccGAAGTGAARSTTGAGGAGTC3 
HB16 5ggcggcggcggctccggtggtggtggatccCAGGTTACTCTRAAAGWGTSTG3 
HB17 5ggcggcggcggctccggtggtggtggatccCAGGTCCAACTVCAGCARCC3 
HB18 5ggcggcggcggctccggtggtggtggatccGATGTGAACTTGGAAGTGTC3 
HB19 5ggcggcggcggctccggtggtggtggatccGAGGTGAAGGTCATCGAGTC3 
 
Variable heavy chain forward primers 
HF1 5ggaattcggcccccgaggcCGAGGAAACGGTGACCGTGGT3  
HF2 5ggaattcggcccccgaggcCGAGGAGACTGTGAGAGTGGT3 
HF3 5ggaattcggcccccgaggcCGCAGAGACAGTGACCAGAGT3 
HF4 5ggaattcggcccccgaggcCGAGGAGACGGTGACTGAGGT3  
 
2.2.6 Components and PCR conditions for antibody variable domain genes 
amplification using Krebber-specific primers 
 
The reaction components and volumes for mouse variable chain amplification were as 
follows: 
 
Component               20 L volume 
cDNA          0.8 L 
dNTP mix         0.4 L 
5 X Buffers (A, B, D, G)       4.0 L 
VL/VH Forward Primer       0.4 L 
VH/VL Reverse Primer       0.4 L 
H2O           13.2 L 
Sigma Red Taq polymerase       0.8 L 
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PCR buffer compositions: buffer A (7.5 mM MgCl2, pH 8.5), buffer B (10 mM MgCl2, 
pH 8.5), buffer D (17.5 mM MgCl2, pH 8.5), buffer G (12.5 mM MgCl2, pH 9.0) 
(Figure 3.3). 
 
The PCR conditions for the amplification of the mouse antibody variable chain genes by 
PCR were as follows: 
 
Steps   Temperature (
o
C)  Time (seconds) 
1    94    60 
2    63    55 
3    72    60 
Repeat Steps 1 3 seven times 
4    94    60 
5    69    30 
6    72    60 
Repeat Steps 4 6 twenty three times 
7    72    600 
8    4    Pause 
 
After successful amplification of both the variable heavy (VH) and variable light (VL) 
chain gene fragments, the PCR products were resolved on a 1% (w/v) agarose gel and 
purified using the Promega gel clean up kit. 
 
2.2.7 Purification of VH and VL variable gene fragments using the Promega gel clean up 
Kit 
 
The VH and VL chain genes were purified from a 1% (w/v) agarose gel by excising the 
correct size fragments, 386–440 bp for VH chain, and 375–402 bp for VL chain. The gel 
slices were weighed and binding buffer (add three times the volume of the excised gel 
fragment) added. The mixture was incubated in a water bath for 10 min at 50
o
C. The 
guanidine isothiocyanate-containing binding buffer allows for sufficient binding of the 
DNA to the silica membrane columns. An equal volume of isopropanol to the weight of 
the excised fragment was added and the resulting mixture added to a collection column. 
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Isopropanol encourages precipitation of the excised DNA fragment. The column was 
centrifuged at 14,000 rpm for 1 min to remove remaining residual buffer and the flow-
through discarded.  The column was washed with 750 L wash buffer, centrifuged at 
14,000 rpm for 1 min and washed with 250 L wash buffer. The column was 
centrifuged at 14,000 rpm for 2 min and the DNA eluted from the column using 30 L 
molecular grade H2O into a clean 1.5 mL sterile centrifugation tube. The absorbance of 
the purified DNA was measured at 260 nm using the Nanodrop ND-1000 
spectrophotometer and the concentration calculated using the Beer-Lambert law. 
 
2.2.8 Splice by Overlap extension PCR (SOE-PCR) 
 
The VH and VL gel purified fragments were joined with a glycine-serine linker (G4S)4 
using SOE-PCR to produce an 850 bp DNA fragment. The SOE primers for the 850 bp 
amplification were:- 
 
Single chain forward  5ggaattcggcccccgag3 
Single chain reverse  5ttactcgcggccagccggccatggcggactaccccg3 
 
Initially the PCR was performed using different VH and VL template ratios with Phusion 
polymerase (Finnzymes). The standard 1 x DNA template concentration for each chain 
was 10 ng.  
 
The VH and VL ratios for the SOE-PCR amplification were as follows; (i) 10 ng VH: 10 
ng VL, (ii) 20 ng VH: 20 ng VL, (iii) 5 ng VH: 5 ng VL, (iv) 5 ng VH: 10 ng VL, (v) 5 ng 
VH: 2.5 ng VL, (vi) 5 ng VH: 1.25 ng VL, (vii) 10 ng VH: 5 ng VL, (viii) 2.5 ng VH: 5 ng 
VL, (ix) 1.25 ng VH: 5 ng VL. The concentrations of all other components remained 
equal to give a final concentration of 20 µL per reaction. 
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Component    20 L volume 
Buffer G*         4 L 
10 mM dNTP mix        0.4 L 
scForward Primer        0.4 L 
scReverse Primer        0.4 L 
Phusion polymerase        0.2 L 
VH chain (10 ng DNA)       2 L 
VL chain (10 ng DNA)       2 L 
H20          10.6 L 
 
* For composition of buffer G, see page 51. 
The reaction was performed using the following PCR conditions: 
 
Steps   Temperature (
o
C)  Time (seconds) 
   1    98    60 
   2    98    20 
   3    55    30 
   4    72    30 
Repeat Steps 2 4 six times 
 
   5    98    20 
   6    63    30 
   7    72    30 
Repeat Steps 5 7 twenty times 
 
   8    72    300 
   9    4    Pause 
 
A non-specific 1,000 bp band was preferentially amplified over the desired 800 bp scFv 
product and, therefore, optimisation was required (Figure 3.4). DMSO and BSA were 
added to the PCR mix to decrease the levels of non-specific amplification and improve 
concentration of the desired PCR product. A touchdown PCR was incorporated to 
facilitate the amplification of the product. 
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Component    L volume 
 5X Buffer G*       10 L    
 scForward Primer       1 L     
 scReverse primer      1 L 
 dNTP mix        1 L     
 VH chain       2.66 L    
 VL chain       2 L 
Red Taq Polymerase      2 L 
DMSO        - 
BSA        - 
H20        - 
 
*For composition of Buffer G, see page 51  
      
The PCR amplification was performed using the listed components with varying 
concentrations of DMSO, BSA and H2O. The PCR amplified reactions were as follows 
(i) supplemented with 5% (v/v) DMSO (ii) supplemented with 50 µg/mL BSA (iii) 
supplemented with 5% (v/v) DMSO and 50 µg/mL BSA (iv) no additives (v) positive 
control (in-house scFv) and (vi) negative control (no VH and VL DNA template).  
 
The reaction was performed using the following PCR conditions 
 
Steps   Temperature (
o
C)  Time (seconds) 
   1    94    30 
   2    63    30 
   3    72    60 
Repeat Steps 1 3 five times 
 
   4    94    60 
   5    69    30* 
   6    72    60 
   Repeat Steps 4 6 thirty times 
   7    94    60 
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   8    50    50 
   9    72    60 
Repeat Steps 7 9 six times 
   10    72    600 
   11    4    Pause 
 
*Note: An annealing temperature decrease of 0.5
o
C after each successive cycle. 
 
The non-specific band was preferentially amplified over the desired product and 
therefore the VH and VL DNA template concentrations were increased with a touchdown 
PCR amplification. A range of DMSO concentrations (2%, 4%, 6%, 8% and 10% v/v) 
were used in the PCR with Red Taq polymerase and Phusion polymerase, respectively. 
 
Component    L volume 
 5X Buffer G*       10 L    
 scForward Primer       1 L     
 scReverse primer      1 L 
 dNTP   mix       1 L     
 VH chain (20 ng DNA)     4 L     
 VL chain (20 ng DNA)     4 L 
Red Taq/Phusion polymerase     2 L /0.5 L 
DMSO        - 
H2O        - 
 
*For composition of Buffer G, see page 51 
 
The PCR amplification was performed using the above components with an increased 
DNA concentration of VH and VL (20 ng) with varying concentrations of DMSO and 
H2O investigating 2 different polymerases in the PCR. The PCR amplified reactions 
were as follows (i) supplemented with 2% (v/v) DMSO (ii) supplemented with 4% (v/v) 
DMSO (iii) supplemented with 6% (v/v) DMSO (iv) supplemented with 8% (v/v) 
DMSO (v) supplemented in 10% (v/v) DMSO (vi) positive control (in-house scFv) and 
(vii) negative control (no VH and VL template) for each tested polymerase. 
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The PCR conditions using the Red Taq polymerase were as follows; 
Steps   Temperature (
o
C)  Time (seconds) 
   1    94    60 
   2    69    30* 
   3    72    60 
Repeat Steps 1 3 thirty times 
   4    72    600 
   5    4    pause 
 
*Note: An annealing temperature decrease of 0.5
o
C after each successive cycle. 
The PCR conditions using the Phusion polymerase were as follows: 
 
Steps   Temperature (
o
C)  Time (seconds) 
   1    98    30 
   2    98    10 
   3    69    20* 
   4    72    30 
Repeat Steps 2 4 thirty times 
   5    72    600 
   6    4    pause 
 
*Note: An annealing temperature decrease of 0.5
o
C after each successive cycle. 
 
Other polymerases with proof reading capabilities were investigated. A number of 
polymerases were added to the PCR reaction to determine their influence on 
amplification.  
The various polymerases were (i) Red Taq, (ii) Phusion, (iii) Vent (NEB) and (iv) Pfu 
(Promega) polymerase. A touchdown PCR was performed using the above polymerases 
using the following reaction component compositions:  
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Component    L volume 
 5X Buffer G*       10 L    
 scForward Primer       1 L     
 scReverse primer      1 L 
 dNTP  mix        1 L     
 VH chain (20 ng DNA)     4 L     
 VL chain (20 ng DNA)     4 L 
Polymerase       0.25 L 
DMSO  (5 % (v/v))      2.5 L 
H20        - 
 
*For composition of Buffer G, see page 51 
 
The PCR amplification was performed using the above components with various 
polymerases (Red Taq, Phusion, Vent and Pfu) and H2O. The PCR amplifications were 
(i) supplemented with 5%  (v/v) DMSO using Red Taq polymerase (ii) supplemented 
with 5% (v/v) DMSO using Phusion polymerase (iii) supplemented with 5% (v/v) 
DMSO using Vent polymerase in buffer G (iv) supplemented with 5% (v/v) DMSO 
using Pfu polymerase in buffer G (v) supplemented in 5% (v/v) DMSO in Vent 
polymerase in Vent buffer (vi) supplemented with 5% (v/v) DMSO in Pfu polymerase 
in Pfu buffer (vii) positive control (in-house scFv) and (viii) negative control (no VH 
and VL template). 
 
The PCR conditions using the Red Taq polymerase were as follows; 
Steps   Temperature (
o
C)  Time (seconds) 
   1    94    60 
   2    69    30* 
   3    72    60 
Repeat Steps 1 3 thirty times 
 
   4    72    600 
   5    4    pause 
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*Note: An annealing temperature decrease of 0.5
o
C after each successive cycle. 
 
The PCR conditions using the Phusion, Vent and Pfu polymerase were as follows; 
Steps   Temperature (
o
C)  Time (seconds) 
   1    98    30 
   2    98    10 
   3    69    20* 
   4    72    30 
Repeat Steps 2 4 thirty times 
 
   5    72    600 
   6    4    pause 
 
*Note: An annealing temperature decrease of 0.5
o
C after each successive cycle. 
 
The proof reading polymerases did not enhance the amplification of the desired product. 
Therefore, the PCR amplification was performed with a number of DMSO 
concentrations (3%, 5%, 8% and 12% (v/v)) using Red Taq polymerase and the desired 
800 bp band was successfully amplified and large scale amplification performed. 
 
Components   50 L volume 
5X buffer G*        10 L 
Sc Forward primer       1 L 
Sc Reverse primer        1 L 
dNTP mix        1 L 
VH         4 L 
VL         4 L 
H2O          24.5 L 
5% (v/v) DMSO       2.5 L 
Red Taq polymerase       2 L 
  
*For composition of Buffer G, see page 51 
The PCR conditions using the Red Taq polymerase were as follows; 
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Steps   Temperature (
o
C)  Time (seconds) 
   1    94    60 
   2    69    30* 
   3    72    60 
Repeat Steps 1 3 thirty times 
   4    72    600 
   5    4    pause 
 
The amplified SOE-PCR product (scFv) was separated on a 1% (w/v) agarose gel, DNA 
excised and gel purified.  The DNA was quantified using the Nanodrop ND-1000 
spectrophotometer. The gel-purified DNA was incubated with the restriction enzyme 
SfiI (NEB) in parallel with the pAK 100 phagemid vector. 
 
2.2.9 pAK 100 vector purification using Wizard miniprep DNA purification system 
 
A single colony of E. coli  XL1-Blue cells harbouring the pAK 100 (all vectors were 
donated by Andreas Pluckthun, University of Zurich, Switzerland) was picked from a 
streaked agar plate and grown overnight at 37
o
C at 200 rpm in 2xTY media 
supplemented with 25 µg/mL chloramphenicol. The overnight culture was centrifuged 
at 4,000 rpm for 10 min at room temperature. The supernatant was discarded and the 
pellet thoroughly resuspended in 250 L cell resuspension solution. The suspension was 
transferred to a 1.5 mL sterile centrifuge tube and 250 L cell lysis solution added, 
inverted 4 times and incubated at room temperature for 5 min. The mixture was 
homogenised by inversion and incubated at room temperature for 5 min. Neutralisation 
solution containing guanidine hydrochloride, potassium acetate and glacial acetic acid 
(350 L) was added and mixed by inverting the tube, as indicated before. This solution 
causes the genomic DNA and proteins present in the solution to precipitate. The 
bacterial lysate was centrifuged at 14,000 rpm at room temperature for 10 min and the 
supernatant-containing plasmid DNA carefully transferred to a spin column and 
centrifuged at 14,000 rpm at room temperature for 1 min. The plasmid DNA binds to 
the membrane of the column which was washed using 750 L column wash solution 
(previously diluted in 100% (v/v) ethanol). The column was re-washed using 250 L 
column wash solution and centrifuged at 14,000 rpm at room temperature for 2 min. 
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The DNA membrane spin column was transferred to a new sterile 1.5 mL centrifuge 
tube and the plasmid DNA eluted using 100 L molecular grade H2O. The eluted 
plasmid DNA was stored at -20
o
C. 
 
2.2.10 SOE-PCR restriction using SfiI enzyme and ligation into pAK 100 vector for 
phage display analysis and ethanol precipitation 
 
The gel-purified scFv fragment and pAK 100 vector for phage selection were cut using 
SfiI restriction enzyme. The SfiI restriction enzyme allows for the unidirectional cloning 
of scFv fragment into the pAK 100 phage display vector. It recognises 8 bases which 
are interrupted by 5 non-recognised nucleotides (5ggccnnnnnggcc3), thus virtually 
eliminating internal digestion in antibody sequences. The fragments were incubated at 
50
o
C for 5 hours in a water bath.  
The pAK 100 vector and SOE-PCR fragment were digested using SfiI as follows: 
 
  Components    40 L volume 
  SOE-PCR product        1.23 L 
  NEB 10 X buffer 2        4 L 
  10 X BSA         4 L 
  H2O           24.77 L 
  SfiI          6 L 
 
  Components    40 L volume 
  pAK 100 vector        6 L 
  NEB 10 X buffer 2        4 L 
  10 X BSA         4 L 
  H2O           25 L 
  SfiI          1 L 
 
Following large scale digestion, the restricted pAK 100 vector and scFv fragment were 
gel-purified from a 1% (w/v) agarose gel using the Promega gel clean up kit. The DNA 
concentrations were determined on the Nanodrop ND-1000 spectrophotometer and the 
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purified scFv fragment ligated into the purified pAK 100 vector using a ratio of 3:1 
(insert to vector) using T4 DNA ligase overnight at 16
o
C.  
 
The ligation mixture contained the following components; 
  Components    60 L volume 
  pAK 100 vector        24 L 
  scFv fragment         14.62 L 
  5 X ligase buffer        12 L 
  H2O           7.28 L 
  NEB T4 DNA ligase        2 L 
 
After ligation the mixture was ethanol precipitated to remove any salt which would 
interfere with the electroporation and cause arcing. 
  Components    218 L volume 
  Ligation mixture        60 L 
  3 M sodium acetate        6 L 
  100% (v/v) ethanol        150 L 
  Novagen pellet paint        2 L 
 
The ligation mixture was stored overnight at -20
o
C. It was centrifuged at 14,000 rpm for 
20 minutes at 4
o
C and the pellet washed using 70% (v/v) ice cold ethanol. The mixture 
was centrifuged at 14,000 rpm for 10 min at 4
o
C and the pellet resuspended in 10 L of 
molecular grade H2O.  After precipitation the DNA was resuspended in a small volume 
of water sterile molecular grade H2O to ensure a high DNA concentration for the 
transformation. 
 
2.2.11 Preparation of electrocompetent E. coli cells 
 
The surface, pipettes, shaking incubator, culture flasks, centrifugation bottles and rotor 
were thoroughly bleached prior to electrocompetent cell preparation thus ensuring a 
clean working environment free of phage contamination. A 10 mL volume of SB 
medium supplemented with 30 µg/mL tetracycline was inoculated with a single E. coli 
colony picked aseptically from a freshly streaked agar plate and grown overnight at 
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37
o
C at 200 rpm. Three conical flasks each containing 500 mL of SB with 20% (w/v) 
glucose and 1 M MgCl2 were individually inoculated with 2.5 mL aliquots of the 
overnight culture. The flasks were shaken at 200 rpm at 37
o
C until the optical density 
(600 nm) reached 0.7. The conical flasks were then incubated on ice and chilled with 
the centrifugation bottles at 4
o
C for 15 minutes. The culture was carefully transferred 
into the pre-chilled centrifugation bottles and centrifuged at 4,000 rpm for 20 min at 
4
o
C. The supernatant was removed and the pellets resuspended in 25 mL of ice cold 
10% (v/v) glycerol. Two pellets were combined with 10% (v/v) glycerol and 
centrifuged at 4,000 rpm for 20 min at 4
o
C. The pellets were resuspended in 10% (v/v) 
glycerol and centrifuged at 4,000 rpm for 20 min at 4
o
C. The supernatant was removed, 
the pellet resuspended in 25 mL 10% (v/v) glycerol, transferred to prechilled 80 mL 
polypropylene tubes and centrifuged at 3,500 rpm for 15 min at 4
o
C. The supernatant 
was carefully removed without disturbing the pellet. It was resuspended in 5 mL 10% 
(v/v) glycerol, transferred to 1.5 mL centrifugation tubes, flash frozen in liquid nitrogen 
and stored at -80
o
C. 
 
2.2.12 Electro-transformation of XL-1 blue E. coli cells with an scFv-containing 
plasmid 
 
An aliquot of electrocompetent XL-1 blue E. coli cells were transformed with the 
ethanol precipitated ligation mixture (Section 2.2.10). This was executed using a Gene 
Pulser Xcell electroporation system with the controls set at 25 F, 1.25 kV and the 
Pulse Controller at 200 . The E. coli cells were thawed on ice and the ligated product 
carefully added to the cells, mixed, incubated on ice for 1 min, the mixture was 
transferred to an ice-cold 0.2 cm electroporation cuvette. The mixture was gently tapped 
to the bottom of the electroporation cuvette. The cuvette was placed in the ShockPod 
and the chamber lid closed. A pulse was passed through the suspension in the cuvette 
chamber. The cuvette was removed from the chamber and quickly flushed with pre-
warmed SOC medium (37
o
C). The electroporated cells were quickly resuspended using 
a sterile 1 mL filter tip. The period between applying the pulse and transferring the cells 
to the growth media is crucial for recovering E. coli transformants. A delay in transfer, 
even by 1 min, causes a 3-fold drop in transformation. The 1 mL suspension was 
transferred to a 20 mL sterile centrifugation tube and the cuvette flushed with a further 2 
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mL of SOC media. The transformed cells were shaken for 1 hour at 250 rpm (Sanyo 
orbital incubator) at 37
o
C. Serial dilutions of the transformed library were performed by 
diluting the library in SOC media and spreading 100 µL of each dilution on 2xTY plates 
supplemented with 25 g/mL chloramphenicol and 1% (w/v) glucose. The 3 mL library 
suspension was centrifuged at 4000 rpm for 10 min, resuspended in SOC media and 
uniformly spread on 2xTY plates supplemented with 25 g/mL chloramphenicol and 
1% (w/v) glucose. A vial containing non-transformed XL-1 blue E. coli cells (negative 
control) was plated out on agar plates with 25 g/mL chloramphenicol and 1% (w/v) 
glucose. The plates were incubated overnight at 37
o
C.  Individual colonies were counted 
on the dilution plates and the library size determined. The transformed colony stock 
plates were scraped using a spreader and the suspension centrifuged at 4,000 rpm for 10 
min. The cells were resuspended in 20% (v/v) glycerol-supplemented 2xTY media, 
transferred to sterile 1.5 mL centrifugation tubes and flash frozen in liquid nitrogen. The 
cell library stocks were stored at -80
o
C.  
 
2.2.13 Rescue of scFv-displaying phages and precipitation of phage-displayed 
fragments 
 
To rescue the scFv-displaying phages, a conical flask containing 200 mL 2xTY media 
with 2% (w/v) glucose and 25 g/mL chloramphenicol was inoculated with 200 L 
from the glycerol library stocks. The flask was shaken at 200 rpm and 37
o
C until the 
mid-exponential phase of growth was reached (OD600 ~ 0.400) and the contents then 
centrifuged at 4,000 rpm for 10 min at room temperature. The pellet was resuspended in 
fresh 200 mL 2xTY media with chloramphenicol (25 g/mL) and 2 x 1011 pfu/mL 
helper phage. The mixture was incubated without shaking for 30 min at 37
o
C enabling 
the initiation of the infection process (F pilus conjugation) of the E. coli cells. The 
culture was shaken at 200 rpm at 37
o
C for 2 hours, 50 g/mL kanamycin (helper phage 
resistance gene) added and the culture incubated overnight at 200 rpm at 30
o
C.  
 
2.2.14 Phage precipitation using PEG/NaCl 
 
The 200 mL culture was transferred to a sterile 250 mL Sorvall and centrifuged at 4,000 
rpm for 15 min at 4
o
C to remove the bacterial pellet. The phage were precipitated by 
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transferring the supernatant to a clean, sterile 250 mL Sorvall centrifuge tube and 
adding 8 g of PEG 8,000 (4% w/v) and 6 g of sodium chloride (3% w/v). The 
PEG/NaCl was dissolved by shaking the suspension at 180 rpm for 10 min at 37
o
C. The 
250 mL centrifuge tube was placed on ice for 1 hour at 4
o
C to precipitate and 
concentrate the phage-scFv particles. After incubation the centrifugation tube was spun 
at 8,000 rpm (7,649 x g) for 25 min at 4
o
C. The phage scFv pellet was resuspended in 2 
mL TE buffer in 2% (w/v) BSA solution. The resuspended phage scFv pellet was 
transferred to sterile 1.5 mL centrifuge tubes and centrifuged at 14,000 rpm (19,500 x g) 
for 5 min at 4
o
C. The supernatant containing phage scFv was placed on ice and stored at 
4
o
C until required for selection against the required antigen. 
 
2.2.15 Selection of antigen-binding phage scFv fragments by biopanning using 
immobilised antigens 
 
Immunotubes (Nunc, Maxisorp) were coated with 500 L of 50 g/mL fPSA overnight 
at 4
o
C. After blocking with 3% (w/v) BSA in PBS (150 mM, pH 7.4) for 2 hours at 
room temperature, 500 L of rescued phage were added and the tubes incubated on a 
roller mixer SRT1 (Stuart) for 2 hours at room temperature. The immunotubes were 
washed with PBST (x 3) and PBS (x 3). The washing steps remove any non-specific 
phage particles that do not bind the immobilised antigen which if not removed could be 
propagated in subsequent rounds of selection. PBST removes phage adsorbed due to 
non-specific hydrophobic interactions, while PBS removes phage adsorbed by non-
specific ionic interactions. Bound phages were eluted using 500 L of 100 mM glycine-
HCl, pH 2.2, for 10 min, removed and transferred to a sterile 1.5 mL centrifugation tube 
containing 30 L of 2 M Tris-HCl, pH 8.0, for neutralisation purposes. Half of the 
eluted phage (265 L) was added to mid-exponential phase (OD600 ~ 0.4) XL-1 Blue 
cells and allowed to infect for 30 min at 37
o
C without shaking for pilus retraction. After 
30 min the culture was shaken at 200 rpm for 1 hour at 37
o
C and centrifuged at 4,000 
rpm (3,824 x g) for 10 minutes at room temperature. The pellet was resuspended in 600 
L fresh 2xTY media and spread on 2xTY agar plates supplemented with 25 µg/mL 
chloramphenicol and 1% (w/v) glucose and incubated overnight at 37
o
C at 200 rpm. 
Input and output titres for each round of selection were performed by infecting E. coli 
cells and performing serial dilutions of the phage. The infected cells were incubated for 
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15 min at 37
o
C and 100 µL of each dilution spread on 2xTY agar plates containing 25 
g/mL chloramphenicol and 1% (w/v) glucose. The serial dilution plates were 
incubated overnight at 37
o
C. 
 
The input and output titres were calculated by counting the number of cells present on 
the dilution plates.  The stock plates containing the eluted phage were scraped using 
2xTY media for the next round of selection. The infected cells were grown in 100 mL 
of 2xTY media with 2% (v/v) glucose and 25 g/mL chloramphenicol until the mid-
exponential phase of growth was attained (OD600 ~ 0.4). The enriched cells were 
centrifuged and resuspended in glucose-free 2xTY media supplemented with helper 
phage. The helper phage were allowed infect the E. coli cells for 30 min at 37
o
C and the 
culture vigorously shaken for 2 hours at 37
o
C. After 2 hours, kanamycin was added and 
the culture was shaken at 200 rpm overnight at 30
o
C. In the second round of selection 
the antigen coating concentration on the surface of the immunotubes for antigen binding 
phage remained the same (500 µL of 50 µg/mL fPSA) but more stringent washes (PBST 
(x 5) and PBS (x 5)) were utilised to reduce non-specific binding of phage to the 
immobilised antigen. The phage were eluted in the same manner as described in the 
previous round of selection. Input and output phage plates were incubated at 37
o
C and 
XL-1 Blue cells infected with half of the eluted phage, incubated for 30 min at 37
o
C 
without shaking initially, then with shaking for 1 hour at 37
o
C and the cells were 
subsequently uniformly spread on 2xTY agar plates. The third round of selection 
involved using 100 mL 2xTY media containing 2% (v/v) glucose and 25 g/mL 
chloramphenicol with less antigen (500 L of 10 g/mL fPSA) coated on the surface of 
the immunotubes and an increased number of washes (PBST (x 10) and PBS (x 10) to 
enhance the selection process and ensuring enrichment of positive clones. The fourth 
round of selection involved rescuing the phage-scFv fragments in 100 mL of 2xTY 
media with 2% (v/v) glucose and 25 g/mL chloramphenicol and biopanning against 
500 L of 2 g/mL fPSA immobilised on the surface of the immunotubes with a further 
increase in the number of washing steps (PBST (x 10–15) and PBS (x 10–15)). After 
washing, an antigen challenge was performed which involved incubating fPSA (500 µL 
of 10 µg/mL) in the immunotubes for 10 min to remove any weakly binding phage-scFv 
fragments. Phage-scFv particles bound to the fPSA-coated immunotube were eluted and 
the phage infected into mid-exponential phase E. coli cells. During the fifth round of 
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biopanning, the immunotube was coated with 500 µL of 5 g/mL fPSA and washed 
(PBST (x 13) and PBS (x 13)). 
 
2.2.16 Polyclonal and monoclonal phage ELISA and scFv check. 
 
An ELISA plate was incubated with 100 L of 2 g/mL fPSA overnight at 4oC.  The 
fPSA was removed from the wells and a blocking solution of 3% (w/v) BSA in PBS 
(150 mM, pH 7.4) added to each well, plates were incubated for 1 hour at 37
o
C. The 
cells containing the rescued phage from the original library and each round of selection 
were grown in 10 mL 2xTY media until a culture OD600 ~ 0.4 was reached, and then 
centrifuged. The cells were resuspended in 2xTY media supplemented with helper 
phage, incubated for 30 min at 37
o
C without shaking, shaken at 200 rpm for 2 hour at 
37
o
C, kanamycin added and cultures incubated overnight at 30
o
C at 200 rpm to ensure 
protein expression. The cultures were centrifuged at 4,000 rpm (3,824 x g) for 10 min at 
room temperature and the phage supernatant diluted 10-fold in 1% (w/v) BSA PBST. 
One hundred L of diluted phage supernatant were added in duplicate to the plate and 
the plate was incubated for 1 hour at 37
o
C. After incubation the wells were washed with 
PBST (x 3) and PBS (x 3). After washing, 100 L of 1/3,000 dilution of a HRP-
conjugated anti-M13 antibody (Pharmacia) in 1% (w/v) BSA PBST were added and the 
plate incubated for 1 hour at 37
o
C. Binding of HRP-conjugated anti-M13 antibody was 
detected using TMB as substrate for HRP. This solution was left to develop for 20 min 
and the reaction quenched using 50 L of 10% (v/v) HCl. The absorbance was then read 
at 450 nm.  
 
Colonies (20) were randomly picked from the fifth round of biopanning and a colony 
pick PCR performed to ensure the presence of the scFv insert. 
The PCR amplification was performed as follows: 
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Components    Volume (154 L)  
  Buffer G     88 L 
  sc forward primer    8.8 L 
  sc reverse primer    8.8 L 
  DMSO      22 L 
  dNTPs      8.8 L 
  Red Taq polymerase    17.6 L 
 
Individual colonies were picked using sterile tips and mixed with the PCR components 
(above) and a PCR profile executed as follows: 
 
Steps   Temperature (
o
C)  Time (seconds) 
   1              94    60 
   2              69    30 
   3              72    60 
Repeat Steps 13 thirty times 
    4             72    600 
    5              4    Pause 
 
The amplified scFv fragments were resolved on a 1% (w/v) agarose gel. The polyclonal 
phage ELISA showed the high absorbance signal from round 5 of biopanning. 
Therefore, a monoclonal phage ELISA was performed on individual colonies selected 
from rounds 4 and 5 of biopanning. Individual colonies were grown in 200 L 2xTY 
media supplemented with 2% (v/v) glucose and 25 g/mL chloramphenicol in sterile 96 
well plates until the mid-exponential growth phase. The plates were centrifuged at 4,000 
rpm for 10 min at room temperature and the pellets resuspended in fresh 2xTY media 
(180 L) containing 25 g/mL chloramphenicol and helper phage. After 30 minutes 
incubation at 37
o
C the cultures were shaken for 2 hours at 200 rpm at 37
o
C.  After the 2 
hour incubation period 2xTY media (20 L) supplemented with 500 g/mL kanamycin 
was added to each well and incubated overnight at 30
o
C. 
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An ELISA plate, coated overnight with 100 L of 2 g/mL fPSA, was blocked with 200 
L of 3% (w/v) BSA in PBS (150 mM, pH 7.4) for 1 hour at 37oC. The overnight 
phage-scFv expressed cultures were centrifuged at 4,000 rpm for 10 min at room 
temperature.  One hundred µL of the supernatant was incubated with 100 µL of 1% 
(w/v) BSA in PBST for 1 hour at 37
o
C. The pre-blocked phage (100 L) were added to 
single wells for 1 hour at 37
o
C. Following washing with PBST (x 3) and PBS (x 3), 100 
L of HRP-conjugated anti-M13 antibody (1:3,000 dilution) were added to each well 
and the plate incubated for 1 hour at 37
o
C. The wells were washed using PBST (x 3) 
and PBS (x 3). The substrate, TMB, was added, incubated for 20 min and quenched 
using 10% (v/v) HCl. The absorbance was read at 450 nm.  
 
2.2.17 Inhibition phage ELISA 
 
Three individual clones were grown in 20 mL 2xTY media containing 2% (v/v) glucose 
and 25 g/mL chloramphenicol until the mid-exponential phase of growth was reached. 
The cultures were centrifuged at 4,000 rpm for 10 min at room temperature and the 
pellet resuspended in fresh 2xTY media (20 mL) supplemented with 40 L commercial 
helper phage (NEB) and 25 g/mL chloramphenicol. The mixture was placed at 37oC 
for 30 minutes without shaking and then shaken at 200 rpm for 2 hours at 37
o
C. The 
antibiotic kanamycin (20 µl of 50 µg/mL) was added, and the cultures shaken overnight 
at 30
o
C. An ELISA plate coated overnight with 100 L of 2 g/mL fPSA was blocked 
using 3% (w/v) BSA in PBS for 1 hour at 37
o
C. The cultures containing individual 
phage scFv clones were centrifuged at 4,000 rpm for 10 min at room temperature. The 
supernatant was incubated with various fPSA concentrations in 1% (w/v) BSA in PBS 
(final concentration 5 g/mL, 1 g/mL and 200 ng/mL fPSA) for 30 min at room 
temperature in 1.5 mL centrifugation tubes. Varying fPSA concentrations were 
incubated with the phage-scFv supernatant to determine if the selected clones were 
binding fPSA in solution. The supernatant for each clone containing no fPSA was 
diluted to ensure the same concentration for each selected clone. The phage 
supernatants (100 L) were added in triplicate to the ELISA plate and incubated for 1 
hour at 37
o
C. Any phage binding to the fPSA in solution was removed by the washing 
steps (PBST (x3) and PBS (x3)). An anti-M13 bacteriophage HRP-labelled antibody 
(1/3,000 dilution) was added to detect any phage-scFv fragments binding positively to 
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the adsorbed fPSA on the surface of the ELISA plate. The substrate, TMB, was added 
and the reaction quenched after 20 min by adding 50 L of 10% (v/v) HCl. The 
absorbance was read at 450 nm. 
 
2.2.18 ScAb expression vectors (pMoPAC 16 & 53), plasmid preparation and gel 
purification 
 
The pMoPAC series of vector DNA were kindly donated by Dr. Andrew Hayhurst 
(Department of Virology and Immunology, Southwest Foundation for Biomedical 
Research, 7620 NW Loop 410, San Antonio, TX 78227, USA). The DNA was 
transformed into E. coli XL-1 Blue cells using the Gene Pulser using the same 
procedure as previously described (Section 2.2.12). The transformed cells were rescued, 
spread uniformly on 2xTY agar plates, containing 25 g/mL carbenicillin and 2% (w/v) 
glucose, and incubated overnight at 37
o
C. A single colony containing the plasmid DNA 
was picked, used to inoculate 2xTY media containing 25 g/mL carbenicillin, cultures 
were grown overnight at 37
o
C. The plasmid preparation was performed using a Wizard 
miniprep kit as described in Section 2.2.9. Vector DNA was stored at -20
o
C until 
required. 
 
2.2.19 Vector and SOE-PCR product digestion 
 
The plasmid DNA and the scFv fragment were cut by incubation with the restriction 
enzyme SfiI for 5 hours at 50
o
C in a water bath. For soluble expression the scFv was 
subcloned into the pMoPAC vector from the pAK 100 phagemid vector. Plasmid 
purification was carried out on an overnight culture of the pan 5 rescue glycerol cell 
stock. The E. coli cells containing the scFv fragments from the fifth round of selection 
were chosen due to the large number of positive fragments represented in the polyclonal 
phage pool as determined by ELISA (Figure 3.9)  The plasmid DNA was subsequently 
amplified by PCR using the SOE primers to generate the scFv fragment.  
 
The murine anti-fPSA scFv was amplified from the plasmid DNA using the following 
components and PCR conditions: 
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  Components    Volume (500 L) 
  Plasmid DNA           20 L 
  Buffer G           50 L 
  sc forward primer          10 L 
  sc reverse primer          10 L 
  dNTPs            10 L 
  H2O             365 L 
  3% (v/v) DMSO          15 L 
  Red Taq polymerase          20 L 
 
Steps   Temperature (
o
C)  Time (seconds) 
   1            94    60 
   2            69    30* 
   3            72    60 
Repeat Steps 13 thirty times 
    4            72    600 
    5             4    Pause 
 
* 0.5
o
C decrease in annealing temperature after each consecutive completed cycle. 
 
The amplified scFv was gel-purified from a 1% (w/v) agarose gel and DNA quantified 
using the Nanodrop ND-1000 spectrophotometer. The recombinant pMoPAC vector 
DNA and the gel-purified scFv were digested using the restriction enzyme, SfiI, for 5 
hours at 50
o
C in a water bath. After digestion the fragments were resolved on a 1% 
(w/v) agarose gel and gel purified. The DNA was quantified using the Nanodrop ND-
1000 spectrophotometer and the scFv subcloned into the pMoPAC vectors. 
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Components    Volume (100 L) 
  pMoPAC 16 & 53 Vector         50 L 
  NEB 10 X buffer 2           10 L 
  10 X BSA           10 L 
  H2O             20 L 
  SfiI restriction enzyme         10 L 
 
  Components    Volume (50 L) 
  Mouse scFv insert          16.88 L 
  NEB 10 X buffer 2          5 L 
  10 X BSA           5 L 
  H2O             7.12 L 
  SfiI restriction enzyme         16 L 
 
2.2.20 Sub-cloning the restricted scFv fragment into the restricted vector fragments for 
scAb expression 
 
The gel-purified SfiI restricted scFv insert fragment was subcloned into scAb soluble 
expression vectors overnight.  
 
  Components   Volume (30 L) 
  pMoPAC 16 & 53 vector        4.66 L & 4.57 L 
  scFv fragment          12 L 
  NEB 5 X ligase buffer        6 L 
  H2O            2.34 L & 2.43 L 
  T4 ligase enzyme         5 L 
 
The ligated product was ethanol-precipitated and transformed into Tuner cells (Novagen 
Section 2.1.5) which were previously transformed with the pRARE plasmid (supplied 
by Dr. Paul Clarke, DCU, Ireland). The transformed cells were rescued using SOC 
media (3 mL) with shaking for 1 hour at 200 rpm (37
o
C). Serial dilutions were 
uniformly spread on 2xTY agar plates supplemented with 25 g/mL carbenicillin 
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(pMoPAC vector resistance) and stock plates incubated overnight at 37
o
C. The stock 
plates were scraped to prepare glycerol stocks which were stored in the -80
o
C freezer 
until required. 
 
2.2.21 Soluble expression of scAb fragments in pMoPAC 16 and pMoPAC 53 vectors 
 
Individual colonies were picked and grown in 2xTY media supplemented with 25 
g/mL carbenicillin overnight at 180 rpm at 37oC, in sterile 96 well plates. These 
colonies were used as back-up stocks for each positive clone selected. Twenty L from 
the overnight cultures were inoculated into fresh 2xTY media (180 L) containing 0.5 
% (v/v) glycerol and 0.05 % (v/v) glucose (final concentration) (1 x 505 – allows auto-
induction of cells without changing growth media) (Studier et al., 2005), 1mM MgSO4 
and 25 g/mL carbenicillin. The sterile 96 well plates were shaken at 37oC at 180 rpm 
until a cell density of ~0.600 (cells appear turbid) was achieved. A final concentration 
of 1 mM IPTG was added to each individual well and plates were shaken overnight at 
180 rpm at 30
o
C. An ELISA plate coated overnight with 100 L of 1 g/mL fPSA was 
blocked with 3% (w/v) BSA in PBS for 1 hour at 37
o
C. The expressed antibody culture 
lysate was extracted by placing the plates at -80
o
C for 10 min until frozen and then 
thawing the plates at 37
o
C. This freeze-thaw method of extraction bursts the E. coli cells 
releasing periplasmic proteins. This procedure was repeated 3 times in total and the 
plates centrifuged at 4000 rpm for 10 minutes at room temperature. One hundred L of 
scAb was added to the ELISA plate and incubated for 1 hour at 37
o
C. The plates were 
washed using PBST (x 3) and PBS (x 3) to remove non-specific proteins. The scAb was 
detected using 100 L of anti-human kappa C light chain antibody labelled with 
alkaline phosphatase (1/2000 dilution). The substrate, 4pNPP, was added, the plate 
incubated for 30 minutes at 37
o
C and the absorbance read at 405 nm.  
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2.3 Generation of chicken-derived anti-fPSA recombinant antibody library 
 
2.3.1 Removal of spleens from chickens immunised with fPSA, RNA extraction and 
cDNA synthesis 
 
Chickens (Leghorn females) were immunised between the ages of 5–8 weeks. When the 
titre was deemed sufficient (after 3
rd
 booster administration with over 1:100,000 
response determined by ELISA) for recombinant antibody library generation the spleens 
(2) were removed, RNA extracted, as described in Section 2.2.3, and cDNA synthesised 
by reverse transcription, as outlined in Section 2.2.4. The cDNA acted as the template 
for the generation of both chicken anti-fPSA scFv and Fab antibodies by PCR. 
Preparation of the chicken anti-fPSA scFv library involved amplifying the VH and VL 
chains separately and linking them with a glycine-serine linker, as described in Section 
2.2.8. The generation of the chicken anti-fPSA Fab library was more complicated and 
involved a number of essential steps: 
(i) amplifying the VH and VL chain genes separately, 
(ii)  performing the first PCR-overlap of the VH with the constant heavy chain (CH) 
and VL with the constant light chain (CL), 
(iii) final PCR-overlap of the VH/ CH with VL/ CL to generate the Fab. 
 
2.3.2 PCR Primers 
 
VH Primers 
CHybVH (forward) 
5-GCT GCC CAA GCC ATG GCC GCC GTG ACG TTG GAC GAG TCC 3 
CHybIg-B (reverse) 
5-CGA TGG GCC CTT GGT GGA GGC GGA GGA GAC GAT GAC TTC GGT 
CCC 3 
 
Vλ Primers 
CSCVK (forward) 
5-GTG GCC CAG GCG GCC CTG ACT CAG CCG TCC TCG GTG TC 3 
CHybL-B (reverse)  
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5-AGA TGG TGC AGC CAC AGT TCG TAG GAC GGT CAG GGT TGT CCC 
GGC 3 
 
CH Primers 
HIgGCH1-F (forward) 
5-GCC TCC ACC AAG GGC CCA TCG GTC 3 
dpseq (reverse) 
5-AGA AGC GTA GTC CGG AAC GTC 3 
 
CL Primers 
HKC-F (forward) 
5-CGA ACT GTG GCT GCA CCA TCT GTC 3 
Lead-B (reverse) 
5-GGC CAT GGC TGG TTG GGC AGC 3 
 
VH /CH  Overlap Primers 
LeadVH (forward) 
5-CGA ACT GTG GCT GCA CCA TCT GTC 3 
Dpseq (reverse) 
5-AGA AGC GTA GTC CGG AAC GTC 3 
 
Vl /Cl  Overlap Primers 
CSC-F (forward) 
5-GAG GAG GAG GAG GAG GAG GTG GCC CAG GCG GCC CTG ACT CAG 3 
Lead-B (reverse) 
5-GGC CAT GGC TGG TTG GGC AGC 3 
 
Primers for assembly of chimeric heavy chain with chimeric light chain sequence 
CSC-F (forward) 
5-GAG GAG GAG GAG GAG GAG GTG GCC CAG GCG GCC CTG ACT CAG 3 
dp-Ex (reverse) 
5-GAG GAG GAG GAG GAG GAG AGA AGC GTA GTC CGG AAC GTC 3 
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The primers listed above were obtained from Eurofins MWG (Anzinggerstr. 7a, 85560, 
Ebersberg, Germany) and are compatible with the primers set described by Barbas for 
the pComb vector system (Barbas et al., 2000). 
  
2.3.3 Amplification of VH and VL chain genes for Fab library generation 
 
Each PCR amplified chain (VH or VL) was resolved on an agarose gel, gel-purified and 
the purified DNA quantified using the Nanodrop ND-1000 spectrophotometer. The 
variable region genes were amplified using different concentrations of MgCl2 (1.5, 2.0, 
2.5 and 3.0 mM), respectively. MgCl2 promotes activity of the DNA polymerase and is 
a crucial component for successful amplification. The VH and Vλ chain genes were 
amplified by PCR using the following components and conditions: 
 
Component             L volume 
cDNA       1 L 
dNTP       1 L 
5 X Buffer (Promega)     5 L 
Forward Primer     1 L 
Reverse  Primer     1 L 
H2O        -  
Taq polymerase     0.25 L 
MgCl2       - 
 
Steps   Temperature (
o
C)  Time (seconds) 
   1    94    300 
   2    94    15 
   3    56    15 
   4    72    90 
Repeat Steps 2 4 thirty times 
   5    72    600 
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The constant heavy and light chains were amplified from the pComb3XTT vector by a 
co-worker (Dr. William Finlay) and used in the first SOE-PCR by joining the VH chain 
with the CH and VL chain with the CL chain genes. 
 
Component            20 L volume 
Variable region      1 L 
Constant region      1 µL 
dNTP        1 L 
5 X Buffer (Promega)      5 L 
Forward Primer      1 L 
Reverse Primer      1 L 
H2O         6.75 µL 
Taq polymerase      0.25 L 
MgCl2        3 µL 
 
Steps   Temperature (
o
C)  Time (seconds) 
   1    94    300 
   2    94    15 
   3    56    15 
   4    72    120 
Repeat Steps 2 4 fifteen times 
   5    72    600 
 
The heavy and light chain constructs were gel-purified, ethanol-precipitated and 
quantified using the Nanodrop ND-1000 spectrophotometer. The final SOE-PCR 
involved joining the 2 gel-purified domains to generate the Fab construct. The final 
overlap was performed using a Platinum Taq high fidelity polymerase (Bio Sciences 
Ltd., 3 Charlemont Terrace, Crofton Road, Dun Laoghaire, Dublin, Ireland) to eliminate 
the introduction of mutations in the construct which may inhibit binding to the antigen. 
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Component            50 L volume 
Heavy chain region     1 L 
Light chain region     1 µL 
dNTP       1 L 
10 X Buffer       5 L 
Sense Primer      0.5 L 
Reverse Primer     0.5 L 
H2O        38.8 µL 
Platinum Taq polymerase    0.2 L 
MgSO4      2 µL 
 
Steps   Temperature (
o
C)  Time (seconds) 
   1    94    300 
   2    94    15 
   3    56    15 
   4    72    180 
Repeat Steps 2 4 Twenty five times 
   5    72    600 
 
After large scale amplification, the construct was resolved on a 2% (w/v) agarose gel, 
purified and quantified using the Nanodrop ND-1000 spectrophotometer. The next stage 
involved SfiI digestion of both the gel-purified Fab construct and pComb3XSS 
phagemid vector at 37
o
C for 5 hours. 
 
Component             200 L volume 
Fab construct       60 µL 
10 x buffer 2        20 µL 
10 x BSA       2 µL 
SfiI        8 µL 
H20        110 µL 
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Component             200 L volume 
pComb3XSS        60 µL 
10 x buffer 2         20 µL 
10 x BSA        2 µL 
SfiI         8 µL 
H20         110 µL 
 
After gel purification, the digested overlap PCR product was ligated into the 
pComb3XSS vector (supplied by Barbas). The ligation was performed overnight at 
room temperature and the plasmid DNA ethanol precipitated at -20
o
C. The ethanol 
precipitate was centrifuged at 4
o
C and the pellet resuspended in molecular grade H2O. 
 
Component             400 L volume 
pComb3XSS vector       120 µL 
Fab construct       90 µL 
5 x ligase buffer      80 µL 
Ligase enzyme      10 µL 
H2O        100 µL 
 
2.3.4 Transformation into XL-1 Blue E. coli cells 
 
The ligation mixture was transformed into electrocompetent E. coli XL-1 Blue cells and 
the library size determined by counting the number of colonies from plate dilutions. 
Both chicken anti-fPSA scFv and Fab antibodies were selected by biopanning the phage 
against fPSA adsorbed onto the wells of ELISA plates. In the first round of biopanning 
8 wells of an ELISA plate were coated with 100 L of fPSA (10 g/mL), blocked with 
3% (w/v) BSA in PBS (150 mM, pH 7.4), and the eluted phage, after PEG precipitation, 
added to each well and allowed to bind for 1 hour at 37
o
C. Each well that contained 
phage was washed with PBST (x 3) and PBS (x 3). After washing 100 L of 10 mg/mL 
trypsin in PBS (150 mM, pH 7.4), was added to each well and the plate incubated for 30 
min at 37
o
C. The pComb 3XSS vector has a trypsin-sensitive site that is cut following 
the addition of trypsin. Phage were aspirated from the wells by pipetting the content of 
the wells vigorously i.e. removing the liquid in each and releasing it again into the well. 
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Half of the eluted phage (400 L) were added to mid-exponential phase E. coli XL-1 
Blue cells. The culture was placed at 37
o
C for 15 min and then shaken for 1 hour at 200 
rpm and 37
o
C. Input and output phage titres were determined, as previously described in 
the mouse anti-fPSA scFv biopanning protocol. In round two of selection, 2 ELISA 
plate wells were coated with 100 L of fPSA (10 g/mL) and in round three of 
selection, 1 ELISA plate well was coated with 100 L of fPSA (10 g/mL). The 
numbers of washing steps for each round of selection were PBST (x 5–10), PBS (x 5–
10 second round) and PBST (x 10–15) and PBS (x 10–15 third round), respectively. 
Gradually decreasing the concentration of antigen and increasing the washing 
stringency encourages the selection of positive antibody recombinant fragments from 
the generated library. Phage were eluted as before using 100 L of 10 mg/mL trypsin 
per well and used to infect E. coli XL-1 Blue cells. After each round of selection the 
infected E. coli cells were spread on 2xTY agar plates containing 100 g/mL 
carbenicillin and 2% (v/v) glucose. Individual colonies (5) from each round of 
biopanning were selected and a scFv check performed. This involved picking a colony 
and performing a scFv-specific PCR. The components and PCR conditions were as 
follows: 
   
Components    Volume (20 L) 
  Forward primer          0.2 L 
  Reverse primer          0.2 L 
  dNTPs            0.4 L 
  Buffer G           2 L 
  H2O             16.4 L 
  Red Taq polymerase          0.8 L 
 
Steps   Temperature (
o
C)  Time (seconds) 
   1            94    60 
   2            69    30 
   3            72    60 
Repeat Steps 13 thirty times 
    4            72    600 
    5             4    Pause 
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A polyclonal phage ELISA was performed, as described previously (Section 2.2.16), 
and colonies from round 3 of biopanning analysed for soluble expression of chicken 
anti-fPSA scFv fragments. Individual clones were selected from 2xTY agar plates, 
supplemented with 100 g/mL carbenicillin, and functionally expressed. The positive 
clones binding to fPSA on the surface of the ELISA plate were subjected to further 
examination.  A DNA fingerprinting assay was performed on 5 anti-fPSA Fab clones 
selected from the original library and 5 clones from the final round of selection. The 
clones were cut using a high frequency cutting enzyme, AluI to check for diversity. The 
DNA from the clones was resolved on a 3% (w/v) agarose gel. The eluted phage from 
both the chicken anti-fPSA scFv and Fab antibodies were used to infect E. coli 
TOP10F cells for soluble expression of the antibodies. Individual clones were picked, 
grown overnight at 37
o
C, sub-cultured into fresh 2xTY media supplemented with 1 x 
505 (50 % (v/v) glycerol and 5 % (v/v) glucose solution) and 1 mM MgSO4 and grown 
until turbid (OD600 ~ 0.6). Media supplemented with IPTG (1mM) was added to each 
clone and the plate shaken overnight at 30
o
C. Antibodies expressed in the periplasmic 
space were extracted from the E. coli cells using the freeze-thaw method and individual 
clones analysed by ELISA. The positive clones were stored in 2xTY media 
supplemented with 20% (v/v) glycerol at -80
o
C. High throughput screening of selected 
positive anti-fPSA clones were evaluated on the Biacore A100 by Dr. Paul Leonard and 
the data analysed. 
 
2.4 Murine anti-fPSA scAb analysis using the Biacore 3000 instrument 
 
Analysis of murine anti-fPSA scAb was performed on a Biacore 3000
TM
 instrument 
using a CM5 dextran chip. The running buffer was HBS buffer, pH 7.4, containing 10 
mM HEPES, 150 mM NaCl, 3.4 M EDTA, and 0.05% (v/v) Tween 20. The running 
buffer was passed through a 0.22 µm nylon filter and degassed using a Millipore 
filtration unit directly before use.  
 
2.4.1 Mouse monoclonal anti-human kappa light chain purification 
 
The mouse monoclonal anti-human kappa light chain clone KP-53, supplied in ascites 
fluid from Sigma, was purified by Protein G affinity chromatography. The Protein G-
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Sepharose 4B fast flow slurry resin (500 µL) was equilibrated using 20 mL of PBS (300 
mM, pH 7.4). An aliquot (200 L) of anti-human kappa light chain monoclonal 
antibody, diluted in 5 mL of PBS (300 mM, pH 7.4) was added to the resin. The 
solution was passed through the resin and re-circulated 5 times in total. The resin was 
washed using 20 mL of PBS (300 mM, pH 7.4), to remove the ascites fluid. The 
captured monoclonal antibody was eluted in 0.1 M glycine-HCl solution, pH 2.4. 
Collected fractions were neutralised with 1 M Tris-HCl solution, pH 7.5. The fractions 
were pooled and passed through a PD-10 desalting column (removal of low-molecular 
weight compounds) to remove any NaCl residue that may affect downstream processing 
(for successful immobilisation the ligand must be in a pure form). The PD-10 column 
was equilibrated with 20 mL H2O and the eluted protein G-purified fraction applied to 
the resin. The anti-human kappa light chain mAb passes quickly through the resin by 
size exclusion; 500 L fractions were collected. An Immunodot blot was performed 
using an AP-labelled anti-mouse antibody to determine the fractions containing the 
purified antibody. The fractions were pooled and centrifuged in a Millipore Amicon 
ultrafiltration device (Vivaspin 6 – 10,000 molecular weight cut-off) to ensure a high 
concentration for preconcentration studies and immobilisation.   
 
2.4.2 Biacore maintenance  
 
The Biacore instrument was cleaned using a ‗super desorb‘ program at 25oC. This 
method involves cleaning the unit thoroughly prior to starting an assay. It is imperative 
that the instrument is properly sanitized to remove any residual protein, thus, ensuring 
high-quality data and complete confidence in results generated. A maintenance chip was 
docked and primed 5 times with desorb solution 1 (0.5 % v/v sodium dodecyl sulphate 
(SDS)), once with water, 5 times with desorb solution 2 (50 mM glycine, pH 9.5), and, 
finally, 5 times with water.  
 
2.4.3 Preconditioning of the CM5 dextran sensor chip 
 
After docking the CM5 chip, the dextran layered surface was cleaned and hydrated 
using 2 consecutive injections each of 100 mM HCl, 50 mM NaOH and 0.5% (v/v) 
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SDS. These solutions were passed over each of the 4 flow cells for 10 seconds at a flow 
rate of 100 µL/min. 
 
2.4.4 Preconcentration studies  
 
To achieve maximum immobilisation of the desired protein to the sensor surface, 
preconcentration studies were performed. This important step results in an electrostatic 
interaction between the negatively charged carboxyl group-rich sensor surface and 
positively charged amine groups on the protein surface. At pH values lower than the 
isoelectric point (pI), the protein carries a ‗net‘ positive charge and this facilitates the 
binding event. The protein G-purified anti-human kappa light chain antibody diluted in 
10 mM sodium acetate solution at pH values of 4.0, 4.2, 4.4, 4.6, 4.8 and 5.0, was 
injected over a blank surface for 1 min at a flow rate of 5 µL/min. The pH at which the 
highest ‗apparent‘ binding was observed, compared to the underivatised surface and was 
used for immobilisation purposes. 
 
2.4.5 Immobilisation conditions 
 
The CM5 dextran surface is a three dimensional surface containing carboxyl groups 
(COOH) attached to the gold surface layer. It was activated by mixing equal volumes of 
400 mM EDC (N-ethyl-N-(dimethyl-aminopropyl) carbodiimide hydrochloride) and 
100 mM NHS (N-hydroxysuccinimide) and injecting the mixture over the surface for 7 
min at a flow rate of 10 µL/min. The EDC solution strips a H ion from the carboxyl 
group resulting in a negatively charged sensor surface. The NHS solution encourages 
binding of the amine groups in the protein to the COO
-
 -rich (negatively charged) 
surface. The anti-human kappa light chain, diluted in the appropriate pH buffer, was 
injected over the activated surface for 30 min at 10 µL/min. Unreactived NHS groups 
were capped, and deactivated and non-covalently bound proteins removed using 1 M 
ethanolamine hydrochloride, pH 8.5, for 10 minutes at 10 µL/min. After capping the 
surface was regenerated using 10 µL of 10 mM NaOH solution. 
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2.4.6 High throughput analysis of murine anti-fPSA scAbs using Biacore 3000 
 
A fPSA custom kinetics wizard program was created to analyse and appropriately rank 
the murine anti-fPSA scAbs selected from the library after biopanning. A capture assay 
format was designed for the analysis and subsequent ranking of the murine anti-fPSA 
scAbs. Each murine anti-fPSA scAb clone was grown in 20 mL 2xTY media 
supplemented with 100 g/mL carbenicillin, 1 x 505 (50 % (v/v) glycerol and 5 % (v/v) 
glucose solution), 1 mM MgSO4 and expressed overnight at 30
o
C after induction with 
ITPG. The cultures were centrifuged at 4,000 rpm (3,824 x g) for 10 min at 4
o
C, pellets 
were resuspended in 900 L PBST and the protein lysates extracted using the freeze-
thaw method. The bacterial pellets were centrifuged at 14,000 rpm (13,384 x g) for 10 
min and the lysate (900 µL) added to 100 L 10X BSA/CM dextran (120 mg/mL) 
solution to reduce the chance of non-specific binding to the dextran chip surface. The 
assay involved capturing three scAb clones on flow cells 2, 3 and 4 while leaving flow 
cell 1 blank for reference subtraction. Each murine anti-fPSA scAb was injected over 
the anti-human kappa mAb-immobilised surface for 5 min at a flow rate of 20 µL/min. 
After capturing 3 murine anti-fPSA scAbs, the fPSA (30 nM) was passed over the 
captured scAbs for 3 minutes at a flow rate of 30 µL/min. The fPSA molecule was 
allowed dissociate for 5 min over the captured scAbs and early and late stability 
responses recorded. HBS was passed over the captured scAbs and the binding response 
subtracted from the fPSA binding response. Thus, double subtractive referencing was 
employed. The chip surface was regenerated using a 30 second pulse of 20 mM NaOH 
at a flow rate 30 L/min. The percentage stability of each clone was determined by 
exporting the raw data for each curve generated using BIAevaluation software and 
evaluating it in Excel. Early stability report points were calculated for a 10 second 
period (between 10 and 19 seconds) starting 10 seconds after the end injection of 30 nM 
fPSA, while the late stability percentage report point was calculated for a 10 second 
period between 291 and 300 seconds. The complex stability was determined by dividing 
the stability late by the stability early. If the stability early was less than 5 RU it was 
discarded. Using a 68% complex stability cut-off of 30 nM fPSA remaining after 5 
minute dissociation, selected murine anti-fPSA scAbs were further analysed by kinetic 
analysis.  
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2.4.7 Kinetic analysis of selected clones using Biacore 3000 instrument 
 
The best performing murine anti-fPSA scAbs were captured on the anti-human kappa 
mAb-immobilised surface and various concentrations of fPSA (1, 0.5, 0.25, 0.125, 
0.063 and 0.03 g/mL) injected over the captured antibody using HBS buffer as a 
negative control for reference subtraction. The data were analysed using BIAevaluation 
software and the kinetic curves generated. Association and dissociation rate constants 
were calculated in addition to the affinities of each selected scAb. The calculated 
affinities were very similar to those determined by kinetic analysis.  
 
2.5 Murine anti-fPSA scAb clone sequencing  
 
The murine anti-fPSA scAbs were sent to Eurofins MWG for sequencing. The clones 
were sent as agar stab cultures in 1.5 mL centrifugation tubes supplemented with 
carbenicillin (100 µg/mL) and chloramphenicol (25 µg/mL) antibiotics. The DNA 
sequences for each scAb was received and the amino acid sequences determined. The 
heavy and light chain regions of the antibody were identified using the Kabat rules for 
antibody CDR regions. The programmes used for the amino acid sequence 
determination and alignment of the clones were found in the Expasy website. 
Expasy translate tool: http://www.expasy.ch/tools/dna.htmL 
ClustalW: http://www.ebi.ac.uk/Tools/clustalw2/index.htmL 
 
2.6 Selection of most sensitive murine anti-fPSA scAb by ELISA 
 
The affinities determined by Biacore were generally quite similar, with a 10-fold 
difference between the best and worst analysed scAb. Therefore, to determine the most 
suitable clones for assay development an ELISA was performed. The clones were 
expressed and the protein extracted by freeze-thawing. A plate coated overnight with 1 
µg/mL fPSA was blocked with 3% (w/v) BSA and serial dilutions of each scAb  
incubated for 1 hour at 37
o
C. Any binding scAbs were detected using AP-labelled anti-
human kappa antibody and 4pNPP as substrate. The absorbances were read at 405 nm. 
Once the optimal scAb dilution was calculated, an inhibition assay was performed with 
500, 333, 222, 148, 98, 66, 44, 29, 19.5, 13 and 8.67 ng/mL fPSA. These fPSA dilutions 
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were incubated with the optimal murine anti-fPSA scAb dilution for each clone for 1 
hour and added to the ELISA plate. After 1 hour incubation the wells were washed and 
any bound scAb detected using AP-labelled anti-human kappa antibody and 4pNPP as 
substrate. The absorbances of the wells were read at 405 nm and the scAb with the 
highest degree of inhibition selected for immunoassay design. 
 
2.7 Large-scale expression of a murine anti-fPSA scAb and subsequent purification 
using immobilised metal affinity chromatography (IMAC) 
 
Centrifugation tubes containing a culture of cells which have been induced overnight 
(500 mL SB media), was spun at 12,000 rpm (11,472 x g) for 10 min at 4
o
C. The pellets 
were resuspended in 30 mL of sonication buffer (1X PBS + 0.5 M NaCl + 20 mM 
imidazole). The resuspended pellets was transferred into thirty 2 mL centrifugation 
tubes (thirty one mL samples) and each sample sonicated on ice using the appropriate 
setting (40 amp for 45 seconds with 3 second intervals). The sonicated-scAb containing 
samples were centrifuged at 14,000 rpm (13,384 x g)  for 10 min at 4
o
C and the lysate 
was passed through a 0.2 m sterile filter. A 4 mL column of nickel NTA resin slurry 
(Qiagen) was prepared and equilibrated with 30 mL of running buffer (sonication buffer 
+ 1% v/v Tween). The filtered lysate was passed through the column once and the flow-
through collected. The column was washed with 30 mL of running buffer to remove any 
non-specifically adsorbed proteins. The recombinant antibody fragment was eluted with 
20 mL of 100 mM sodium acetate solution, pH 4.4. The eluted antibody fragment was 
collected in 1.5 mL centrifugation tubes (final volume 500 L in each tube) containing 
50 L 10X PBS (filtered through a 0.2 m filter) and 50 L 100 mM NaOH. An 
immunodot blot was performed on each eluted fraction where 2.5 L was spotted onto 
Whatman chromatography paper (0.45 µm Protran BA 85 nitrocellulose). The blot was 
blocked with 3% (w/v) BSA for 1 hour at room temperature on a rotation table. The 
membrane was washed with PBST (x 1) and PBS (x 1) and an AP-labelled anti-human 
C kappa antibody diluted in 1% (w/v) BSA in PBS was added to the blot for 1 hour at 
room temperature. After washing the blot with PBST (x 3) and PBS (x 3) the liquid 
substrate (BCIP) was added. The positive fractions were pooled together and added to a 
spin column with a 5,000 Dalton MWCO. This column was centrifuged at 4,000 rpm 
(3,824 x g)  at 4
o
C until concentrated to a volume of 500 L. Five mL of filtered PBS 
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was added to the column. This was stored on ice overnight at 4
o
C. The following day 
the sample was centrifuged at 4,000 rpm (13,384 x g) at 4
o
C until concentrated to a 500 
L volume. The concentration of protein was calculated on the Nanodrop ND-1000 
spectrophotometer and an SDS-PAGE and Western blot performed. The recombinant 
antibody was stored in 20 L aliquots at -20oC until required.  
 
2.8 Induced scAb cell expression profile 
 
A culture (100 mL SB media) supplemented with 100 g/mL carbenicillin, 25 g/mL 
chloramphenicol, 1 x 505 and 1 mM MgSO4 was inoculated with 500 L of the murine 
anti-fPSA scAb clone B5 culture and grown until an OD600 of 0.7 was reached. A 1 mL 
sample was removed from the culture and stored at -20
o
C. The culture was then induced 
with IPTG (1 mM final concentration) and shaken overnight at 30
o
C. One mL samples 
were removed from the culture every hour and stored at -20
o
C. The protein was 
extracted from each sample using the freeze-thaw method (-80
o
C, 37
o
C (x3)). 
Periplasmic extracts were analysed by SDS-PAGE, Western blot and ELISA.   
 
2.9 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
The following stock solutions were prepared for gel casting: 30% (w/v) acrylamide 
containing 0.8% (w/v) bis-acrylamide, 1.5 M Tris-HCl, pH 8.8, 0.4% (w/v) SDS, 0.5 M 
Tris-HCl, pH 6.8, 0.4% (w/v) SDS and 10% (w/v) ammonium persulfate. The glass 
plates were washed with acetone and sealed with a gasket and grips. Free radical-
induced polymerisation of the resolving gel acrylamide (Table 2.1) was catalysed by 
addition of ammonium persulphate and the accelerator TEMED and the gel added to the 
space between the plates and covered with a layer of ethanol. Following polymerisation 
of the gel, the ethanol was removed and the stacking gel placed directly onto the 
resolving gel. A plastic comb was placed in this gel creating the wells for sample 
application. Once the gel had fully polymerised, the plates were then placed in an 
electrophoresis chamber, the comb was removed and the chamber and wells filled with 
electrophoresis buffer (25 mM Tris, 250 mM glycine (electrophoresis grade), pH 8.3 
and 0.1% (w/v) SDS).  
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Table 2.1: SDS-PAGE gel reagents  
Solution Resolving Gel Stacking Gel 
30 % Acrylamide (w/v) 10 mL 1.66 mL 
Distilled Water 5.0 mL 5.75 mL 
Resolving Gel Buffer 5.0 mL - 
Stacking Gel Buffer - 2.5 mL 
Ammonium Persulphate 200 mL 70 mL 
TEMED 20 µL 14 µL 
 
The gel was removed from the casting tray apparatus and stained using Coomassie blue 
solution. The gel was transferred to destain solution and incubated until the protein 
bands were clearly visible.  
 
2.10 Western blotting 
 
The SDS-PAGE gel was resolved and the proteins transferred to nitrocellulose paper. 
The gel, extra thick blotting paper and nitrocellulose were incubated in transfer buffer 
for 20 min before the actual transfer. Extra thick blotting paper (Sigma - #P7176) was 
placed on the bottom of the transfer apparatus, the nitrocellulose was carefully placed 
on top of the blotting paper, the SDS-PAGE gel was added on top of the nitrocellulose 
and extra thick blotting paper placed over the SDS-PAGE gel. The proteins were 
transferred to the nitrocellulose using 15 V for 20 min. The nitrocellulose was carefully 
removed from the apparatus and placed in 3% (w/v) BSA solution for 1 hour. The 
membrane was washed and incubated with anti-human C kappa AP-labelled antibody in 
1% (w/v) BSA in PBST for 1 hour. The membrane was washed and BCIP liquid 
substrate carefully added to the blot. The reaction was quenched using 100 mM EDTA 
to stop the development of background colour. 
 
2.11 Avian clone analysis on Biacore A100  
 
The avian anti-fPSA scFvs and Fabs were analysed by Dr. Paul Leonard in Uppsala, 
Sweden using the A100 Biacore. An anti-Cλ surface was created on the surface of all 
four flow cells using amine coupling chemistry. Ninety six anti-fPSA Fab antibodies 
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were screened with each antibody tested against three fPSA concentrations (30, 5 and 0 
nM). The analysis consisted of 3 ‗start-up‘ cycles with buffer followed by 72 sample 
cycles. Each analysis cycle consisted of a 5 minutes injection of antibody across the 
whole flow cell. Free PSA (fPSA) was then injected for 2 minutes with a 10 minutes 
dissociation time. The surface was finally regenerated with a 30 second injection 
duration of 10 mM NaOH. The time required to analyse 96 anti-fPSA Fab was 26 hours 
in total. All sensorgrams were reference subtracted against an unmodified CM5 surface. 
The zero concentration was then subtracted from the 30 and 5 nM sensorgrams (double 
referencing) to remove any systematic instrument disturbances. A 1:1 Langmuir 
equation with a mass transfer term and two separate Rmax for the two surfaces was 
globally fitted to the data. Twenty six series were found acceptable (classified OK) by 
the software and the determined kinetic constants can be trusted. Seventeen were 
classified as inspect by the software but the reasons were either a large residual segment 
or low signal to noise ratios. 
 
Since a capture system was used and the baseline drift after the capture injection was 
significant a double referencing procedure was used before the % remaining calculation 
was performed. The report point at 0 nM fPSA was subtracted from the same report 
point collected at 30 nM fPSA. The % remaining after dissociation was calculated by 
dividing the response after 5 min dissociation (stability late response) with a report 
point placed immediately after the end of the sample injection (stability early response). 
 
2.12 Epitope Mapping of murine and avian anti-fPSA recombinant antibody 
fragments using the Biacore 3000 instrument 
 
Using an anti-human C kappa mAb-immobilised CM5 dextran chip (4-3 subtractive 
referencing) epitope mapping was investigated using fPSA sandwiched between a 
captured murine anti-fPSA scAb and avian anti-fPSA scFv/Fabs. The purified murine 
anti-fPSA scAb clone B5 was passed over the surface of the sensor chip for 6 min at a 
flow rate of 5 L/min.  An aliquot containing 30 nM fPSA (1 g/mL) was passed over 
the captured scAb for 2 min at a flow rate of 5 µL/min. The extracted avian clone 
lysates were passed over the captured fPSA molecule for 2 min at a flow rate of 5 
µL/min and the data analysed for binding. The surface was regenerated using 10 mM 
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NaOH solution for 1 min using an increased flow rate of 30 µL/min. Two negative 
controls were employed to ensure no non-specific binding to the anti-human C kappa 
mAb-immobilised surface or to the captured scAb fragment. FPSA (30 nM) was passed 
over the immobilised anti-human kappa mAb surface to ensure no non-specific binding 
to the surface had occurred. The other negative control involved passing the avian clone 
lysate directly over the captured murine anti-fPSA scAb with no fPSA intermediate 
molecule. No non-specific binding was observed. 
 
2.13 Biacore subtractive inhibition assay for the detection of fPSA using the purified 
murine anti-fPSA scAb 
 
After preconcentration studies, a CM5 dextran chip was immobilised with fPSA using 
EDC/NHS chemistry with approximately 6,968 RU binding. Regeneration studies were 
performed to ensure a reliable, reusable working surface. The murine anti-fPSA scAb 
was injected over the fPSA surface with 40 regeneration cycles using 10 mM NaOH 
solution.  The binding signal after each injection was measured to verify a suitable and 
stable working surface for assay development. Serial dilutions of the purified murine 
anti-fPSA scAb (1:50, 1:100, 1:200, 1:400, 1:800, 1:1,600, 1:3,200, 1:6,400, 1:12,800, 
1:25,600, 1:51,200 and 1:102,400) diluted in HBS buffer were injected over the fPSA 
immobilised surface for 2 min at a flow rate of 10 µL/min. The contact time of the 
murine anti-fPSA was evaluated by increasing the injection time from 2 min to 4 and 6 
min, respectively. The flow rate was evaluated to determine if more antibodies could 
potentially bind to the surface at a higher flow rate. The inhibition assay was performed 
using 2 murine anti-fPSA scAb dilutions (1:10,000 and 1:20,000 dilution) with a 
number of fPSA concentrations (1.56 g/mL, 312, 62.5, 12.5, 6.25, 2.5, 1.0 and 0.5 
ng/mL). These samples were incubated for 1 hour at 37
o
C and injected over the surface. 
A decrease in binding response was observed with increasing fPSA concentrations. 
Inter-day studies were performed at both scAb dilutions with coefficients of variation 
and percentages accuracies (determined for each concentration) back-calculated from 
the calibration curve.  
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2.14 Murine anti-fPSA scAb inhibition ELISA 
 
The optimal working dilution was determined by incubating serial dilutions (1:400, 
1:800, 1:1,600, 1:3,200, 1:6,400, 1:12,800, 1:25,600 and 1:51,200) of the murine anti-
fPSA in 1% (w/v) BSA PBST for 1 hour at 37
o
C on a pre-blocked fPSA-coated ELISA 
plate. The murine anti-fPSA scAb was detected using anti-human kappa AP-labelled 
antibody and 4pNPP as substrate. The plate was incubated for 30 min at 37
o
C and the 
absorbance read at 405 nm. The inhibition assay was performed using 2 scAb dilutions 
(1:10,000 and 1:20,000) with a number of fPSA concentrations (100, 66, 44, 29, 19, 13, 
8.7, 5.6 and 3.9 ng/mL). These samples were incubated for 1 hour and then added to a 
fPSA-coated plate which was subsequently incubated for 1 hour at 37
o
C. Binding was 
detected using anti-human C kappa AP-labelled antibody and 4pNPP as substrate. The 
absorbances of each well was determined at 405 nm. Inter-day studies were performed 
at both scAb dilutions with coefficients of variation and percentages accuracies, 
determined for each concentration, back-calculated from the calibration curve.  
 
2.15 Biacore sandwich assay using commercial anti-tPSA mAb (CanAg PSA 36 mAb) 
 
After pre-concentration studies, the anti-tPSA mAb was successfully immobilised 
(approximately 17,000 RU) onto the surface of a CM5 dextran chip using EDC/NHS 
chemistry. Aliquots of fPSA (10, 5, 1 g/mL, 500, 250, 125, 62.5, 31.25, 15.63 and 7.81 
ng/mL) were injected over the anti-tPSA mAb-immobilised surface and the data points 
exported into Excel and a graph plotted. Various dilutions of a commercial anti-fPSA 
mAb (CanAg PSA 30 mAb) (1:40,000, 1:32,000, 1:16,000, 1:8,000, 1:4,000 and 
1:2,000) and murine anti-fPSA scAb (1:40,000, 1:25,000, 1:20,000, 1:15,000, 1:10,000, 
1:8,000, 1:4,000, 1:2,000, 1:1,000 and 1:500) in HBS buffer containing 10X CM 
Dextran/BSA (120 mg/mL) were passed over 60 ng/mL captured fPSA at 20 µL/min for 
4 min. Non-specific binding was observed by injecting the diluted antibodies over the 
anti-tPSA mAb surface without the fPSA interface so the assay was unreliable as the 
detection antibody was binding non-specifically to the immobilised anti-tPSA mAb. 
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2.16 Biotinylation of purified murine anti-fPSA scAb for sandwich assay development 
 
The purified murine anti-fPSA scAb was biotinylated using the Pierce EZ-link 
biotinylation kit. The concentration of antibody and the levels of successful biotinylated 
were calculated as follows: 
 
A 20-fold molar excess of biotin reagent was incubated with the antibody to ensure a 
high ratio level of biotin per antibody molecule. The millimoles (mmol) of biotin 
reagent to add to the antibody to have a 20-fold molar excess were calculated using 
equation (A): 
 
(A) 560 µL scAb x 1.6 mg scAb  x   1 mmol scAb     x  20 mmol biotin  
               560 µL scAb     45,000 mg scAb       1 mmol scAb 
 
= 0.000711 mmol biotin 
To calculate microlitres of 10 mM biotin reagent solution to add to the scAb reaction 
equation B (below) was used: 
 
(B) 0.000711 x      557 mg  x    400 L 
mmol biotin       2.2 mg 
= 72 µL biotin added to 560 µL scAb 
 
557 = molecular weight of Sulfo-NHS-LC-biotin 
400 = microlitres of H2O in which 2.2 mg Sulfo-NHS-LC-biotin is dissolved to make a 
10 mM solution 
 
A vial of sulfo-NHS-LC-biotin was removed from the freezer and equilibrated at room 
temperature until required. The concentration of purified scAb (PBS) was calculated 
using the Nanodrop ND-1000 spectrophotometer and the scAb then placed on ice. A 10 
mM sulfo-NHS-LC-biotin solution was prepared immediately before use by dissolving 
2.2 mg sulfo-NHS-LC-biotin in 400 L ultra pure H2O. Twenty seven L of this 
mixture was incubated with the protein for 2 hours on ice. The NHS esters react to form 
stable amide bonds with primary amino groups of proteins. After an incubation period 
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of 2 hours the protein was buffer-exchanged to remove excess non-protein bound biotin. 
This was performed using a Zebra
TM
 desalt spin column. The column was initially 
centrifuged at 1,000 x g for 2 minutes to remove the storage buffer. The column was 
equilibrated with 2.5 mL of PBS 150 mM, pH 7.4 and centrifuged at 1000 x g for 2 min. 
The flow-through was discarded and this equilibration step was repeated twice. The 
biotinylated scAb sample was applied to the resin and allowed adsorb to the resin. The 
column was centrifuged at 1,000 x g for 2 min and the purified protein collected in the 
flow-through. This was immediately dispensed into 20 L volumes and stored at -20oC.  
 
The degree of biotin incorporation was determined using the HABA assay test 
(http://www.piercenet.com/files/1776gj4.pdf). This involved mixing the biotinylated 
antibody with a mixture of HABA and avidin. Due to the higher affinity of avidin for 
biotin, the HABA is displaced and this can be evaluated at 500 nm. One mg of avidin 
was mixed with 60 L of 10 mM HABA and 1.94 mL of PBS. One hundred and eighty 
L of this solution was dispensed into the well of a Nunc microtitre plate and the 
absorbance measured at 500 nm (A500 HABA/avidin). Twenty L of the biotinylated 
protein were added to the well and the solution was mixed using a plate shaker 
(IKA

MTS-2/4 digital-Lennox). The HABA/avidin/biotin absorbance at 500 nm was 
determined. The moles of biotin per mole of protein was calculated using the Beer 
Lambert Law  
 
     A=bC  
 
where A is the absorbance at a particular wavelength-no units for absorbance 
 is the absorptivity or extinction coefficient at the wavelength (). For HABA/Avidin 
at 500 nm the extinction coefficient is equal to 34000 M
-1
cm
-1
.  
b is the cell path length expressed in centimetres (cm). For the microtitre plate format 
the path length is 0.5 cm. 
C is the concentration of the protein sample expressed in molarity (= mol/L = 
mmol/mL) 
 
Other values needed to calculate moles of biotin per moles of scAb were 
Concentration of scAb in the reaction expressed as mg/mL, 
95 
 
Molecular weight of the scAb in grams per mole, 
Absorbance of HABA/avidin solution at 500 nm (A500 H/A) 
Absorbance of HABA/Avidin/biotin solution at 500 nm (A500 H/A/B) 
 
Calculation of mmol protein per mL 
 
mmol protein per mL = 1.18 mg/mL  
        45,000 
   = 0.00003 
 
The biotin was incubated with murine anti-fPSA scAb, the complex purified and the 
concentration of biotin linked to the scAb determined by adding the biotinylated scAb 
(B) with a HABA (H)/avidin (A) solution. Biotin has a higher affinity for avidin and the 
HABA becomes displaced. This can be measured spectrophotometrically at 500 nm. 
  
Calculation of change in absorbance after adding the biotinylated scAb to the 
HABA/avidin solution: 
 
∆ A500 = ((A500 (0.969) – (A500 (0.747)) 
                             = 0.222  
Calculation of the concentration of biotin in mmol per mL of reaction mixture 
 
        mmol biotin____  =      ∆ A (0.222)   
  mL reaction mixture          ( 34,000 x 1)  
                             = 0.00000653 
 
Calculation of mmol of biotin per mmol of protein 
 
=             (0.00000653) (10) (dilution factor)  
       0.00002622 mmol per mL protein in original sample 
                              = 2.49 mmol biotin per mmol scAb 
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2.17 ELISA-based assay for detection of biotinylated murine anti-fPSA scAb B5 
 
The biotinylated scAb was analysed by ELISA to determine the optimal working 
dilution for an inhibition assay. The unbiotinylated scAb was used as a negative control 
to ensure no non-specific binding between the secondary extrAvidin-HRP-labelled 
antibody and the purified murine anti-fPSA scAb. A plate was coated with 1 g/mL 
fPSA, blocked with 3% (w/v) BSA in PBS and serial dilutions (1:100, 1:200, 1:400, 
1:800, 1:1600, 1:3200, 1:6400, 1:12800 and 1:51200) of the biotinylated and 
unbiotinylated scAb in 1% (w/v) BSA in PBST added in duplicate to replicate wells. An 
extrAvidin-HRP-labelled antibody was added and this was detected using TMB 
substrate. The reaction was quenched after a 10 minute period and the absorbance read 
at 450 nm.  
 
2.18 Sandwich assay development for improved assay sensitivity 
 
A sandwich ELISA using the purified anti-fPSA biotinylated scAb as the capture 
antibody and avian anti-fPSA clone lysates (1 scFv and 4 Fab) as detection antibodies 
was investigated. A plate was coated using 5 g/mL neutravidin in PBS (150 mM, pH 
7.4) for 1 hour at 37
o
C. The wells were blocked using 3% (w/v) BSA in PBS for 1 hour 
at 37
o
C, washed with PBST (x 1) and PBS (x 1) and incubated with biotinylated murine 
anti-fPSA scAb for 1 hour at 37
o
C. The wells were washed with PBST (x 2) and PBS (x 
2) and a number of fPSA concentrations (100, 10, 1 and 0.1 ng/mL) were added to 
individual wells, in duplicate, for 1 hour at 37
o
C. Any binding of fPSA was detected 
using avian anti-fPSA clone lysates to determine whether the selected clones bind 
different epitopes on the fPSA molecule. The wells were washed again with PBST (x 3) 
and PBS (x 3) and an anti-HA-HRP-labelled secondary antibody added for 1 hour at 
37
o
C. The wells were washed with PBST (x 3) and PBS (x 3). The substrate, TMB, was 
added and plates were incubated for 10 min at room temperature. The reaction was 
quenched using 10% (v/v) HCl and the absorbance read at 450 nm. The avian anti-fPSA 
scFv was successfully purified by IMAC and utilised in a sandwich assay format. 
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2.19 Biacore sandwich assay using a neutrAvidin-immobilised CM5 dextran surface  
 
After pre-concentration studies the neutravidin was successfully immobilised onto the 
surface of a CM5 dextran chip (24425 RU). The biotinylated murine anti-fPSA scAb 
was injected over flow cell 2 and the captured levels recorded. Aliquots of fPSA (1 
g/mL, 500 ng/mL, 250 ng/mL, 125 ng/mL, 62.5 ng/mL, 31.75 ng/mL, 15.75 ng/mL, 
7.5 ng/mL, 3.9 ng/mL, 1.9 ng/mL and 0.8 ng/mL) in HBS buffer were injected over the 
captured biotinylated scAb at a flow rate of 10 L/min for 2 min using subtractive 
referencing (2-1). The purified avian anti-fPSA scFv (1:500 dilution) was injected over 
the captured fPSA using a flow rate of 30 µL/min for 2 min. The surface was 
regenerated using a 30 second pulse of 2.5 mM NaOH solution. 
 
2.20 ELISA sandwich assay using a neutravidin-coated ELISA plate 
 
A plate (Nunc Maxisorp) coated with 5 µg/mL neutrAvidin in PBS (150 mM, pH 7.4) 
for 1 hour at 37
o
C was blocked using 3% (w/v) BSA in PBS for 1 hour at 37
o
C and 
washed using PBST (x 1) and PBS (x 1). An aliquot containing 1 µg/mL biotinylated 
scAb (1:1,000 dilution) was incubated for 1 hour at 37
o
C and the plate washed with 
PBST (x 2) and PBS (x 2). Serial dilutions of fPSA (25, 18.75, 14, 10.5, 7.9, 5.9, 4.45, 
3.33, 2.5, 1.8, 1.4, 1.0, 0.79 and 0.59 ng/mL) in 1% (w/v) BSA in PBST were incubated 
for 1 hour at 37
o
C. After washing with PBST (x 3) and PBS (x 3), the four anti-PSA 
antibodies, (i) avian anti-fPSA scFv (1:100 dilution),  (ii) commercial anti-fPSA mAb 
(PSA 30) (1:1,000 dilution), (iii) commercial anti-tPSA mAb (PSA 36) (1:1,000 
dilution) and (iv) commercial anti-cPSA mAb (PSA 53) (1:1,000 dilution) were 
incubated in individual wells for 1 hour at 37
o
C in 1 % (w/v) BSA in PBST. The plate 
was washed with PBST (x 3) and PBS (x 3) and each antibody detected. The avian anti-
fPSA scFv was detected using HRP-labelled anti-HA antibody (1:2,000 dilution) and 
the commercial antibodies with HRP-labelled anti-mouse IgG (1:2,000 dilution) 
prepared in 1% (w/v) BSA in PBST, following incubation for 1 hour at 37
o
C. The plate 
was washed with PBST (x 3) and PBS (x 3), substrate, TMB was added and the plate 
incubated for 10 min and the reaction quenched using 10% (v/v) HCl. Absorbance 
values were read at 450 nm. 
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2.21 Neutravidin ELISA plate coating concentration optimisation for improved 
sandwich assay performance 
 
Previous experience within the Applied Biochemistry Group indicated that a high 
coating concentration of neutravidin was required for a workable assay format. 
Therefore, a plate was coated with 10 µg/mL and 5 µg/mL neutrAvidin for 1 hour at 
37
o
C. After the plate was blocked with 3% (w/v) BSA in PBS, a 1 µg/mL solution of 
biotinylated scAb was added to plate wells and the plate incubated for 1 hour at 37
o
C. 
After washing, a range of fPSA concentrations (25, 18.75, 14, 10.5, 7.9, 5.9, 4.45, 3.33, 
2.5, 1.8, 1.4, 1.0, 0.79 and 0.59 ng/mL) were incubated (in duplicate) for 1 hour at 37
o
C. 
After washing the avian anti-fPSA scFv (1:1,000 dilution) was added for 1 hour at 37
o
C 
and this was detected using anti-HA-HRP-labelled antibody and TMB as substrate. The 
reaction was quenched using 10% (v/v) HCl and absorbance read at 450 nm. The 
optimal coating concentration determined was 5 µg/mL neutravidin. 
 
2.22 TMB incubation time optimisation 
 
The sandwich assay was repeated using the optimised conditions, as described in 
Section 2.21, and the TMB incubation time was evaluated. The substrate was incubated 
for 10 and 20 min, respectively, before quenching with 10% (v/v) HCl. The absorbance 
was read at 450 nm. The sensitivity of the assay was improved using a longer TMB 
incubation period with no increase in background signal. Therefore, by incubating the 
substrate for 20 min a more sensitive assay was achieved.  
 
2.23 Inter-day and intra-day studies on sandwich assay for precision and accuracy 
determination 
 
Inter-day and intra-day assay studies were performed on the sandwich ELISA using the 
optimised neutravidin coating concentration and biotinylated scAb dilution with a 20 
min TMB incubation period. Calibration curves were generated for both assay formats 
using BIAevaluation software and the data points exported. The curves were generated 
in Excel and the coefficient of variation and percentages accuracies calculated for each 
concentration of fPSA.  
99 
 
2.24 Determination of the limit of detection (LOD) for fPSA in samples 
 
A sandwich ELISA was performed using 20 blank replicates (1% (w/v) BSA in PBST) 
with 20 replicates of 2.5 and 1.8 ng/mL fPSA diluted in 1% (w/v) BSA PBST (150 mM, 
pH 7.4), respectively. Binding of fPSA was detected using the avian anti-fPSA scFv 
clone (1:500 dilution), plates were washed with PBST (x 3) and PBS (x 3), then 
incubated with HRP-labelled anti-HA antibody, washed again using PBST (x 3) and 
PBS (x 3), and finally detected with TMB substrate, the reaction was quenched after 20 
min using 10% (v/v) HCl. The absorbance was read at 450 nm. The LOD of the assay is 
defined as where one can detect with 95% confidence at least 19 out of 20 positive 
samples mixed with 20 negative samples. It is the lowest concentration of analyte where 
a response can be reliably distinguished from the background.  
 
2.25 Sandwich assay in spiked female serum 
 
Blood was kindly donated by female members within the DCU faculty and centrifuged 
at 3,500 rpm for 10 min. The serum was aliquoted and stored at -20
o
C. An inter-day 
sandwich assay using the biotinylated scAb as the capture antibody and the avian scFv 
as the detection antibody was performed using fPSA-spiked female serum. A number of 
concentrations of fPSA (25, 18.75, 14, 10.5, 7.9, 5.9, 4.45, 3.33, 2.5, 1.8, 1.4, 1.0, 0.79 
and 0.59 ng/mL) were added to the plate. The assay was repeated over 3 days and the 
coefficient of variation and percentages accuracies determined from the calibration 
curve.  
 
2.26 Patient serum sample analysis 
 
Serum samples from patients with PCa were kindly donated by Professor William 
Watson, Conway Institute, UCD, Belfield, Dublin and stored at -80
o
C. The individual 
samples with known tPSA concentrations, but unknown fPSA concentrations, were 
analysed in duplicate using the sandwich assay format. A calibration curve was 
generated and the unknown concentrations back-calculated from the curve data. The 
concentration of fPSA was determined for each sample analysed and compared to the 
tPSA concentration for the appropriate sample.  
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2.27 Immunohistochemical analysis  
 
2.27.1 Sample preparation for murine and avian anti-fPSA analysis (by hand) 
 
Representative full face sections from 2 radical prostatectomy cases of PCa were 
examined for PSA expression. The sections consisted of histologically benign glands 
and prostate adenocarcinoma. Suitable formalin-fixed paraffin embedded blocks from 
the cases were collected, sections (4 µm thick) from the formalin fixed paraffin 
embedded blocks were cut using a microtome (Leica RM2135 Rotary Microtome) and 
mounted onto VBS Glass Slides Plus (S21.1910.110, Leica). The sections were dried 
overnight at 37°C. 
 
2.27.2 Immunohistochemistry using avian and murine anti-fPSA recombinant antibody 
fragments  
 
Parraffin sections were deparaffinized with two 5 min incubations in clean xylene 
followed by three washes with absolute ethanol and finally by distilled water. Antigen 
retrieval was carried out by incubating the sections in tri-sodium citrate (10 mM), pH 
6.0, for 15 min, at high power, in a microwave oven prior to immunohistochemical 
staining. After incubation the slides were rinsed for 5 min (x 2) in Tris buffer saline 
(TBS – 150 mM, pH 7.6) followed by endogenenous peroxidase blocking in blocking 
buffer (Envision Kit (HRP), K4006, Dako) at room temperature. The sections were then 
washed for 5 minutes (x 2) in TBS and incubated with primary antibody (1:100 dilution 
avian anti-fPSA scFv and murine anti-fPSA scAb) for 1 hour. After rinsing in TBS for 5 
min (x 3) the sections were incubated with HRP-labelled anti-HA antibody. The 
sections were washed with TBS for 5 min (x 3) and incubated with DAB chromagen 
substrate (Envision Kit (HRP), K4006, Dako) for 10 min at 37
o
C. The reaction was 
quenched by immersing the sections in distilled water. The sections incubated with the 
DAB chromogen (Envision Kit (HRP), K4006, Dako) were counterstained with 
haematoxylin (RBA-4213-00A, Reagecon), dehydrated, and the cover slip applied using 
an automated coverslip machine (Shandon Consul Coverslipper). The tissue sections 
were visualised under high magnification (100 x magnification). 
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2.27.3 Protocol for immunohistochemistry for diagnostic antibody to PSA (Dako) 
(automated immunohistochemistry) 
 
Deparrafinization, antigen retrieval and immunohistochemistry were performed on the 
paraffin-embedded 4 µm tissue sections using an automated IHC platform (Bond 
Max
TM 
- Leica Microsystems). A polymer-based detection system with 3,3-
diaminobenzidine (DAB) as the chromogen was used for the generation of a brown 
colour. The optimal antigen retrieval, concentration of primary antibody and antigen 
retrieval for PSA (anti-PSA monoclonal A0562, Dako) of 1:15,000 ER 1 for 20 min 
(Epitope retrieval method 2 Bond Max
TM 
- Leica Microsystems) were determined by 
serial dilution. The maximum signal without background immunostaining using the 
appropriate positive control was determined. Sections were counterstained with 
haematoxylin, dehydrated, and cover slip applied. The tissue samples were visualised 
under high magnification (100X magnification).  
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Chapter 3 
 
The generation of recombinant antibodies 
to human prostate-specific antigen using 
avian and murine immune systems 
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3.1 Introduction 
 
This chapter gives an insight into the generation of recombinant antibody fragments, 
phage library construction and includes an in-depth overview on the process of selecting 
positively binding anti-fPSA-specific antibodies. Phage display is the predominant 
technique utilised in recombinant antibody selection. A phage is a virus capable of 
infecting male E. coli cells and replicating without causing cell lysis. Random segments 
of DNA can be inserted into the phage particle and amplified in bacterial cells. 
Antibody variable genes are commonly inserted into the coat protein of the phage and 
expressed on the surface of the phage after superinfection with helper phage (Oh et al., 
2007). The phage-scFv particle can be isolated using solid phase selection with the 
cognate antigen. A major advantage of using phage display is the link between the 
phenotype (protein) and corresponding genotype DNA (Schmitz et al., 2000) allowing 
for selection of antigen-specific phage clones. The gene encoding the displayed protein 
is within the phage-scFv particle and this can easily be re-infected into E. coli cells for 
propagation and further affinity maturation. 
 
Recombinant antibody technology is an alternative approach to hybridoma technology 
for generating antibodies. Recombinant antibodies can be developed using many animal 
sources as long as the genome in known (Schmitz et al., 2000). Chickens have become 
an ideal immunological host for the generation of recombinant antibodies due to the 
selection of high affinity antibodies against highly conserved mammalian proteins 
(Leonard et al., 2007). Desired clones may be selected using high throughput automated 
screening facilities whereby 1,000–10,000 clones or more can be rapidly identified 
(Buckler et al., 2008). It is important to note that since there is less germ-line diversity 
in chickens than in mice and humans, fewer primers are required for amplifying heavy 
and light chains. (Barbas et al., 2001). 
 
The major advantage of using immunised animals over the conventional naïve antibody 
library is that the host animal immune system refines specificity towards the cognate 
antigen. This increases the possibility of selecting high affinity antibodies from a 
generated recombinant antibody fragment library due to in vivo affinity maturation 
(Schmitz et al., 2000). Although naïve libraries are becoming more popular for 
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recombinant antibody selection they lack the diversity of the immune system (somatic 
hypermutation) for generating a large panel of different antibodies.  
 
Mice and chickens were immunised with the fPSA molecule according to protocols 
described by Krebber et al. (1997) and Barbas et al. (2001), respectively. The animals 
were sacrificed, the spleens were harvested and the ribonucleic acid (RNA) extracted 
with Trizol reagent using a well established protocol (Section 2.2.3 Barbas et al., 2001). 
The amplified antibody variable genes were assembled by splice by overlap extension 
polymerase chain reaction (SOE-PCR Section 2.2.8) and ligated into the pAK 100 
(murine scFv) and pComb3XSS (avian scFv/Fab) vectors for ‗biopanning‘ (Section 
2.2.15). This is a selection process whereby antigen-specific clones are recovered and 
enriched for subsequent rounds of panning.  
 
3.2 Murine antibody library generation 
 
The Krebber system for recombinant antibody fragment generation allows for the 
reliable cloning of functionally active antibody variable domains from a secreting 
hybridoma cell or spleen primed cells (lymphocytes Krebber et al., 1997). This system 
was successfully employed to generate a murine recombinant antibody fragment library 
(Section 2.2.12) from the spleen cells of Balb/c mice immunised with fPSA.  
 
3.2.1 Mice immunisation with fPSA antigen 
 
Balb/c mice were subcutaneously immunised with fPSA over a period of 3 months and 
the serum extracted from the tail of the mouse analysed by ELISA to determine the 
antibody titre (level of immune response Section 2.2.2). The antibody serum titre was 
determined to ensure fPSA-specific antibodies were being generated and the titre was 
sufficiently high for recombinant antibody library production. The specific antibody 
titre obtained was 1/100,000 when screened against fPSA (Figure 3.1). The mouse was 
sacrificed to harvest the B cells from the spleen for recombinant antibody library 
generation and selection of positive antibodies to fPSA. 
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Figure 3.1: Titration of serum antibodies. Serum was harvested from the tail of mice immunised 
with fPSA and an antibody serum titre determined by ELISA. Bound murine antibodies were 
detected using alkaline phosphatase (AP)-labelled anti-mouse antibody followed by the addition 
of 4pNPP substrate. The absorbance was read at 405 nm. A high signal was observed at the 
1:4,000 dilution and gradually decreases with decreasing concentration of antibody. At 
1:128,000 dilution the signal is twice the background and sufficiently high for recombinant 
antibody library generation. 
 
3.2.2 Primer selection for murine heavy and light chain gene amplification 
 
The primer sets for the amplification and assembling of the mouse variable light and 
variable heavy chain domains are listed in Section 2.2.5. The respective gene fragments 
(VH and VL) were amplified by PCR using these primers after successful RNA 
extraction and cDNA synthesis. The gene fragments were gel purified, and coupled with 
a 20 amino acid glycine-serine repeat linker. The PCR amplified recombinant antibody 
fragment was compatible for use with the Krebber pAK series of vectors for selection. 
The gel-purified scFv fragment and pAK 100 vector were digested for 5 hours at 37
o
C 
using the SfiI restriction enzyme. The restricted fragments were gel-purified, quantified 
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using a Nanodrop ND-1000 spectrophotometer and ligated overnight at room 
temperature using T4 DNA ligase. This enzyme catalyses the formation of covalent 
phosphodiester bonds between the 3 hydroxyl end and the 5 phosphate end. The 
ligated mixture was precipitated using ethanol to concentrate the ligated DNA and to 
remove any contaminating salts which may interfere with the efficiency of 
electroporation (arcing is a problem often associated with electroporation where the 
sample is too conductive due to salt concentration and therefore for library construction 
it is vitally important to remove any residual salt prior to transformation). The DNA was 
transformed into electrocompetent E. coli XL-1 Blue cells, rescued and recovered on 
chloramphenicol (pAK 100 vector resistance gene) supplemented agar plates. The 
library size (2.02 x 10
6
 cfu/mL) was calculated, as described in Section 2.2.12, and the 
library subjected to 5 rounds of selection on fPSA-immobilised immunotubes. 
Immunotubes offer high binding capacity with a large surface area for maximum 
antigen immobilisation and recovery of potential clones. The phage-scFv particles were 
incubated in the fPSA-coated immunotube, eluted after washing and propagated in E. 
coli cells. 
 
3.3 Isolation of RNA from murine B cells (spleen) and first-strand DNA synthesis 
 
The spleen was removed from the immunised mouse and carefully homogenised in 
Trizol reagent. The total RNA was extracted from the tissue sample, quantified using a 
Nanodrop and first-strand cDNA synthesised by reverse transcription. The RNA and 
cDNA were resolved on a 1% (w/v) agarose gel (Figure 3.2) to confirm the presence of 
good quality templates for further gene amplification.  
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Figure 3.2: Preparation of cDNA by reverse transcription of RNA isolation from the B 
lymphocytes from a mouse spleen. Lane 1, 1 kb
+
 DNA molecular weight marker; lane 2, the 
cDNA and lane 3, the extracted RNA. 
 
Good quality RNA and DNA were extracted from the spleen of the immunised mouse 
(Figure 3.2). The cDNA template was used in the amplification of the mouse variable 
heavy and light chain genes using a range of different buffers. The variable genes were 
successfully amplified by PCR (Figure 3.3) and large scale amplification was 
performed. 
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3.4 PCR buffer optimisation for murine variable heavy and light chain generation 
 
 
Figure 3.3: VH and VL chain optimisation using different buffer compositions. The buffer 
composition used for each variable chain PCR amplification was as follows: buffer A (7.5 mM 
MgCl2, pH 8.5), buffer B (10 mM MgCl2, pH 8.5), buffer D (17.5 mM MgCl2, pH 8.5), buffer G 
(12.5 mM MgCl2, pH 9.5). Lane 1 and 10, 1 kb
+
 DNA molecular weight marker; lanes 2–5:  VH  
chain  amplification using buffers A, B, D and G, respectively, and lanes 6–9 represent VL chain 
amplification using buffer A, B, D and G, respectively. 
 
The buffer composition that yielded the greatest amplification was buffer G. The role of 
MgCl2 in the PCR is to promote DNA/DNA interactions and to form complexes with 
dNTPs. The gel-purified DNA encoding VH and VL fragments were linked by splice-by 
overlap extension PCR (SOE-PCR) whereby the purified fragments were joined by an 
oligonucleotide encoding 20 amino acid glycine-serine linker (G4S)4. A smaller linker 
would cause multimerisation of the scFv and this longer linker provides sufficient 
flexibility for the VH and VL domains to associate predominantly as scFv monomers. 
The SOE-PCR protein product, commonly known as the scFv fragment of the IgG 
molecule, is much smaller than the IgG antibody but still retains its antigen binding 
specificity to the target molecule and can be exploited for immunoassay development. 
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3.5 Murine SOE-PCR of variable heavy and light chains  
 
The gel-purified mouse variable heavy and light chain genes were used for the 
generation of the 800 bp scFv by PCR amplification. The initial PCR involved 
amplifying different VH and VL template ratios to generate the desired 800 bp product.  
 
 
 
Figure 3.4: SOE-PCR optimisation of murine variable domain gene DNA. Lane 1 contains the 
1 Kb
+
 ladder for DNA size determination. Lanes 2 – 10 represent different concentrations of 
VH: VL in the SOE-PCR. Lane 2, 10 ng VH : 10 ng VL; lane 3, 20 ng VH : 20 ng VL; lane 4, 5ng 
VH : 5 ng VL; lane 5, 5 ng VH: 10 ng VL; lane 6,5 ng VH : 2.5 ng VL; lane 7, 5 ng VH : 1.25 ng VL; 
lane 8, 10 ng VH: 5 ng VL; lane 9, 2.5 ng VH : 5 ng VL and lane 10 contains a PCR template 
ratio of 1.25 ng VH : 5 ng VL. The PCR was performed using Phusion polymerase using the 
PCR conditions described in section 2.2.8. 
 
A non-specific band of approximately 1,000 bp was amplified in addition to the 800 bp 
SOE-PCR product (Figure 3.4). A number of additives have been proven to enhance 
PCR amplification (Frankman et al., 1998) increasing specificity and maximising yield 
of the desire product. Therefore, after comprehensively searching the literature it was 
decided to evaluate two of these additives (DMSO and BSA) which could potentially 
eliminate the non-specific 1,000 bp band. The PCR annealing temperatures of the 
primers can have a major effect on the amplification of a product. A touchdown PCR 
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was also performed in conjunction with the addition of DMSO (5% v/v) and BSA (50 
g/mL) to the PCR amplification reaction. A touchdown PCR (Don et al., 1991) 
enables binding of the primers at high initial annealing temperatures without non-
specific amplification. The annealing temperature decreases after each successive cycle 
but the desired template should be abundantly present and is preferentially amplified. 
Fixed concentrations of 10 ng of the VH and VL chains were utilised during the PCR 
(Figure 3.5). 
 
 
Figure 3.5: SOE-PCR optimisation using DMSO and BSA additives with a 0.5
o
C primer 
annealing temperature decrease after each consecutive cycle. Lane 1 contains the 1 Kb
+
 DNA 
ladder for DNA size determination; lane 2 represents the PCR amplification product in the 
presence of 5 % (v/v) DMSO; lane 3 represents the PCR amplification product in the presence 
of BSA (50 µg/mL); lane 4 represents the PCR amplification product in the presence of 5 % 
(v/v) DMSO and BSA (50 µg/mL); lane 5 represent the PCR amplification product without any 
additives and lane 6 is a positive scFv fragment control (internal antibody fragment).  
 
The presence of DMSO in the PCR amplification did have a positive effect on reducing 
the amplification of the non-specific 1,000 bp band. Therefore, a touchdown PCR was 
performed using varying concentrations of DMSO (2%, 4%, 6%, 8% and 10% v/v) in 
the PCR reaction. The touchdown PCR was performed using Phusion and Red Taq 
polymerase to investigate if the type of polymerase had an effect on amplification of the 
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desired product. Betaine was another additive used for the PCR amplification. However, 
no improvement in amplification was observed (results not shown). 
 
 
 
Figure 3.6: An SOE-PCR was performed with varying DMSO concentrations using Phusion 
polymerase and Red Taq polymerase. Lane 1 and 8 contain the 1 Kb
+
 DNA ladder for size 
determination; lanes 2–6 represent the PCR amplification in the presence of 2%, 4%, 6%, 8% 
and 10% (v/v) DMSO using Red Taq polymerase, respectively. Lane 7 is blank. Lanes 9–13 
represent the PCR amplifications in the presence of 2%, 4%, 6%, 8% and 10% (v/v) DMSO using 
Phusion polymerase, respectively. 
 
Due to the clear difference in amplified PCR product quality provided using DMSO and 
the difference between Taq and Phusion polymerases (Figure 3.6) the SOE-PCR was 
also evaluated with additional polymerases with proof reading capabilities. A 
touchdown PCR was performed using a number of different polymerases - Red Taq, 
Phusion, Vent and Pfu polymerases in the presence of a fixed concentration of DMSO 
(5%). The objective was to determine if amplification could be enhanced by using a 
number of high fidelity DNA polymerases (Figure 3.7). 
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Figure 3.7: Optimisation of SOE-PCR using different polymerases for the amplification of the 
scFv product. Lane 1 and 8 contain the 1 Kb
+
 universal ladder for DNA size determination; 
lane 2 represents the PCR amplification using Red Taq polymerase; lane 3 represents the PCR 
amplification using Phusion polymerase; lane 4 represents the PCR amplification using Vent 
polymerase in buffer G; lane 5 represents the PCR amplification using Pfu polymerase in buffer 
G; lane 6 represents a positive scFv PCR amplification using Red Taq polymerase; lane 7 
represents a negative control; lane 9 represents the PCR amplification using Vent polymerase 
in Vent buffer and lane 10 represents the PCR amplification using Pfu polymerase using Pfu 
buffer. 
 
Figure 3.7 shows that the optimal amplification was achieved using Red Taq 
polymerase (lane 2) with little non-specific amplification of the 1,000 bp product. 
Therefore, the SOE-PCR was repeated using Red Taq polymerase with various DMSO 
concentrations to improve amplification. The purified VH and VL fragments were 
successfully ligated together using a glycine-serine linker (Figure 3.8) after considerable 
optimisation to yield an 800 bp product. 
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Figure 3.8: SOE-PCR using different DMSO concentrations to optimise the product yield. A 1 
Kb
+
 DNA molecular weight marker was added to lane 1. The final concentration of DMSO in 
each PCR reaction was 3%,  5%, 8% and 12%, respectively, as represented by lanes 2,3,4 and 
5. The optimal DMSO concentration for the SOE-PCR was 3% (lane 2), as the highest yielding 
product was obtained.  
 
After large-scale amplification of the desired 800 bp PCR fragment, this DNA fragment 
was gel purified, precipitated in ethanol, quantified and digested using the SfiI 
restriction enzyme (Section 2.2.10). The scFv fragment was ligated into a digested pAK 
100 vector and then transformed into high efficiency electrocompetent E. coli XL-1 
blue cells (developed in-house), rescued and the library size calculated. The mouse anti-
fPSA scFv library size was 2.02 x 10
6
 cfu/mL. The library size is limited by the 
transformation efficiency of electrocompetent cells and the concentration of DNA 
available for electroporation (Lin et al., 2002). Large libraries sizes can be generated 
and transformants rescued to yield a large panel of positive clones. In contrast, 500–
2,000 clones would be expected after a typical hybridoma fusion (Schmitz et al., 2000). 
PSA-specific antibody fragments were selected on fPSA immobilised on the surface of 
an immunotube, as described in Section 2.2.15.  
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3.6 Selection of fPSA-specific phage-scFv particles by ‘biopanning’ 
 
Five rounds of panning were performed and input and output titres for each round of 
selection determined (Table 3.1). During the selection process, the concentration of 
fPSA was decreased and the number of washes were increased as described in Section 
2.2.15. This increase in stringency after each successive round of panning is important 
to ensure positive clones are selected and reduces the levels of clones which have no 
specificity to the target antigen. After each round of selection, the infected E. coli  XL-1 
Blue cells were spread uniformly across the entire surface of chloramphenicol-
containing agar plates. The plating of the bio-panned library allows every clone the 
opportunity to be screened. This is important as certain clones may grow more slowly 
than other clones due to the antibody toxicity within the cell. Therefore, by plating the 
cells on agar plates there is an increased chance of selecting high affinity antibody 
fragments. This affinity selection process allows for enrichment of recombinant phage-
scFv particles against the immobilised fPSA (Oh et al., 2007). 
 
Table 3.1: Selection of murine phage displaying anti-fPSA-specific antibody fragments. A 
phage-titre, before and after selection on fPSA-immobilised immunotubes, expressed as colony 
forming units (cfu), is shown. 
Round (cfu/mL) 
Round 1 Input 
Round 1 Output 
4.9 x 10
11
 
5.0 x 10
6
 
Round 2 Input 
Round 2 Output 
2.0 x 10
12
 
5.2 x 10
7
 
Round 3 Input 
Round 3 Output 
1.3 x 10
12
 
3.9 x 10
4
 
Round 4 Input 
Round 4 Challenge remaining bound 
Round 4 Challenge dissociated 
1.6 x 10
12
 
3.0 x 10
2
 
1.2 x 10
5
 
Round 5 Input 
Round 5 Output 
2.4 x 10
12
 
1.3 x 10
6
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3.7 Murine polyclonal phage ELISA 
 
Five rounds of selection were successfully completed and the eluted phage from each 
round analysed by polyclonal phage ELISA described fully in Section 2.2.16 (Figure 
3.9). The results of the polyclonal phage ELISA give an indication whether or not 
positive clones were successfully selected from the panned library. The ELISA signal 
towards the antigen of interest should increase during the course of the selection process 
if positive anti-fPSA phage scFv fragments were recovered from the generated mouse 
anti-fPSA library. The pooled phage contains a collection of recombinant antibody 
fragments with a range of affinities for fPSA and, therefore, individual clones were 
analysed by ELISA to determine the binding patterns of the clones. 
 
Figure 3.9: Phage pools from the unpanned mouse anti-fPSA scFv glycerol library stock and 
the phage pool obtained after subsequent rounds of panning were tested for binding to fPSA by 
ELISA. Bound phages were detected with an anti-M13-HRP-conjugated antibody and the 
absorbance read at 450 nm. A challenge was performed which involves incubating the 
immunotube with free antigen to remove any weak binding phage-scFv particles. High affinity 
antibodies remain attached to the fPSA-coated surface and are subsequently propagated for the 
next stage of selection. A significant absorbance signal increase in pan five suggests the 
presence of anti-fPSA scFv-phage fragments.  
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Sixty colonies from round 4 and 5 of selection were picked from the bio-panned stock 
plates, grown in sterile 96 well microtitre plates, infected with helper phage and shaken 
overnight at 30
o
C after the addition of kanamycin. Phage were analysed for binding to 
fPSA-coated ELISA plates and detected with an HRP-conjugated anti-M13 antibody. 
Approximately 8% of the selected clones showed binding to fPSA coated on the surface 
of an ELISA plate from Pan 4 output and 60% were positive from the colonies selected 
from Pan 5 output (Figures 3.10 and 3.11).  
 
3.8 Murine monoclonal phage ELISA 
 
 
Figure 3.10: Sixty individual colonies were randomly selected and analysed by ELISA. Five of 
the expressed clones showed significant binding to a fPSA-coated ELISA plate suggesting 
positive selection of phage-scFv particles from the fourth round of ‘biopanning’. Two of the five 
positive clones were expressed at high levels with a ‘cut-off’ of twice the background (red 
dotted line). 
 
Figure 3.10 shows the binding of individually selected phage-scFv fragments to fPSA 
following four rounds of panning. Five of the sixty individual colonies selected were 
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shown to be positive for binding to fPSA by ELISA. A ‗cut-off‘ of twice the 
background was selected for positive fPSA-specific clones (red dotted line). The 
monoclonal phage ELISA performed on sixty colonies selected from the fifth round of 
biopanning showed that 60% of the selected clones positively bound fPSA. The 
expression levels of the positive phage-scFv particles were different with varying 
degrees of binding to the fPSA-coated ELISA wells. 
 
Figure 3.11: Sixty individual colonies were randomly selected and analysed by ELISA from the 
fifth round of ‘biopanning’. Sixty percent of the recombinant clones showed significant binding 
to a fPSA-coated ELISA plate. The expression levels were different for each selected clone with 
a selected cut-off of twice the background (red dotted line). 
 
Three individual clones were selected at random from the positive anti-fPSA scFv 
monoclonal phage ELISA plates and an inhibition phage ELISA performed using 3 
fPSA concentrations (5 µg/mL, 1 µg/mL and 200 ng/mL) to investigate if the selected 
clones were displaced when mixed with fPSA in solution i.e. that the antibodies 
demonstrated competitive inhibition (Figure 3.12). 
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Figure 3.12:  A monoclonal phage inhibition ELISA was performed on 3 random murine anti-
fPSA scFv clones. The phage were incubated for 1 hour with fPSA (5 µg/mL, 1 µg/mL and 200 
ng/mL) and added to a fPSA-coated plate. Binding phage-scFv were detected using an anti-
M13 HRP-labelled antibody. The absorbance readings were normalised whereby the 
absorbance for each fPSA concentration incubated with antibody (A) was divided by the 
maximum absorbance for each selected antibody without antigen (Ao). 
 
The three random clones were competitive at the selected concentrations of fPSA as 
there was a decrease in absorbance with increasing fPSA concentration. Two of the 
clones showed similar binding patterns to fPSA and could potentially be the same clone 
while the third clone has a completely different binding profile. Figure 3.12 showed that 
the selected antibodies were competitive inhibitors and were displayed with fPSA in 
solution (Section 2.2.17). 
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3.9 Soluble expression of mouse anti-fPSA scAb fragments 
 
Soluble expression of the clones selected for binding to fPSA from the fifth round of 
biopanning involved subcloning the scFv fragment into an appropriate expression 
vector. The Krebber system uses pAK 400 expression vector for soluble expression of 
mouse scFv‘s. However, it has been widely accepted that murine scFv express poorly, 
have problems with folding and tend to aggregate in the periplasm (Hayhurst et al., 
2003). These issues have been raised in our laboratory and after extensively reviewing 
of the literature, papers were sourced where these problems were overcome by 
reformatting the scFv into a scAb. A paper by Hayhurst et al., (2003) addresses the 
common pitfalls with murine scFv‘s (poor expression levels and solubility). These 
scientists revealed that reformatting the recombinant antibody to a scAb significantly 
improves expression levels and overall stability. The pMoPAC vectors are loosely 
based on the pAK 400 Krebber vector for soluble expression of mouse scFv. The vector 
has an additional human constant kappa domain upstream of the scFv insert cloning 
sites. This allows for expression of a scAb format and the presence of a downstream 
Skp chaperone also improves scAb solubility. The pMoPAC DNA was kindly donated 
by Dr. Andrew Hayhurst after setting up collaboration with his group. It was 
transformed in electrocompetent E. coli XL-1 Blue cells and stored at -80
o
C. The scFv 
was amplified by PCR from a plasmid preparation on E. coli XL-1 Blue cells-
containing biopanning output round 5 of selection. In parallel, a plasmid purification 
was performed on the pMoPAC vectors. The scFv fragment was digested using SfiI 
restriction enzyme and ligated into pMoPAC 16 and pMoPAC 53 restricted vectors. 
These vectors express the scFv as a single chain Ab (scAb) with a human constant 
kappa domain which gives extra stability to the expressed antibody fragment and 
improves overall protein expression. Electrocompetent Tuner cells were prepared and 
transformed with the pRARE plasmid. Following sub-cloning the scFv into the 
pMoPAC vectors, electrocompetent Tuner cells containing the pRARE plasmid were 
transformed with the ligation mixture and individual clones expressed. The pRARE 
plasmid codes for 6 rare tRNA codons than enhance expression of eukaryotic proteins 
in prokaryotic systems. Tuner cells allow uniform entry of IPTG into the cell population 
and expression can be easily regulated. One hundred and ninety two clones were grown 
in 96 microwell plates and analysed by direct ELISA. Sixty percent of the selected 
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clones bound to fPSA passively immobilised on the surface of the ELISA plate (Figure 
3.13). 
 
Figure 3.13 : One hundred and ninety two individual mouse anti-fPSA scAb clones were 
functionally expressed in 2xTY media supplemented with 1 x 505 (0.5% (v/v) glycerol, 0.05% 
(w/v) glucose final concentration) containing 100 g/mL carbenicillin and 25 µg/mL 
chloramphenicol overnight at 30
o
C after induction with 1 mM  IPTG. A 1 µg/mL fPSA -coated 
ELISA plate was blocked with 200 l of 3% (w/v) BSA in PBS. The lysates were diluted 2 fold 
with 1% (w/v) BSA in PBST and added to the ELISA plate. The scAb clones were detected with 
an anti-human kappa light chain antibody labelled with alkaline phosphatase. The substrate, 
pNPP, was added for 30 minutes at 37
o
C and the resulting absorbance read at 405 nm. Sixty 
percent of the expressed recombinant antibody fragments successfully bound a fPSA-coated 
ELISA plate. A cut-off of twice the background (red dotted line) was selected for positive anti-
fPSA-secreting clones. 
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3.10 Differential expression profile of an anti-PSA scFv and reformatted scAb 
 
A comparative analysis of the expression profile between the murine anti-fPSA scFv 
and its corresponding scAb was performed. A scAb with high expression levels was 
selected for this study and the aim was to evaluate the expression levels of the 
recombinant antibody fragments (scFv and scAb) in the same cell strain (Tuner) 
containing the pRARE plasmid, induced at the same time and expressed overnight at 
30
o
C. An ELISA was performed on the extracted recombinant antibody constructs 
(scFv and scAb) to evaluate the improvement in expression of the scAb over its scFv 
counterpart. The recombinant antibody fragments were expressed in 3 mL 2xTY media 
overnight and analysed by ELISA (Figure 3.14). 
 
 
Figure 3.14: A direct ELISA was performed where a plate was coated with 1 µg/mL fPSA, 
blocked with 3 % (w/v) BSA and serial dilutions (1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256 
and 1:512 dilution) of the antibody lysate incubated for 1 hour at 37
o
C. The lysate was detected 
using an anti-His-HRP-labelled antibody with TMB as the substrate of choice. The wells were 
read at 450 nm. The expression level of the murine anti-fPSA scAb was considerable higher 
than its murine anti-fPSA scFv counterpart. 
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This result confirms the low level of expression of the murine scFv. This is mainly due 
to improper folding and protein aggregation of the scFv. Importantly, the problem of 
poor expression was addressed by sub-cloning the scFv into pMoPAC series of vectors 
for scAb expression. The result in Figure 3.14 confirms that by altering the recombinant 
antibody format, protein expression levels can be significantly enhanced. Another 
important aspect is the scAb is expressed with a human constant Kappa domain which 
facilitates the detection of the expressed antibody by ELISA. This was also utilised later 
in Section 4.2.3 for Biacore ranking of the selected mouse clones. The key result from 
Figure 3.14 is the significant improvement of expression which allows for further 
analysis of selected antibody fragments. 
 
3.11 Selection of chicken anti-fPSA scFv fragments 
 
Another animal model used to generate recombinant antibodies to fPSA was chickens. 
Chickens were immunised with fPSA and a large library generated (3.10 x 10
8
 cfu/mL). 
The objective was to compare the selected antibody fragments from the anti-fPSA 
chicken and mouse library and to determine whether or not the chicken antibodies 
recognised different epitopes than the mouse antibodies on the fPSA antigen and to use 
them in a sandwich assay format. Chickens are a valuable source of antibodies and have 
been used extensively in biotechnology for the production of polyclonal antibodies. It 
has been shown that these animals can be immunised easily with a mixture of multiple 
antigens and recombinant antibodies selected, using phage display, with little or no 
cross-reactivity. This section describes the selection of chicken anti-fPSA scFv 
fragments from a chicken anti-fPSA library.  
 
The avian immune system is phylogenetically distant from mammals therefore making 
chickens a very good source of antibodies against some highly conserved targets, like 
PSA in mammals. Large diverse chicken recombinant antibody libraries have been 
generated and high affinity antibodies selected through phage display (Finlay et al., 
2005). It is important to note that one chicken can be immunised with a number of 
target antigens and produce high affinity antibodies to each target with little or no cross-
reactivity (Finlay et al., 2006). Both the VH and VL chain loci in chickens consist of 
single functional V-region genes and J-region genes. The VH has an additional D 
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segment for diversification purposes. Further diversification is achieved due to the 
presence of upstream pseudogenes in both the VH and VL chains. The relative ease of 
amplification of VH and VL chains due to only 2 primer sets for library production is 
another advantage for using this source for recombinant antibody production. The eggs 
from immunised hens are a source of large quantities of polyclonal antibodies which 
can be extracted and subsequently purified. IgY antibodies have important diagnostic 
and therapeutic applications particularly in detecting antigens in blood and serum 
(Greunke et al., 2006).   
 
A chicken was immunised with two antigens (PSA and BNP) for recombinant antibody 
library generation. The spleen and bone marrow were removed from an immunised 
chicken and the RNA extracted as previously described in the mouse antibody library 
generation section. After reverse transcription the cDNA template was amplified by 
PCR to generate the VH and VL chain genes. These were resolved on a 1% (w/v) 
agarose gel and purified by electroelution. The purified VH and VL DNA were amplified 
by PCR to generate the scFv. The Fab was generated by doing two separate SOE-PCR 
amplifications and performing a final overlap to link the two constructs. The variable 
heavy construct was amplified using the VH and CH chain genes and the variable light 
construct was amplified using the VL and CL chain genes. Both these fragments were 
gel purified by electroelution and used in the final SOE-PCR to generate the Fab. The 
scFv and Fab were SfiI digested with the pComb3XSS for 5 hours at 37
o
C. The DNA 
was purified by electroelution and the DNA concentration determined. A ligation was 
performed overnight and the ligation mixture was ethanol-precipitated before the 
electroporation. The transformants were rescued on carbenicillin-supplemented agar 
plates at 37
o
C. 
 
3.12 Optimisation of avian VH and VL chain genes amplification for Fab library 
construction 
 
The avian anti-fPSA scFv and Fab libraries were generated in conjunction with Dr. 
William Finlay. The generation of the avian scFv library involved amplifying the VH 
and VL chain genes separately and joining the gel-purified fragments with a glycine-
serine linker, as described fully in the murine anti-fPSA scFv library Section 2.3. The 
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generation of a Fab library is different as the VH and VL genes are joined to their 
respective CH and CL chain genes and the Fab construct is amplified by SOE-PCR 
joining the heavy variable constant domain with the light variable constant domain. 
 
A MgCl2 gradient (3.0, 2.5, 2.0 and 1.5 mM) PCR was used for the amplification of the 
avian VH and VL (kappa and lambda chain) genes. The genes were resolved on a 1% 
(w/v) agarose gel (Figure 3.15) and gel-purified. 
 
 
Figure 3.15: Amplification of the avian variable genes using a MgCl2 gradient. Lanes 1 and 
14:1 kb
+
 DNA molecular weight marker; Lanes 2–5: amplification of the variable heavy chain 
gene using 3.0, 2.5, 2.0 and 1.5 mM MgCl2, respectively. Lanes 6–9: amplification of the 
variable light kappa chain gene using 3.0, 2.5, 2.0 and 1.5 mM MgCl2, respectively. Lanes 10-
13: amplification of the variable light lambda chain gene using 3.0, 2.5, 2.0 and 1.5 mM MgCl2, 
respectively. The PCR amplification for each chain was successful with optimal concentrations 
amplified using 3.0 mM MgCl2. 
 
The first PCR overlap involved joining the variable chains with their counterpart human 
constant genes to give an 800 bp product (Figure 3.16). It is important to ensure the 
construct is amplified specifically as incorrect amplification would affect the final SOE-
PCR overlap. 
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Figure 3.16: The first SOE-PCR using the avian variable genes and the constant human chain 
genes. Lane 1: 1 kb
+
 DNA molecular weight marker; lane 2: heavy chain construct (VH and CH), 
lane 3: kappa light chain construct (VL and CL) and lane 4: lambda light chain construct (VL 
and CL). The amplification of each construct was successful using the gel-purified VH and VL 
fragments. 
 
After large scale amplification these fragments were gel purified and the Fab construct 
amplified by SOE-PCR. The Fab generated consisted of the heavy/kappa chain 
construct and the heavy/lambda chain construct joined using a glycine-serine linker 
region. These were separately resolved on a 1% (w/v) agarose gel (Figure 3.17), 
purified, pooled and ligated into the pComb 3XSS vector, ethanol precipitated and 
transformed in electrocompetent E. coli XL-1 Blue cells for selection.  
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Figure 3.17: The final overlap for the generation of the Fab construct. Lane 1: 1kb
+
 DNA 
molecular weight marker; lane 2: heavy/kappa light chain Fab and lane 3: heavy/lambda chain 
Fab. The Fab fragments were successfully amplified without any non-specific amplification.   
 
3.13 Chicken anti-fPSA scFv selection on fPSA-coated ELISA wells 
 
The avian anti-fPSA Fab library was screened and the chicken anti-fPSA scFv library 
(3.10 x 10
8
 cfu/mL) was bio-panned against fPSA immobilised on the surface of an 
ELISA plate, as described in Section 2.3.4. The input and output titres were measured 
and are shown in Table 3.2. It is important to ensure no cross contamination between 
libraries. If a scFv-phage particle infected the generated Fab library it would be 
preferentially be packaged quicker than the Fab as it is a smaller fragment and could 
potentially be selected from the library over the Fab. This would render the library 
useless and cause unnecessary time loss. 
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Table 3.2: Selection of avian anti-fPSA-specific antibody fragments by phage-display. Input and 
output reflect the number of phage at the start of each round of biopanning and those recovered 
after each subsequent selection round, expressed as colony forming units (cfu). 
Round (cfu/mL) 
Round 1 Input 
Round 1 Output 
3.2 x 10
12
 
5.0 x 10
6
 
Round 2 Input 
Round 2 Output 
3.5 x 10
12
 
7.0 x 10
7
 
Round 3 Input 
Round 3 Output 
2.4 x 10
11
 
1.5 x 10
7
 
 
Three rounds of selection were completed and the eluted phage from each round 
analysed by polyclonal phage ELISA as shown in Figure 3.18. The avian anti-fPSA 
scFv library required 3 rounds of biopanning in comparison to 5 rounds for the murine 
anti-fPSA scFv library because the avian library was 100-fold bigger and provided an 
increased opportunity to select positive clones in fewer rounds of selection. After 
selection the resultant phage pool was tested in an ELISA to evaluate the success of the 
biopanning process. To monitor the selection process, phage pools acquired in each 
round of selection were tested in parallel with phage from the unpanned library. The 
ELISA signal for the antigen, fPSA, should increase during the biopanning process if 
specific binders have been selected. 
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Figure 3.18: The eluted phage from the chicken anti-fPSA scFv library were analysed in 
triplicate by ELISA. Three rounds of selection were performed on fPSA-coated ELISA wells and 
the phage pool obtained after subsequent rounds of biopanning were tested for binding to fPSA. 
Any binding phage particles were detected with a HRP-labelled anti-M13 antibody.  
 
The signal increased from the 1
st
 to the 3
rd
 round of selection indicated that positive 
clones were recovered from the library. The next stage of the selection process involved 
soluble expression of these avian anti-fPSA scFv clones. The pComb3XSS phagemid 
vector contains an amber stop codon (TAG) between the scFv and g3p which is 
suppressed in E. coli XL-1 Blue cells. However, if the phage is directly infected into 
non-suppressor TOP10F' cells the scFv is transcribed without the g3p fusion tag due to 
the amber stop codon. Therefore, E. coli TOP10F' cells were infected with the eluted 
phage pool from round three of selection and spread uniformly over the surface of agar 
plates supplemented with carbenicillin (phagemid antibiotic resistance gene). The E. 
coli TOP10F' cells will grow on the carbenicillin agar plates only if they have been 
infected with the phagemid. Uninfected TOP10F' cells will not grow as they do not have 
the appropriate antibiotic resistance gene. The plates were incubated overnight at 37
o
C 
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and one hundred and ninety two colonies picked and functionally expressed in sterile 96 
well plates. The protein was extracted using a freeze (-80
o
C x 3) - thaw (37
o
C x 3) 
method and each clone analysed by ELISA (Figure 3.19) to evaluate binding to fPSA. 
The ELISA result revealed forty five clones (23%) were positively binding fPSA.   
 
3.14 Soluble expression of chicken anti-fPSA scFv and analysis by ELISA 
 
 
Figure 3.19: One hundred and ninety two individual chicken anti-fPSA scFv clones were 
solubly expressed and analysed by ELISA. An ELISA plate coated with 100 L of 1 g/mL fPSA 
was blocked with 200 L of 3% (w/v) BSA in PBS. The lysates were diluted two fold with 1 % 
BSA (w/v) in PBST and added to the ELISA plate. Any binding scFv clones were detected with a 
HRP-conjugated anti-hemagglutinin (HA) antibody.  
 
The avian Fab library was bio-panned, E. coli TOP10F' cells infected with eluted phage 
and 60 individual colonies screened. The expressed clones were analysed by ELISA 
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(Figure 3.20) to determine whether the selected clones were kappa or lambda light 
chain-specific.  
 
 
Figure 3.20: The avian anti-fPSA Fab lysates were analysed by ELISA to determine if they were 
predominantly lambda or kappa light chains. The Fabs were analysed using an anti-lambda-
HRP-labelled antibody and detected with TMB substrate. The majority selected were lambda 
chain-specific (4 selected clones were not lambda chain-specific). 
 
The majority of the selected Fabs (56) were lambda chain specific while 4 clones were 
kappa chain specific (results not shown) as determined by ELISA. The clones showed a 
high degree of antibody expression when grown in small scale (96-well sterile plate). 
The expression levels have different patterns and could potentially be different 
recombinant antibody fragments so the library diversity was checked. Individual Fab 
clones from the generated library (5 clones) and from the final round of biopanning (5 
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clones) were subjected to an AluI digest. This enzyme is a high frequency cutting 
restriction enzyme that recognises the sequence AG/CT and generates blunt ends. The 
Fabs were resolved on a 2% (w/v) agarose gel (Figure 3.21) to visualise the diversity in 
the library and the similarity in the Fabs selected from panning as described in Section 
2.3.4. 
 
 
Figure 3.21: AluI fragment analysis of selected avian anti-fPSA Fab clones to investigate the 
diversity between the clones. Lane 1: 100 bp ladder (Invitrogen); lanes 2–6: selected clones 
from the library. Lanes 7–11: clones selected from the final round of selection. 
 
The 5 analysed clones from the new library have no similar fragment patterns 
confirming a diverse selection of individual clones. Two of the 5 selected Fab clones 
from the final round of selection have identical DNA sequence patterns (9 and 11). This 
would suggest that these clones are potentially the same antibody fragment and are 
specific for a certain epitope of the fPSA molecule. The other selected clones are less 
diverse than the selected clones from the original library but are different. 
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3.15 Discussion 
 
This chapter gives a detailed description on the generation of three recombinant 
antibody fragment libraries developed from the spleens of mice and chickens 
immunised with fPSA. Positively-binding anti-fPSA recombinant antibodies were 
selected from the generated libraries and preliminary studies by ELISA indicated a 
range of positive clones. 
 
Separate approaches were performed for the generation of the murine and avian 
recombinant antibody libraries. The murine anti-fPSA scFv library was constructed 
using a method described by Krebber et al. (1997). The spleen, a rich source of 
antibody-producing cells (lymphocytes) was isolated from the immunised mouse after 
confirming anti-fPSA-specific antibodies were present in the serum by ELISA. The 
RNA was extracted and reversed transcribed to cDNA. The variable antibody genes (VH 
and VL) were successfully amplified using the primer set given in Section 2.2.5. 
Problems with amplifying the SOE-PCR were encountered as a 1000 bp non-specific 
band was observed initially. The SOE-PCR was optimised using DMSO in the PCR mix 
and by using a touchdown PCR. The DMSO inhibits secondary structure by disrupting 
base pair in GC rich templates and improves the efficiency of amplification. The 
touchdown PCR enables amplification of the desired product at a high initial annealing 
temperature with a decrease in annealing temperature after each successive cycle.  A 
range of polymerases were investigated in the PCR amplification to determine the 
optimal amplification. The desired single chain Fv fragments were assembled with a 
glycine-serine interface in a VL-(G4S)4-VH orientation. The flexible linker region (20 
amino acids) allows folding of the generated scFv. After optimisation, the SOE-PCR 
product was cloned into pAK 100 Krebber phagemid (phage plasmid) for g3p fusion 
protein display. The phagemid carries a plasmid origin of replication and a phage origin 
of replication. After cloning E. coli XL-1 Blue electrocompetent cells were transformed 
with the DNA and the library selected on agar plates supplemented with 
chloramphenicol (antibiotic resistance gene). The size of the generated library was 2.2 x 
10
6
 cfu/mL. The generated library size indicates a large number of possible clones 
which could potentially bind fPSA. However, these needed to be selected from the 
generated murine anti-fPSA recombinant antibody library. Krebber et al. (1997) yielded 
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a library size of 10
6
 after electroporation. The library size is dependent on the 
concentration of DNA and the efficiency of the E. coli cells. 
 
Antigen-specific antibodies were selected from the generated library by ‗biopanning‘. 
After five rounds of selection on fPSA-coated immunotubes a polyclonal ELISA 
revealed the presence of positively binding anti-fPSA phage-scFv clones.  Krebber et al. 
(1997) reported 3 rounds of selection to be optimal for the murine scFv generated 
library. The murine anti-fPSA library required 5 rounds of ‗biopanning‘ for the 
selection of positive phage-scFv particles. Individual colonies were analysed by 
monoclonal phage ELISA and a number of clones successfully bound fPSA-coated 
wells. In the laboratory problems, where poor expression levels of murine scFv were 
observed and after extensively searching of the literature, Dr. Andrew Hayhurst was 
contacted about the pMoPAC vectors. The plan was to investigate if improvements in 
expression levels and stability could be achieved by reformatting the recombinant 
antibody. The scFv was amplified by PCR from round 5 output of selection and 
subcloned into the pMoPAC series of vector for soluble expression of a scAb. This 
construct greatly enhanced soluble protein expression and overall protein stability. The 
ligated product was transformed in E. coli Tuner cells containing the pRARE plasmid. 
Tuner cells are lacZY deletion mutants of BL21 and allow uniform entry of IPTG into 
the cell population ensuring homogenous protein levels of induction. The pRARE 
plasmid codes for mammalian tRNAs rarely occur in E. coli yet enhance protein 
expression levels in bacterial cells restricted by codon usage. Individual colonies were 
analysed for expression by ELISA confirming solubly expression of murine anti-fPSA 
scAb clones. A differential expression profile of an anti-fPSA scFv and reformatted 
scAb was performed by ELISA to show the significant expression levels between the 
two antibody formats (Section 3.10 Figure 3.14).  
 
Chickens were immunised with fPSA and the spleen extracted for recombinant antibody 
generation. Avian anti-fPSA scFv and Fab libraries were constructed using a method 
described by Andris-Widhopf and co-workers (2000). A library size of 3.10 x 10
8
 
cfu/mL for the avian anti-fPSA scFv was bio-panned against fPSA passively 
immobilised on the surface of ELISA wells (Section 2.3.4). Three rounds of selection 
were performed and a polyclonal phage ELISA confirmed the presence of anti-fPSA-
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specific antibodies. E. coli TOP10F' cells were infected with the phage and individual 
clones selected and expressed in sterile 96 wells plates. Twenty three of the 192 selected 
clones were positive by ELISA. The avian anti-fPSA Fab library was bio-panned, 
individual colonies selected, expressed and screened by ELISA. ELISA showed that the 
Fab lysates were predominantly lambda light chain domain fragments. The Fab 
construct contains the human constant domain regions and these allow for extra stability 
when expressed in E.coli cells. Overall, antigen-specific recombinant antibody 
fragments were successfully selected from the generated immune libraries by phage 
display. A large panel of soluble clones were individually expressed and analysed by 
ELISA. These selected recombinant antibodies fragments were further characterised as 
described in the next chapter. 
 
Both Krebber et al. (1997) and Andris-Widhopf et al. (2000) reported the generation of 
recombinant antibody libraries from different animal sources (mice and chickens, 
respectively). Krebber et al. (1997) generated 2 libraries (spleen cells fused to a tumour 
cell line and B cells) of 4 x 10
6
 and 6 x 10
6
 transformants. Three rounds of ‗biopanning‘ 
were required for selection of positive binders. Andris-Widhopf and colleagues 
generated 3 large chicken libraries (approximately 10
7
 transformants), 2 scFvs (long and 
short glycine-serine linker for monomeric and dimeric expression, respectively) and 1 
Fab. Four rounds of ‗biopanning‘ using phage display were performed for each library 
and individual antibody fragments expressed and screened with a high proportion of 
positive antibody fragments selected from the library. Three rounds of selection were 
required for the selection of positive chicken anti-fPSA recombinant antibody 
fragments. Therefore, highly sensitive recombinant antibody fragments were selected 
earlier than the expected number of rounds of ‗biopanning‘. Rojas et al. (2002) 
generated a PSA recombinant antibody library size of 1.51 x 10
5 
transformants. They 
used a mouse heavy variable chain with a human light chain and successfully selected 2 
scFvs that recognised PSA after 5 rounds of biopanning. Both the murine and avian 
anti-fPSA libraries generated in this research were 10-fold bigger than the libraries 
reported by Rojas and Andris-Widhopf (2002; 2000). The library size is very important 
for selection of positive antibody fragments. The larger the library size diversity the 
greater the chance of recovering high affinity antibody fragments towards the antigen.  
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Chapter 4 
 
Screening and characterisation of putative 
anti-fPSA scFv and Fab antibodies 
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4.1 Introduction  
 
This chapter describes the strategy for selecting high affinity recombinant antibody 
fragments from a panel of clones using the Biacore system. Ninety four murine anti-
fPSA scAb-secreting clones were evaluated using a custom designed wizard on the 
Biacore 3000 instrument. A capture assay was employed where the individual scAbs 
were captured by anti-human C kappa mAb immobilised on the sensor surface and 
fPSA was subsequently passed over the captured scAb lysates. The scAbs were ranked 
according to their percentage binding stability to fPSA (30 nM) after 5 min. Preliminary 
kinetic analysis was performed on 11 clones with good performance characteristics and 
sequencing of the individual antibodies confirmed that they had different amino acid 
sequences with variation in the complementary determining region (CDR). The best 
murine anti-fPSA scAb was selected on the basis of an inhibition ELISA as the 
affinities of the selected antibodies were similar. The selected clone was expressed in 
large quantities and successfully purified by IMAC. The selected avian anti-fPSA scFv 
and Fab clones (Section 3.11, Figures 3.19 and 3.20) were subjected to further analysis 
and their affinities determined by Dr. Paul Leonard on the Biacore A100 in Uppsala, 
Sweden. The same capture approach for analysing the murine anti-fPSA scAb 
antibodies was pursued using two different immobilised surfaces (anti-lambda (Fab) 
and anti-HA (scFv)) on the Biacore A100. After pre-concentration studies an anti-
lambda antibody was immobilised onto the surface of a CM5 dextran chip and the Fab 
lysates passed over the surface. The fPSA (30 nM) molecule was passed over the 
captured Fab, the percentage binding stability calculated and the clones ranked 
accordingly. Ninety six clones were evaluated using both a single fPSA concentration 
injection and multiple fPSA concentration injections to determine if the association and 
dissociation rate constants changed significantly due to the number of fPSA injections. 
The effect of temperature (37 and 25
o
C) on assay performance was evaluated. 
Temperature can cause shifts in the binding abilities of antibody and, therefore, is an 
important parameter in assay design (Zedar-Lutz et al., 1997). The avian anti-fPSA 
scFvs were examined using the capture assay format on an anti-HA immobilised 
surface. Nineteen of the selected clones showed high affinities towards fPSA. 
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4.2 Biacore capture assay design 
 
A Biacore capture assay was employed to analyse the selected antibody fragments and 
to rank them based on their binding abilities.  
 
4.2.1 Preconcentration studies of anti-human C kappa mAb 
 
Preconcentration involves determining the optimal buffer conditions for maximum 
binding of the ligand to the surface of the chip (Section 2.4.4). The protein G-purified 
anti-human C kappa mAb was diluted in a low ionic strength buffer (10 mM sodium 
acetate) with different pH values.  The principle behind using an array of pH buffers is 
that the protein carries a ‗net‘ positive charge at pH values less than its isoelectric point 
causing an electrostatic interaction between the negatively charged dextran surface and 
the positively charged protein. This results in a higher coupling efficiency with a lower 
requirement for protein. The study is performed to ensure maximum binding levels of 
the protein to the chip surface thus, ensuring a reusable assay format. The anti-human C 
kappa mAb diluted in 10 mM sodium acetate buffer at various pH increments was 
passed over a blank CM5 dextran surface and the response recorded. The selected pH 
should be the highest pH that provides adequate immobilisation levels (Murphy et al., 
2006). The maximum potential antigen binding was observed in sodium acetate buffer, 
pH 4.0 (Figure 4.1), and this was used for immobilisation of anti-human C kappa mAb 
to the surface of all 4 flow cells.  
 
4.2.2 Immobilisation of anti-human C kappa mAb on to the CM5 dextran sensor chip 
surface 
 
The immobilisation of a ligand to a CM5 dextran chip involves a number of steps 
described in Section 2.4.5. The chip is firstly activated by (N-ethyl-N‘-
(dimethylaminopropyl) carbodiimide (EDC) and (N-hydroxysuccinimide) (NHS), the 
ligand is subsequently passed over the surface and the chip surface is then deactivated to 
block and eliminate any potential non-specific binding (NSB) to the cell surface. The 
most utilised method of immobilisation involves the activation of the dextran surface 
using EDC and NHS chemistry. The EDC solution, in the presence of NHS, activates 
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the CM dextran carboxyl groups into functional ester groups. The surface NHS esters 
react with primary amino groups such as lysine residues on the protein causing covalent 
binding of the protein to the surface (Murphy et al., 2006). An injection time of 7 
minutes for the EDC/NHS solution activates approximately 40 % of the carboxylated 
groups on the chips surface. The purity of the ligand is of vital importance for 
immobilisation and should be at least 95 % as this avoids the introduction of NSB or 
assay interference. Any remaining available unbound functional ester groups are 
deactivated by passing 1M ethanolamine hydrochloride (pH 8.5) over the chip surface 
(Casper et al., 2004). 
 
Immobilisation of the anti-human C kappa mAb to the dextran surface was performed 
by passing 60 g/mL of anti-human kappa mAb in 10 mM sodium acetate buffer, pH 
4.0, over EDC/NHS activated flow cells 1, 2, 3 and 4 for 30 minutes at a flow rate of 10 
l/min. After 30 minutes any remaining active groups on the surface and non-covalently 
bound material were deactivated and blocked using 1M ethanolamine hydrochloride 
(pH 8.5) with a 10 minute injection at a flow rate of 10 l/min. The surface was 
regenerated using 10 mM NaOH to remove non-covalently attached proteins from the 
surface. Approximately 12,500 RU was immobilised on the dextran surface of each 
flow cell (Figure 4.2). For characterisation of antibodies from clones with varying 
expression levels a high capacity surface area was essential.  
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Figure 4.1:  The protein G-purified anti-human C kappa mAb, diluted in 10 mM sodium acetate 
solutions of pH 4.0, 4.2, 4.4, 4.6, 4.8 and 5.0 was passed over the surface of a CM 5 dextran 
chip at a flow rate of 10 µL/min.  During pre-concentrations studies there is an electrostatic 
interaction between the positive charged protein (due to its charge below the isoelectric point) 
and the negatively charged surface carboxylated groups. The ionic strength (150 mM) of the 
HBS running buffer sufficiently removed the electrostatic charged antibody from the surface. 
The optimal pH for the immobilisation of the anti-human C kappa mAb to the CM5 dextran 
surface was pH 4.0 as the highest levels of apparent binding was observed. 
Immobilisation of anti-human C Kappa 
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Figure 4.2: The surface of a CM5 dextran chip was activated with an EDC/NHS solution and 
the anti-human C kappa mAb passed over the activated carboxyl group surface.  The sample 
was injected for 30 minutes until the surface was fully saturated. Binding of the ligand is via the 
amino groups on the protein with the activated carboxyl groups on the dextran surface chip. 
After sufficient capturing of the ligand had been achieved the remaining activated groups were 
deactivated with ethanolamine-HCl solution. The surface was regenerated using a 10 mM 
solution of NaOH injected over the newly covalently coupled surface. The levels of anti-human 
C kappa mAb immobilised onto the surface of each flow cell were 12556, 12640, 12663 and 
12467 RU for flow cells 1–4, respectively. 
 
Ninety four scAb fragments were further evaluated after preliminary studies showed a 
number of positive clones as described in Section 3.8 (Figure 3.13). These were solubly 
expressed in 20 mL cultures (2xTY media) and high throughput analysis performed 
using a custom wizard application. After successfully immobilising anti-human C kappa 
mAb on the surface of all four flow cells of a CM 5 dextran chip (Figure 4.2), a capture 
format assay was performed by passing the crude bacterial scAb protein-containing 
lysate over the surface of the immobilised anti-human C kappa mAb. Subtractive 
referencing was implemented whereby the scAb lysate was captured on three flow cells 
(2, 3 and 4) leaving flow cell 1 as a negative reference blank with no captured scAb 
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fragment (Figure 4.3). HBS and 1 g/mL fPSA (30 nM) were individually passed over 
the captured scAb fragments. The refractive indexes from flow cell 1 (blank reference) 
and the binding response from HBS buffer injected over each captured scAb was 
subtracted from the refractive index recorded for fPSA binding to the captured scAb. 
The scAbs were ranked according to the antibody-antigen complex percentage stability 
remaining after 5 minute dissociation and the fragments with the highest percentage 
complex stability were subjected to preliminary kinetic analysis (Section 2.4.6). 
 
 
 
Figure 4.3: Anti-human C kappa mAb was immobilised on the surface of a CM5 dextran sensor 
chip. A high throughput capture assay format was performed where the bacterial lysate-
containing scAb fragments were passed over the surface of the immobilised anti-kappa mAb 
(flow cells 2, 3 and 4). A set concentration of fPSA (30 nM) was subsequently injected over all 4 
flow cells and the antibody fragments ranked (double referencing) according to their complex 
stability levels. 
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4.2.3 Designed custom kinetic wizard 
 
After consulting representatives from Biacore I designed a custom wizard for the 
simultaneous analysis of recombinant antibody binding clones (Figure 4.4). The 
designed wizard allowed for the quick analysis and ranking of antibody binding 
fragments to fPSA. 
 
 
Figure 4.4: The custom designed kinetic wizard allowed the analysis of 3 murine anti-fPSA 
scAbs simultaneously using double referencing (HBS over the captured murine anti-fPSA scAb 
(flow cells 2, 3 and 4) and fPSA over flow cell 1 (blank – no captured scAb)). This screen 
snapshot shows the list of commands used for the assay. The command icons are arranged 
across the top of the file. The written file determines the flow cells for analysis (2-1, 3-1, and 4-
1 subtractive referencing), flow rate (50 µL/min), baseline report point before sample 
application, flow path for capturing the murine anti-fPSA scAb (100 µL) at a flow rate of 20 
µL/min for 5 minutes, a data report point to confirm the levels of capture, injection of 30 nM 
fPSA after the 3 murine anti-fPSA scAbs were captured and report points 5 seconds and 5 
minutes after dissociation of the fPSA molecule. 
 
The extracted lysates were captured on the immobilised anti-human C kappa mAb 
surface and 30 nM fPSA passed over the lysates. A report point was recorded at the start 
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of dissociation (stability early) and 5 min (stability late) after the injection and the 
clones ranked on their binding abilities. The percentage stability remaining after a 5 min 
dissociation period gave a good overall indication of the antibody/antigen complex with 
the highest affinities (Canziani et al., 2004). The analysis of 94 murine anti-fPSA scAbs 
took approximately 7 days. The data were analysed using BIAevaluation software and 
the data report points exported into Excel, the graph of each binding profile for each 
analysed scAb were plotted (Figure 4.5). 
 
Figure 4.5: Ninety four scAb antibody fragments were analysed and ranked according to their 
binding to a set concentration of fPSA (30 nM). Each curve represents binding of fPSA to a 
captured scAb fragment. The degree of association and dissociation of fPSA to the scAb 
represents the apparent binding to the antibody fragment. Reports points were recorded 5 
seconds after the end of the injection and 295 seconds after injection and the percentage of 
stability remaining calculated and the scAb clones ranked (Table 4.1). 
 
Each scAb was ranked according to its percentage stability after a 5 min dissociation 
period. The association and dissociation rates for each selected scAb were significantly 
different (Figure 4.5). Some clones have quick on rates and quick off rates while some 
clones have slow on rates and slow off rates suggesting potential differences in binding 
affinities for fPSA. The results were tabulated (Table 4.1) and the percentage stability 
calculated (RU). 
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Table 4.1: This table represents the calculated complex stability of each scAb fragment 
analysed on the Biacore 3000. A range of stability percentage values for the scAb fragments 
were recorded in Excel. Binding responses less than 5 RU indicates little or no binding to 30 
nM fPSA (R<5RU) and such clones were subsequently discarded. 
scAb 
Clone 
Number 
% 
Stability 
fPSA 
scAb 
Clone 
Number 
% 
Stability 
fPSA 
scAb 
Clone 
Number 
% 
Stability 
fPSA 
scAb 
Clone 
Number 
% 
Stability 
fPSA 
1 N/A 25 52.92 49 N/A 73 N/A 
2 53.43 26 68.20 50 N/A 74 48.30 
3 N/A 27 64.29 51 N/A 75 N/A 
4 N/A 28 N/A 52 N/A 76 N/A 
5 70.17 29 62.35 53 N/A 77 N/A 
6 76.13 30 65.67 54 N/A 78 N/A 
7 N/A 31 69.01 55 N/A 79 N/A 
8 N/A 32 N/A 56 N/A 80 N/A 
9 82.04 33 49.36 57 N/A 81 N/A 
10 62.00 34 N/A 58 N/A 82 N/A 
11 60.00 35 33.79 59 N/A 83 49.84 
12 N/A 36 31.31 60 60.74 84 N/A 
13 N/A 37 12.94 61 N/A 85 N/A 
14 60.41 38 N/A 62 61.85 86 52.70 
15 57.94 39 N/A 63 61.96 87 68.39 
16 34.17 40 20.34 64 N/A 88 N/A 
17 71.04 41 58.31 65 N/A 89 N/A 
18 69.22 42 10.48 66 N/A 90 15.13 
19 63.40 43 54.36 67 N/A 91 N/A 
20 N/A 44 70.73 68 N/A 92 N/A 
21 N/A 45 67.55 69 75.47 93 55.76 
22 33.97 46 N/A 70 67.08 94 47.21 
23 N/A 47 69.70 71 6.45   
24 55.31 48 59.49 72 85.00   
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Antibodies with a 68% stability or greater were selected and subjected to preliminary 
kinetic analysis. This ‗cut-off‘ was chosen to reduce the risk of potentially missing high 
binder scAbs. Eleven clones with percentages stabilities above 68%, were selected and 
preliminary evidence demonstrated low nanomolar to picomolar range affinities using a 
1:1 Langmuir model (Table 4.2).  
 
Table 4.2: The affinities of each murine anti-fPSA scAb analysed were determined and ranked 
accordingly. The association and dissociation rate constants of each scAb fragment were 
recorded and preliminary affinities calculated using BIAevaluation software. The percentage 
stability after 5 minute dissociation (Table 4.1) obtained for each selected scAb is presented 
with the scAb name. 
Clone Name ka (1/Ms) kd (1/s) KD (M) 
scAb F5 (68 %) 2.88 x 10
6
 1.04 x 10
-3
 3.62 x 10
-10 
M 
scAb A1 (70 %) 2.51 x 10
6
 1.09 x 10
-3
 4.33 x 10
-10 
M 
scAb F6 (82 %) 2.51 x 10
6
 1.09 x 10
-3
 4.33 x 10
-10 
M 
scAb D8 (69 %) 3.48 x 10
6
 1.55 x 10
-3
 4.46 x 10
-10 
M 
scAb E7 (70 %) 1.17 x 10
6
 5.99 x 10
-4
 5.13 x 10
-10 
M 
scAb B6 (76 %) 1.67 x 10
6
 9.87 x 10
-4
 5.91 x 10
-10 
M 
scAb C8 (69 %) 1.55 x 10
6
 9.71 x 10
-4
 6.28 x 10
-10 
M 
scAb A8 (71 %) 2.76 x 10
6
 2.63 x 10
-3
 9.58 x 10
-10 
M 
scAb B5 (69 %) 3.08 x 10
4
 7.04 x 10
-5
 2.29 x 10
-9 
M 
scAb E4 (85 %) 3.75 x 10
6
 1.32 x 10
-3
 3.51 x 10
-9 
M 
scAb C2 (75 %) 6.70 x 10
6
 2.67 x 10
-3
 3.99 x 10
-9 
M 
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Figure 4.6: Preliminary kinetic analysis of a crude lysate from scAb F5 using a capture 
approach. A number of concentrations of fPSA were passed over the captured scAb and the 
curves plotted using a drifting baseline 1:1 Langmuir model in BIAevaluation. The residual plot 
shows the ‘goodness’ of the fit to the line. 
 
The curve (Figure 4.6) was fitted using a 1:1 Langmuir model with drifting baseline 
with a Chi
2
 value of 0.172. This value gives information about the ‗goodness‘ of the 
curve fit and for good qualitative data this value should be as low as possible. The 
residual plot shows the data points are distributed randomly above and below the zero 
line but are within acceptable limits. Initial evidence suggests that the 11 selected clones 
had similar affinities for fPSA as determined using BIAevalution software on the 
Biacore 3000 (Section 2.4.7). Therefore, the most suitable clone for assay development 
was chosen by inhibition ELISA based on its binding ability to compete for fPSA in 
solution or fPSA adsorbed onto the surface of an ELISA well. This involved expressing 
each individual scAb and analysing the crude protein lysate by ELISA to determine the 
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optimal working dilution for each fragment. Inhibition studies were performed using the 
appropriate working dilution for each antibody. These dilutions were incubated with 
various concentrations of fPSA for 1 hour at 37
o
C and added to a fPSA-coated plate. 
Bound murine anti-fPSA scAb was detected using anti-human C kappa AP-labelled 
antibody. The substrate, pNPP, was added for 30 minutes at 37
o
C and the absorbance of 
the wells read at 405 nm (Figure 4.7). 
 
 
Figure 4.7: An inhibition ELISA using the selected murine anti-fPSA scAbs. The murine anti-
fPSA scAbs were incubated with a range of fPSA concentrations (500, 333, 222, 148, 98, 66, 44, 
29, 19.5, 13 and 8.67 ng/mL) for 1 hour at 37
o
C and added to a fPSA-coated plate. Bound anti-
fPSA scAb was detected using anti-kappa alkaline phosphatase (AP)-labelled antibody. The 
substrate, pNPP, was incubated for 30 minutes at 37
o
C and the absorbance of the wells read at 
405 nm. 
 
The ELISA analysis showed varying degrees of binding to fPSA. The majority of the 
scAbs have different binding patterns as observed by ELISA but the scAb with the best 
potential for immunoassay development was scAb B5. Figure 4.7 would suggest that 
scAb B5 has an IC50 value less than 10 ng/mL. This selected murine anti-fPSA scAb 
was subjected to further characterisation and analysis. The amino acid sequences of 
each of the selected murine anti-fPSA scAbs (A1 to E4) were determined to investigate 
similarities and differences in the fragments. 
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4.2.4 Alignment of scAb clones from murine anti-fPSA library 
 
Bacterial stocks containing the murine anti-fPSA scAb clones were sent for sequencing 
to Eurofins MWG as agar stab cultures in 1.5 mL centrifugation tubes supplemented 
with carbenicillin (Section 2.5). The DNA sequences were received and subsequently 
translated into their amino acid sequence using ExPASy translation tool. The amino 
acid sequences were aligned and the complementary determining binding (CDR) 
regions of the antibody evaluated using ClustalW2 software.  The CDR regions of the 
antibodies were highlighted according to the Kabat scheme. The glycine-serine linker 
region of the clones was highlighted in green and scAb E7 is missing a glycine residue 
(indicated by a dash) in the linker region but this should have no impact on binding of 
the clone. The diversity between the clones is evident from the sequence variation 
between the heavy and light chains which are highlighted in red (Figure 4.8). The CDR 
L2, L3, H1 have slight differences in amino acid residues while CDR H2 is highly 
conserved between the analysed fragments. There is more diversity observed between 
the scAbs in CDR L1 and H3. The scAbs have 2 predominant amino acid sequences in 
the CDR L1 region with the exception of scAb E4. It has a hydrophobic proline amino 
acid residue in the CDR L1 region which is not present in any of the other sequences. 
Despite its hydrophobicity prolines are usually found on protein surfaces and play an 
important role in molecular recognition. Many serine residues are observed in the CDR 
L1 region and these are normally common within tight turns of proteins allowing for 
flexible movement and binding in the antigen pocket. A positively charged arginine was 
found in scAbs B5 and E4 which frequently plays a role in protein structure and prefers 
to be on the outside of proteins. However, this residue can cause non-specific binding to 
negatively charged surfaces (Birtalan et al., 2008). Asparagine was present in scAbs B6, 
A1 and E7 and tends to be frequently found in the active site of the protein. ScAb E7 
has an isoleucine residue which is probably buried deep within the proteins hydrophobic 
core. ScAbs A1, A8 and E7 have the greatest diversity in the CDR H3 region. Ippolite 
et al. (2006) revealed that 40% of the amino acid residues in the CDR H3 are tyrosine 
or glycine. Interestingly, scAb A1 has 5 tyrosine residues in CDR H3 which is an 
important amino acid residue in creating interactions at protein-protein interfaces and 
has a dominant role in antigen recognition (Koide and Sidhu, 2009). ScAb A8 has a 
proline residue at the end of the CDR H3 region while scAb E7 sequence was unclear as 
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a few amino acid residues were missing (indicated by a dash). Tyrosine in combination 
with glycine and serine residues have been shown to mediate high affinity antigen 
recognition (Biratalan et al., 2008) and the sequenced scAb fragments possessed an 
abundant level of these residues. 
 
 
F6              -XXLHGRRTQDIVMETTQSPASLPVSLGQRATISCRASEGVDLYGYSFIQ--WYQQKTGQ 57 
B6              -XXLHGRRTKDIVMETTQSPASLTVSLGQRATISCRASESVDSYGNSFMETHWYQQKPGQ 59 
E4              XMETHGRRTQDIVMETTQSPASLPVSLGQRATISCRAREGVDLYGYSFIP--WYQQKTGQ 58 
A1              ------------RIVITQSPASLAVSLGQRATISCRASESVDSYGNSFMETHWYQQKPGQ 48 
A7              -XXLHGRRTQDIVMETTQSPASLPVSLGQRATISCRASEGVDLYGYSFIQ--WYQQKTGQ 57 
A8              XMETHGRRTQDIVMETTQSPASLPVSLGQRATISCRASEGVDLYGYSFIQ--WYQQKTGQ 58 
B5              XCHRHGG-IKDIVMETTPSPASLPVSLGQRATISCRAREGVDLYGYSFIQ--WYQQKTGQ 57 
E7              -XXCTGWRTQDI--ELTQSPASLAVSLGQRATISCRASESVDNYGISFMETNWFQQKPGQ 57 
 
                
 
F6              PPKLLISRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSRDDPWTFGGGS 117 
B6              PPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSRDDPWTFGGGS 119 
E4              PPKLLISRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSRDDPWTFGGGS 118 
A1              PPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSRDDPWTFGGGS 108 
A7              PPKLLISRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSRDDPWTFGGGS 117 
A8              PPKLLISRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSRDDPWTFGGGS 118 
B5              PPKLLISRASNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSRDDPWTFGGGS 117 
E7              PPKLLIYASSNLKSGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGT 117 
 
                 
 
F6              KLELKRGGGGSGGGGSGGGGGSGGGGSEVQLQQSGTELAKPGASVKMETSCEASGYTFTN 177 
B6              KLELKRGGGGSGGGGSGGGGGSGGGGSEVQLQQSGTELAKPGASVKMETSCEASGYTFTN 179 
E4              KLELKRGGGGSGGGGSGGGGGSGGGGSEVQLQQSGTELAKPGASVKMETSCEASGYTFTN 178 
A1              KLELKRGGGGSGGGGSGGGGGSGGGGSEVQLQQSGTELAKPGASVKMETSCEASGYTFTN 168 
A7              KLELKRGGGGSGGGGSGGGGGSGGGGSEVQLQQSGTELAKPGASVKMETSCEASGYTFTN 177 
A8              KLELKRGGGGSGGGGSGGGGGSGGGGSEVQLQQSGTELAKPGASVKMETSCEASGYTFTN 178 
B5              KLELKRGGGGSGGGGSGGGGGSGGGGSEVQLQQSGTELAKPGASVKMETSCEASGYTFTN 177 
E7              KLELKRGGGGSGGGGSGGGG-SGGGGSQVQLQQSGAELARPGASVKLS--CKASGYTFTD 174 
 
                 
 
F6              YWMETHWIKQRPGQGLEWIGYINPSTGYTEYSQKFKDKATLTADKSSSTAYMETQLSSLT 237 
B6              YWMETHWIKQRPGQGLEWIGYINPSTGYTEYSQKFKDKATLTADKSSSTAYMETQLSSLT 239 
E4              YWMETHWIKQRPGQGLEWIGYINPSTGYTEYSQKFKDKATLTADKSSSTALHA--LSSLT 236 
A1              YWMETHWIKQRPGQGLEWIGYINPSTGYTEYNQKFKDKATLTADKSSSTAYMETQLSSLT 228 
A7              YWMETHWIKQRPGQGLEWIGYINPSTGYTEYSQKFKDKATLTADKSSSTAYMETQLSSLT 237 
A8              YWMETHWIKQRPGQGLEWIGYINPSTGYTEYSQKFKDKATLTADKSSSTAYMETQLSSLT 238 
B5              YWMETHWIKQRPGQGLEWIGYINPSTGYTEYSQKFKDKATLTADKSSSTAYMETQLSSLT 237 
E7              YWMETHWIKQRPGQGLEWIGYINPSTGYTEYSQKFKDKATLTADKSSNTAYMETQLNSLT 234 
 
                 
 
F6              SEDSAVYYCTRSRKLAMETDHWGQGTSVTVSS-ASGAEFAAAAPSVFIFPPSDEQLKSG 295 
B6              SEDSAVYYCTRSRKLAMETDHWGQGTSVTVSS-ASGAEFAAAAPSVFIFPPSDEQLKSG 297 
E4              SEDSAVYYCTRSRKLAMETDHWGQGTSVTVLLGLGGPNSRPPAHLSFLFPPS------- 288 
A1              SEDSAVYYCASYYGSSYATDYXGQGTSVTVSR-PRGPNSRPLHHLSSSSAH-------- 278 
A7              SEDSAVYYCTRSRKLAMETDHWGQGTSVTVSSASGAEFAAAAPSVFIFPPSDEQLKSG-- 295 
A8              SEDSAVYYCTRSRKLAMETDPWGQGNSVTVSSASGAEFAAAAPSVFTFPPSDEQL----- 293 
B5              SEDSAVYYCTRSRKLAMETDHWGQGTSVTVFSASGAEFAAAAPSVFIFPPSDEQLKSG-- 295 
E7              SEDSAVYFCAR------RLYVWGAGTTVTVSSASGAEFAAAAPSVFIFPPSDEQLKSGTASV 290 
 
                      
 
CDR L1 
CDR L2 CDR L3 
CDR H1 
CDR H2 
CDR H3 
Linker region 
Framework 1 Frame- 
work 2             Framework 3 Frame- 
work 4               Framework 1 
Framework 2 Framework 3 
Framework 4 
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Figure 4.8: Murine anti-fPSA scAb gene sequences from the immunised murine anti-fPSA 
library were translated into amino acid sequences using Expasy Translate tool and aligned 
using ClustalW2 sequence alignment program. The highlighted sequences in red show the 
CDRs (heavy and light chain) of the recombinant antibody fragments. The framework regions 
are highlighted in blue and the glycine-serine linker region is green. 
 
4.2.5 Protein expression, extraction, purification and analysis 
 
Large-scale expression of the murine anti-fPSA scAb B5 was performed in 500 mL 
culture as outlined in Section 2.7. The protein was extracted by sonication and the 
bacterial pellet removed by centrifugation. The protein lysate was passed through a 0.2 
µM filter to reduce clogging of the nickel resin. It was then applied to the resin and any 
histidine-tagged expressed proteins captured by the nickel resin. Nickel has a high 
affinity for histidine residues and other proteins pass through the column. Generally, 
histidine residues are uncommon in proteins with only 2% present in globular proteins 
and only half are exposed on the protein surface (Ueda et al., 2003). Material binding 
non-specifically was removed by washing the resin with 20 mL of running buffer (300 
mM NaCl, 20 mM imidazole and 0.5% (v/v) Tween) and the protein successfully eluted 
using a low pH buffer (10 mM sodium acetate pH 4.4) (Section 2.7). An immunodot 
blot visualised using an AP-labelled anti-human kappa antibody was used to confirm 
the presence of the murine anti-fPSA scAb in collected fractions (Figure 4.9). The 
IMAC-purified containing scAb fractions were pooled, centrifuged and analysed by 
SDS-PAGE and Western blotting (Figures 4.10 and 4.11). Bacterial lysate preparation 
is a critical step because the main purpose is to maximise protein extraction while 
minimising unwanted protein oxidation, proteolysis and possible contamination with 
genomic DNA (Structural Genomics Consortium, 2008). During IMAC purification it is 
important to resuspend the protein in high ionic strength buffer to ensure protein 
solubility and stability.  Modest levels of imidazole in the resuspension buffer bind 
proteins with less histidine residues, thus, reducing non-specific binding to the IMAC 
resin (Structural Genomics Consortium, 2008). 
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Figure 4.9: Each fraction was analysed to confirm elution of the murine anti-fPSA scAb from 
the nickel resin column. The individual fractions spotted (2.5 µL) on nitrocellulose paper were 
unpurified lysate, flowthrough, wash and each IMAC-eluted fractions The paper was blocked 
using 3% (w/v) BSA and detected using an anti-human C kappa AP-labelled antibody.  
 
The signal intensity increases significantly after the fifth elution fraction and the 
intensity of the signal is fairly uniform for all eluted fractions thereafter. The eluted 
fractions were pooled and concentrated by centrifugation at 4,000 rpm at 4
o
C using a 
5,000 molecular weight cut-off spin column. It is important to select a molecular weight 
cut-off (MWCO) below (approximately 4-fold lower) the protein size to ensure 
retention of sample. The protein was buffer exchanged to remove any residual sodium 
acetate solution and to ensure a high protein concentration of purified sample for 
analysis. Ultrafiltration is a common technique in separating proteins in size graded 
fractions. The MWCO of the vivaspin column denote the size of the protein for 
retention. The fractions (lysate, flow-through, wash and elution) were analysed by SDS-
PAGE (Figure 4.10) and Western blotting (Figure 4.11) to determine the degree of 
purity and the functionality of the murine anti-fPSA scAb (Section 2.7).  
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Figure 4.10: Lane 1 and 6 represents the Sigma colorburst marker, lane 2 contains unpurified 
sonicated lysate with all the proteins expressed in the bacterial cell lysate; lane 3 contains the 
flow-through with all unbound proteins passing through the resin; lane 4 contains any impure 
non-specific hydrophobic proteins which may weakly bind to the resin and are removed using 
an increased concentration of Tween 20 and lane 5 contains the purified eluted murine anti-
fPSA scAb with few contaminating proteins. 
 
 
Figure 4.11: Lanes 1 and 6 contain the Sigma colorburst marker; lanes 2, 3 and 4 contain the 
unpurified lysate, flow-through and wash fraction from the purification. Lane 5 represents the 
purified protein with a molecular size of 42 kDa’s. The membrane was probed using anti-human 
kappa AP-labelled antibody and developed using BCIP liquid substrate. It was quenched using 
100 mM EDTA. 
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The protein samples were resolved on SDS-PAGE gels to verify that the scAb exhibited 
the correct molecular weight (42 kDa) and to assess the purity of the isolated protein. 
While one gel was stained with Coomassie blue to visualise individual proteins 
expressed within the bacterial cell, the proteins on the other gel were transferred to a 
nitrocellulose membrane and subjected to Western blot analysis using an anti-kappa 
AP-labelled antibody. A large number of proteins were clearly visible in the lysate and 
flow-through with little or no proteins in the wash fraction for the Coomassie blue-
stained SDS-PAGE gel. A single band at the correct molecular weight for the expressed 
scAb fragment was evident in Figure 4.11 indicating its relative purity.  
 
4.2.6 Time course expression profile analysis for scAb expression 
 
An expression time course experiment was performed on the murine anti-fPSA scAb 
described in Section 2.8. Before induction with IPTG (1 mM final concentration) a 1 
mL sample was removed and every hour after induction 1 mL samples were removed 
from the culture and stored at -20
o
C. In addition, a 1 mL sample was removed from the 
expressed overnight culture. The samples were sonicated, the bacterial pellet 
centrifuged and the protein analysed by SDS-PAGE (Figure 4.12), Western blotting 
(Figure 4.13) and ELISA (Figure 4.14). The highest level of murine anti-fPSA scAb 
expression was observed in the overnight sample. 
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Figure 4.12: Time course experiment for the expression of the murine anti-fPSA scAb product. 
Lane 1 represents the fermentas pageruler
TM
 prestained marker for protein size determination 
while lanes 2 – 8 represent 1 mL sample fractions harvested at 0, 1, 2, 3, 4, 5, 6 hours and 
overnight post-induction, respectively. 
 
 
Figure 4.13: The individual samples were analysed to investigate the levels of protein 
expression over time. The proteins were transferred to a nitrocellulose membrane and 
detected with an AP-labelled anti-human C kappa antibody. The level of murine anti-
fPSA scAb increased after 3 hours of induction with the greatest level expressed in the 
overnight sample. 
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Figure 4.14: The individual 1 mL samples (0, 1, 2, 3, 4, 5, 6 hours and overnight) were 
analysed for expression by ELISA. The lysates were detected using an anti-human kappa AP-
labelled antibody. The substrate, pNPP was incubated for 30 minutes at 37
o
C and the 
absorbances read at 405 nm. 
 
The SDS-PAGE (Figure 4.12), Western blotting (Figure 4.13) and ELISA results 
(Figure 4.14) confirmed the maximum expression levels of protein expression for the 
murine anti-fPSA scAb was observed after incubating the culture overnight at 30
o
C 
following induction with 1 mM IPTG. It is important to induce the culture at mid-to-late 
log phase of growth for maximum levels of expression with a lower temperature for 
induction to allow proper folding of the newly transcribed recombinant protein 
(Structural genomics Consortium, 2008). They report that cells should be grown to high 
cell density overnight for sufficient levels of protein expression. Large scale expression, 
protein extraction and IMAC purification of the murine anti-fPSA scAb were performed 
for downstream assay development. 
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4.3 Avian clone analysis 
 
The selected avian anti-fPSA recombinant antibody fragments from panning were 
subjected to further characterisation on the Biacore A100. The assay format employed 
was similar to the custom design method for ranking the murine anti-fPSA scAb. 
However, analysis was performed at a significantly faster rate due major advancements 
in the software and hardware of the A100 compared to the Biacore 3000. The A100 is 
ideal for high sample throughput analysis of proteins with high quality data analysis and 
an integrated evaluation software for rapid interpretation of results.   
 
 4.3.1 Analysis of the avian anti-fPSA Fab and scFv fragments on the Biacore A100 
instrument 
 
The avian anti-fPSA scFv and Fab fragments were analysed by Dr. Paul Leonard in 
Uppsala, Sweden using the A100 Biacore (Section 2.11). The avian anti-fPSA Fabs 
were predominantly expressed with a constant lambda (Cλ) chain as determined by 
ELISA as described in the previous, section 3.11, (Figure 3.20). Therefore, all four flow 
cells were immobilised with an anti-Cλ antibody using amine coupling chemistry. The 
96 avian anti-fPSA Fabs were screened against three concentrations of fPSA (30, 5 and 
0 nM). The recombinant antibody was captured and fPSA injected for 2 minutes with a 
10 minute dissociation time. The surface was finally regenerated with a 30 second 
injection of 10 mM NaOH. The complete analysis time of the 96 anti-fPSA Fabs was 26 
hours. All sensorgrams were referenced subtracted against an unmodified CM5 surface 
(spot 3). The zero concentration was then subtracted from the 30 and 5 nM sensorgrams 
(double referencing) to remove any systematic instrument disturbances. The data were 
evaluated using a 1:1 Langmuir equation with drifting baseline and global fit. Twenty 
six Fabs were classified as ‗OK‘ and therefore, the kinetic rate constant values can be 
trusted. Seventeen were classified as ‗inspect‘ but the reason may be largely attributed 
to low signal to noise ratio. The avian anti-fPSA scFv were analysed using a similar 
capture assay approach with an anti-HA immobilised surface and kinetic analysis 
performed on 7 of the 48 tested fragments.   
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The percentage stability was calculated by dividing the stability late dissociation 
response (after 10 min) by the stability early response (5 seconds after the end of the 
fPSA injection) and multiplying by one hundred. Subtractive referencing was 
implemented whereby the refractive index from the blank flow cell and the binding 
response from HBS buffer injected over the captured antibody fragments were 
subtracted from the fPSA binding response 
 
4.3.1.1 Avian anti-fPSA Fab clone analysis 
 
The selected avian anti-fPSA Fabs were ranked according to the percentage stability of 
binding to 30 nM fPSA after a 10 minute dissociation. The percentage stability for each 
Fab fragment was calculated and a bar chart plotted in Excel (Figure 4.16).  
 
 
Figure 4.16: Percentage stability remaining during dissociation for all Fab samples 
calculated using double reference data for 30 nM on spot 1 (high immobilisation level). X-axis 
scale does not contain all sample names due to space constraints. Samples that due to drift 
were above 100% were set to 100%. 
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Figure 4.17: The percentage stability remaining plotted against the calculated ‘off-rates’. The 
two calculated numbers show high correlation especially for the slower ‘off-rates’.  
 
The majority of the Fabs analysed had high percentage stability after 10 minute 
dissociation. The clone ranking patterns were different suggesting diverse affinities for 
fPSA. An important consideration when designing the Biacore screening assay was to 
determine the most productive approach that can be used for screening large panels of 
antibodies in the shortest time-frame. Ideally, it would be acceptable to screen each 
antibody once and determine the best clones from the data. To evaluate this, association 
and dissociation rates of each clone were analysed against PSA at multiple analyte 
concentrations and at 30 nM (Figure 4.18 and 4.19). 
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Figure 4.18: The association rate of nineteen of the analysed Fabs against single and multiple 
fPSA concentrations were compared. The ‘on-rate’ plot shows that the majority of the Fabs 
gave good correlation between single and multiple analyte analysis. However, there are Fabs, 
such as 2D3, that show large variation in ‘on-rate’. In this assay setup with a very low Rmax 
the system can measure ‘on-rates’ as fast as 1x107 and therefore, the data fitting for clone 2D3 
is not correct and cannot be trusted. However, using multiple analyte concentrations the on-rate 
is still quite fast and would be included for further analysis. 
 
Fourteen of the 19 clones analysed had similar ‗on-rates‘ when analysed using single 
and multiple injections of fPSA. Two (1A4 and 2F8) of the remaining 5 had faster ‗on-
rates‘ when analysing multiple injections while 3 Fabs (1D1, 2D3 and 2E7) had faster 
‗on-rates‘ with a single fPSA injection. 
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Figure 4.19: The dissociation rate of the nineteen analysed Fabs against single and multiple 
fPSA concentrations. It shows that the majority of these antibodies have practically the same 
‘off-rate’. However, we do see some outliers with up to 10 fold difference in ‘off-rate’ for Fab 
1D5. This difference is probably due to sensorgram artefacts which can occur and either 
decrease or increase ‘off-rate’ values.  
 
Sixteen of the 19 Fabs analysed had similar off rates when analysed using single and 
multiple injections of fPSA. Two (1D5 and 2F8) of the remaining 3 had quicker ‗off-
rates‘ when analysing multiple injections while clone 1D1 had quicker off rates with a 
single fPSA injection.  
 
Kinetic analysis was performed on 26 of the best selected avian anti-fPSA Fabs. These 
were selected on the basis of their percentage complex stability (Figure 4.16). The 
individual Fabs were captured and then fPSA injected. The data was interpreted using 
BIAevaluation software using a 1:1 Langmuir model with a drifting baseline and a 
global fit. The curve was fitted with a drifting baseline as the avian anti-fPSA Fab was 
dissociating from the surface and this needs to be taken into final consideration in the 
evaluation of the data. A global fit was applied to the data as the response levels of the 
captured avian anti-fPSA Fab lysate vary due to expression level differences.  
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Figure 4.20: The Biacore A100 instrument software comes with the added advantage of 
automated data evaluation analysis allowing for quality control of data. The software ranks 
the curve fitting into four categories, GOOD, ATTENTION, INSPECT and DISCARD. The 
four sensorgrams shown here are examples of good fits irrespective of capture level. The 
curves on the right demonstrate that the capture level is very low but the fitting is still 
reasonably good.  
 
The capture levels of fPSA are higher for Fabs 1C1 and 1C6 than 2D8 and 2D3 (Figure 
4.20). However, the data curve fitting for all of the sensorgrams was acceptable. All 
these clones were analysed at room temperature and temperature can have a huge effect 
on binding of the antibody to the protein and this needs to be considered when 
designing an immunoassay. Changes in temperature affect the binding abilities of 
antibodies as well as stability. For commercialization purposes it is important to 
determine which antibodies are suited for the proposed assay. The clones were analyzed 
at two temperatures (25 and 37
o
C). Nineteen of the antibodies were classified as either 
‗OK‘ or ‗inspect‘ at both temperatures. The differences in kinetics for these antibodies 
were compared in two bar graphs (Figures 4.21 and 4.22) 
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Figure 4.21: Dissociation rates for the 19 antibodies with well determined kinetics at both 25 
and 37
oC. Most antibodies change by about a factor of 5 in ‘off-rate’. 1A5 changes very 
significantly whereas 1D5 seems relatively unaffected. 
 
 
 
Figure 4.22: Association rates for the 19 antibodies with well determined kinetics at both 25 
and 37
o
C.  Sixteen of the screened clones showed a faster on-rate at 37
o
C with three having a 
slower association (1A4, 1D6 and 2F8).  
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Figure 4.23: ‘On/off-rate’ map of the analysed clones at 37 and 25oC. There is a general shift 
to the top right corner when analysing the fragments at a higher temperature (37
o
C) and the 
association and dissociation rates are faster but the general spread of affinities are the same. 
Interestingly temperature can have a major effect on affinity as seen in clone 1B5 with an 
affinity change from 170 nm at 30
o
C to 5 nm at 37
o
C. The antibodies of major interest are those 
that do not change in affinity with respect to temperature change (e.g. 1D5).  
 
Assay performance can be hugely influenced by temperature (Figure 4.23). Clones with 
unfavourable shifts in performance at different temperatures (clone 1B5) are unsuitable 
for certain assays. Clones (1D5) with similar affinities over a range of temperatures are 
desirable for assay design.  
 
4.3.1.2 Avian anti-fPSA scFv analysis 
 
Forty eight avian anti-fPSA scFv were analysed using an anti-HA immobilised chip. 
Four fPSA concentrations, one in duplicate and a negative (0 nM fPSA) were passed 
over each captured scFv and the interaction studied (Figure 4.24). Among the 48 scFvs 
only 13 showed any binding at 10 nM, which was the highest analyte concentration 
included. Binding kinetics could be determined for 7 of the 13 binders. The remaining 
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scFvs showed too low binding level characteristics preventing a good assessment of the 
kinetics. 
 
 
 
Figure 4.24: Anti-HA-labelled antibody was immobilised onto 4 spots within a flow cell 
using one spot as a blank reference. Two scFv fragments are captured per flow cell and 
fPSA injected over every spot. The binding response from the blank flow cell and the 
reference spot were subtracted from the binding response from the capture scFvs.  
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Figure 4.25: ‘On’ and ‘off-rates’ for the 7 scFv’s for which the kinetics could be determined. 
The ‘off-rates’ are generally faster than for the Fab antibodies against fPSA. 
 
Series 32 (B7), 39 (C4), 22 (D6) are the only three with affinities below 1 nM (Figure 
4.25). They have calculated affinities from 50 to 500 nM. Overall, the avian anti-fPSA 
recombinant antibody fragments were successfully evaluated using the Biacore A100 
and avian anti-fPSA scFv clone D6 was shown to have the best affinity of all the avian 
antibodies analysed. 
 
4.4 Determination of antibody pairs for sandwich assay development 
 
This type of assay is the one of the most common immunoassays performed in which 2 
antibodies recognise different epitopes of the same antigen. The analyte is sandwiched 
between the immobilised capture antibody on the surface and probed using a detection 
antibody. An important consideration when designing a sandwich assay is to 
categorically confirm both antibodies do not bind overlapping antigenic epitopes. 
Therefore, a Biacore sandwich assay was completed to investigate antibody pairs which 
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could be utilised in a sandwich assay format. The purified murine anti-fPSA scAb was 
captured using an anti-human C kappa mAb-immobilised-CM5 dextran surface chip. 
The fPSA molecule (1 µg/mL) was passed over the captured antibody and probed using 
avian anti-fPSA Fab and scFv lysates (Table 4.3).  The assay was repeated without the 
presence of the fPSA molecule to confirm no NSB between the capture and detection 
antibody (Section 2.12).  
 
Table 4.3: Epitope mapping was performed by capturing the purified murine anti-fPSA clone 
B5 scAb on the anti-human kappa mAb immobilised surface, passing over 1 µg/mL fPSA and 
injecting the avian clone lysates. A number of avian antibodies could be considered for a 
sandwich assay format as they seem to bind different epitopes of fPSA. 
Avian Clone Captured scAb (RU) Captured fPSA (RU) Captured Avian (RU) 
2F8 Fab 93.8 110.5 135.1 
1C1 Fab 100.4 118.4 109.3 
1A5 Fab 114.2 131.3 132.5 
1D5 Fab 97.5 110.5 135.1 
1D6 scFv 95.8 115.5 98.1 
 
The epitope mapping Biacore assay identified a number of potential avian antibody 
fragments (2F8 and 1D5 Fabs) which could be utilised in a sandwich immunoassay 
format. These Fabs recognise and bind different epitopes on the fPSA molecule than the 
captured murine anti-fPSA scAb.  
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4.5 Discussion 
 
This chapter describes the screening and characterisation of anti-fPSA scAb, scFv and 
Fab antibody fragments. These antibody fragments were expressed in bacteria with 
different epitope tags (kappa domain for scAb, HA domain for scFv and lambda domain 
for Fab) which do not interfere with the antigen/antibody binding complex formation 
and seldom affect biological activity (Structural Genomics Consortium, 2008). These 
tags facilitated high throughput analysis of positive clones by immobilising anti-kappa, 
anti-lambda or anti-HA antibodies onto the surface of a CM5 dextran chip and 
subsequent Biacore-based analysis. 
 
In the previous chapter the selection of a large panel of positive recombinant antibody 
clones from immunised animals by phage display was outlined. This created a positive 
dilemma as each clone needed to be evaluated to determine the highest affinity 
antibody. The analysis process can be extremely time-consuming and expensive 
depending on the selection format (e.g. ELISA). Also, important information like 
dynamic complex formation cannot be determined from ELISA-based assays. The 
Biacore offers a rapid high-throughput ‗real-time‘ analysis format for ranking individual 
clones. Leonard et al., (2007) reported screening and ranking of avian recombinant 
antibody fragments using crude bacterial lysates on the Biacore A100. They developed 
a capture assay format which could potentially screen 400 antibody clones per day. The 
purity of the immobilising ligand is critical to prevent NSB and ensure good quality 
data for interpretation. The anti-human C kappa antibody was supplied in ascites fluid 
so it had to be purified using protein G, passed through a size exclusion PD-10 column 
and eluted in molecular grade H2O. Preconcentration studies of the protein G-purified 
anti-kappa antibody diluted in 10 mM sodium acetate buffer at different pH values 
(Figure 4.1) were evaluated. The maximum levels of apparent binding were observed in 
10 mM sodium acetate, pH 4.0, which was used for the immobilisation. The purified 
anti-human C kappa antibody was immobilised on all four flow cell surfaces using 
EDC/NHS chemistry. A custom wizard was designed on the Biacore 3000 instrument 
for ranking of the murine anti-fPSA scAb clones. The wizard enabled three scAb clones 
to be captured simultaneously leaving flow cell one as a blank reference. Therefore, a 
capture assay format using a drifting baseline was implemented. One µg/mL fPSA (30 
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nM) was passed over the surface of all four flow cells and the percentage stability 
(stability late/stability early x 100 %) for 94 antibody fragments measured over a five 
minute dissociation period. The 94 fragments were ranked on the basis of their binding 
to 30 nM fPSA (Table 4.1) and the best selected with a ‗cut-off‘ of over 68 % stability 
after 5 minute dissociation. Kinetic analysis was performed with initial affinities 
ranging from 3.99 x 10
-9
 M to 3.62 x 10
-10
 M (Table 4.2). The murine anti-fPSA B5 
scAb was selected as it was found to be more inhibitive in ELISA than the other clones 
even though their affinities were very similar (Figure 4.7). 
 
The murine anti-fPSA B5 scAb was expressed in large scale (500 mL) and the protein 
extracted by sonication. The protein was purified by IMAC and each eluted fraction 
confirmed the presence of the murine anti-fPSA scAb by immunodot blot (Figure 4.9). 
The fractions containing the purified scAb were buffer exchanged and stored at -20
o
C. 
The fractions (lysate, flowthrough, wash and elution) were analysed by SDS-PAGE and 
Western blot (Figures 4.10 and 4.11). A time course experiment confirmed that the 
maximum level of expression of the murine anti-fPSA scAb was achieved overnight at 
30
o
C.  Individual samples were analysed by SDS-PAGE, Western blotting and ELISA 
(Figures 4.12, 4.13 and 4.14, respectively). The murine anti-fPSA scAbs were sent to 
MWG for sequencing and differences in the amino acid residues in binding regions of 
the CDR confirmed the selection of a range of antibody fragments (Figure 4.8). ScAb 
A1 has 3 tyrosine amino acid residues in CDR H3 which has shown to be an important 
residue in protein-protein interactions. A high proportion of the tested scAb fragments 
had serine residues in the CDR L1 which allows flexible movement of the antibody 
fragment which is important for binding in the antigen active site. Two scAb fragments 
(B5 and E5) had a positive arginine residue in the CDR L1 domain which prefers to be 
positioned on the outside of the protein and is involved in protein structure. A recent 
report by Sidhu et al., (2009) suggests that tyrosine, tryptophan and arginine are 
common interface amino acid residues for protein-protein recognition. 
 
The avian anti-fPSA scFvs and Fabs were analysed on the Biacore A100 instrument by 
Dr. Paul Leonard in Uppsala, Sweden. They were ranked based on their percentage 
stability after 10 minute dissociation. Multiple and single injection of fPSA were 
examined to determine similarities or differences in binding with respect to 
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concentration. The binding abilities of the Fabs were analysed under different 
temperatures (25 and 37
o
C) to determine the effect of temperature on each clone. The 
temperature increases the association rate of 18 of the 19 clones and the dissociation 
rate of 16 of the 19 analysed. The affinity of one of the avian anti-fPSA Fab (1D5) 
seemed unaffected by the change in temperature, therefore making it a good antibody 
candidate for assay development.  
 
The avian anti-fPSA scFvs were captured on an anti-HA immobilised chip and 
individually ranked. Out of the 48 scFvs analysed 3 scFv fragments had affinities of less 
than 1 nm (B7, C4 and D6). A significant advantage of using the Biacore A100 over the 
3000 instrument is the time reduction in high throughput analysis. Using the Biacore 
3000 instrument, 94 murine anti-fPSA scAbs were analysed in 7 days while on the 
Biacore A100 96 avian anti-fPSA Fabs were analysed in 26 hours. This is due to the 
number of flow cells available for analysis. The Biacore 3000 has 4 flow cells while the 
A100 has 4 flow cells with 5 spots in each flow cell allowing for 20 interactions per 
cycle. The instrument has a built-in software system that selects the data and evaluates it 
with confidence for good kinetic and affinity values. On the Biacore 3000 data 
interpretation and analysis of results can be a very time consuming but are reliable and 
reproducible. A comparative study reported by Katsamba involved 22 investigators 
exploring assay reliability on the Biacore. The assay design involved immobilising the 
monoclonal antibody onto the chip surface and analysing a series of PSA 
concentrations. Systematic artefacts were removed from the curves for good quality data 
and kinetic analysis determination using BIAevaluation software. The antibody showed 
an overall affinity of 1.1 x 10
-9
 nM (Katsamba et al., 2006). Some of the selected 
murine and avian clones show better affinity than the tested monoclonal antibody in this 
study. Both the murine and avian recombinant antibody fragments have low picomolar 
affinity as determined by Biacore.  
 
Currently, few papers describing murine and avian anti-fPSA recombinant antibody 
fragments have been published as most researchers have generated monoclonal 
antibodies. Rojas et al. (2002) constructed a phage antibody fragment library by 
combining a synthetic human light chain variable region (VL) with a diverse set of 
heavy chain variable regions selected from a mouse immunised with PSA. The apparent 
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affinities for 2 clones selected were 3.5 x 10
-9
 M and 1.5 x 10
-9
 M as determined by 
ELISA. Leinonen et al. (2004) investigated the development of monoclonal antibodies 
against PSA by genetic immunisation. Only five monoclonal antibodies were 
successfully obtained and their affinity constants were between 3.2 x 10
-8
 and 7.0 x 10
-9
 
M. Popkov et al. (2004) developed rabbit monoclonal antibodies that recognise cell 
surface tumour-associated antigens expressed in PCa. Their study involved using phage 
display technology for the selection of human prostate cancer cell reactive antibodies, 
namely, Fab antibody fragments. New Zealand white rabbits were immunised with 
human prostate cancer cell lines (LNCap or DU145). Chimeric rabbit/human Fab 
libraries were generated and selected by a positive/negative selection strategy. Acevedo 
et al. (2002) developed a quantitative ELISA for the measurement of PSA 
concentration. Mouse monoclonal antibodies with affinities of 3.7 x 10
-9
 M and 4.7 x 
10
-10 
M were used to develop this assay. The assay can detect both free and complex 
PSA in the sera of patients. The monoclonal antibodies discussed in this paper have 
similar affinities to the generated anti-fPSA scAbs (3.99 x 10
-9
 M to 3.62 x 10
-10
 M). 
However, 4 of the selected murine scAb fragments (F5, A1, F6 and D8) show better 
affinity determined by Biacore. A number of the analysed avian antibody fragments 
(1A5 Fab and D6 scFv) have better affinities over the reported monoclonal antibodies. 
 
Several surface-plasmon resonance (SPR)-based assays for the detection of PSA have 
been reported. Huang et al. (2005) have recently reported the development of an 
immunosensor using a commercial SPR biosensor (Biacore 2000) for detection of PSA 
concentrations as low as 1 ng/mL. Biacore SPR chips are usually composed of a 
carboxymethyl dextran matrix linked to a gold substrate on the sensor surface. 
However, self-assembled monolayers (SAMs) have been used as the immobilisation 
substrate and have been shown to give better sensitivities than dextran layers (Frederix 
et al., 2003). The PSA assay reported by Huang and co-workers used camel anti-PSA 
antibody fragment attached to a mixed SAM of thiols for PSA capture, and a 
biotinylated mouse monoclonal anti-PSA antibody and streptavidin-modified gold 
nanoparticles for detection. Yu et al. (2004) reported the use of a CM5 Biacore chip as a 
dextran surface onto which a sandwich assay for fPSA was located. The assay 
combined SPR and fluorescent labelling, i.e. surface plasmon field-enhanced 
fluorescence spectroscopy (SPFS). This technology uses surface plasmons to excite the 
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fluorescent label and produce the signal. The limit of detection observed was 80 fM for 
a 40 minute contact time, many orders of magnitude lower than detection limits of PSA 
assays commercially available today. The murine and avian recombinant antibody 
fragments were analysed using the Biacore 3000 and A100, respectively. Capture assays 
were developed with low picomolar affinity antibodies selected for both species. 
Thaxton et al. (2009) reported an ultrasensitive nanoparticle-based bio-barcode assay 
for the detection of PSA. The assay is approximately 300 times more sensitive than 
commercially available immunoassays and has the ability to detect 330 fg/mL. It is a 
promising diagnostic tool capable of detecting extremely low levels of PSA in men after 
radical prostatectomy which would go unnoticed using commercial immunoassays.   
 
Researchers are aiming to develop point-of-care testing (POCT) which will undoubtedly 
help in PCa detection. Currently, the turnaround time for patient results could be a 
number of weeks as samples are analysed at dedicated clinical centres. There is a 
progression towards the use of label-free biosensors formats for PSA detection and the 
success of these biosensor formats in future POCT devices depends on the ability to 
integrate the format into devices that include simple and efficient sample handling and 
readout systems (Healy et al., 2007).  
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Chapter 5 
 
Assay development and 
immunohistochemistry studies for fPSA 
detection 
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5.1 Introduction 
 
This chapter focuses primarily on the development of a sensitive assay for the detection 
of fPSA by Biacore and ELISA. Inhibition and sandwich-based assays were performed 
using the murine anti-fPSA scAb and avian anti-fPSA scFv. A subtractive Biacore 
inhibition assay was developed using a fPSA-immobilised CM5 dextran surface chip. 
The purified murine anti-fPSA scAb was incubated with varying concentrations of 
fPSA, injected over the fPSA-immobilised chip surface and the binding response 
recorded. A decrease in the binding levels of antibody (reported in RU) to the surface 
was observed with increasing fPSA concentration. The results were normalised by 
dividing the binding response for each concentration by the maximum binding response 
(Ro, scAb incubated with no fPSA). The Biacore inhibition assay confirmed that the 
murine anti-fPSA scAb was displaced in the presence of fPSA. Inter-day and intra-day 
assays were performed to verify the accuracy and precision of the immunoassay format. 
The coefficients of variation (CV‘s) were determined for each concentration and 
calibration curves generated from the data using a four-parameter equation for 
immunoassays using BIAevalution 3.1 software
TM
 and the percentage accuracies for 
each sample back-calculated from the curve. An inhibition ELISA using the murine 
anti-fPSA scAb was also evaluated to compare the level of sensitivity to the Biacore 
inhibition assay. Inhibition studies showed that the ELISA assay format was not as 
sensitive as the Biacore assay.  
 
The assay sensitivity was significantly improved by performing a sandwich-based 
ELISA assay. The murine anti-fPSA scAb was successfully biotinylated and 
subsequently captured using neutravidin with the avian anti-fPSA clones used as the 
detection antibodies. The five avian (4 Fabs/1 scFv) antibody fragments were retested 
by ELISA to determine whether or not they bind non-overlapping epitopes of fPSA. 
Intra-day and inter-day assay calibration curves were generated with CVs and 
percentage accuracies for each analyte. A Biacore-based sandwich assay was 
investigated but showed no improvement in assay performance over the direct murine 
anti-fPSA scAb Biacore inhibition assay. Precision assays were evaluated using 20 
blanks and 20 replicates of fPSA at 2 concentrations (2.5 and 1.8 ng/mL in PBST) to 
determine the limit of detection of the assay. The sandwich ELISA assay approach was 
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repeated using serum from females spiked with fPSA to determine sensitivity levels in 
the serum matrix. The serum of individuals presenting with PCa and with known tPSA 
values were analysed using the sandwich ELISA to determine the performance of the 
assay on clinical samples. Immunohistochemistry studies were performed on prostate 
tissue samples using both murine and avian anti-fPSA recombinant antibody fragments. 
A key parameter for the generated recombinant antibodies is that they recognise PSA in 
the context of the secreted protein in tissue samples. Therefore, studies involving 
normal and PCa tissues samples were undertaken in Beaumont Hospital. It is vital that 
the protein is not altered by subtle downstream changes (e.g. proteolysis) that could 
minimise binding of the recombinant antibody fragments. It was confirmed that both 
murine and avian anti-fPSA antibodies bound successfully to the tissue samples 
analysed. However, the degree of tissue staining intensity was less than the positive 
control but this was expected since the control antibody was a polyclonal and detects 
tPSA while both the avian and murine recombinant antibody fragments bind fPSA 
which is approximately 25 % of tPSA. This study showed that recombinant antibodies 
can be successfully employed in detecting secreted proteins in prostate tissue samples 
and can be used in the diagnosis of prostate cancer. 
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5.2 Development of a subtractive inhibition Biacore assay for fPSA 
 
The purified murine anti-fPSA scAb B5 was chosen based on its overall ability to bind 
fPSA in solution, as determined by ELISA in Section 4.2.4 (Figure 4.7). The fPSA 
molecule was successfully immobilised onto the surface of a CM 5 dextran chip and, 
following optimisation of the conditions for assay performance an inter-day study was 
completed. The range of assay sensitivity as determined by Biacore was 31.3 – 6.3 
ng/mL (results not shown). Biacore-based PSA assays have been reported in the 
literature. Huang et al. (2005) reported a PSA SPR immunoassay using camel 
antibodies immobilised on the chip surface. The concentration detected using the direct 
approach was 10 ng/mL PSA. However, sensitivity was improved to the sub ng/mL by 
employing a sandwich assay approach. Cuong et al. (2005) fabricated a sandwich SPR 
strategy for the detection of PSA-ACT in both HBS buffer and human serum samples 
with detection concentrations of 10.2 and 18.1 ng/mL, respectively.  
 
5.3 Murine anti-fPSA inhibition ELISA assay with inter-day and intra-day studies 
 
A solid phase inhibition-based ELISA was performed using the purified murine anti-
fPSA scAb to compare levels of assay sensitivity with the Biacore assay format, 
described in Section 5.2. After optimising the antibody working dilution for assay 
development inter-day and intra-day inhibition studies were performed. Calibration 
curves were generated with percentage CV and accuracy values. The range of 
sensitivity for the ELISA-based inhibition assay was 100 to 3.9 ng/mL fPSA (results not 
shown). This ELISA assay format showed similar levels of sensitivity as the Biacore 
assay. Therefore, the assay format was modified to investigate if sensitivity could be 
improved. 
 
As reported in the literature by both Huang et al. (2005) and Cuong et al. (2005) assay 
sensitivity could be further improved by implementing a sandwich-based assay. They 
reported using a biotinylated antibody for sandwich assay development. Therefore, the 
murine anti-fPSA scAb was biotinylated and utilised in ELISA and Biacore-based 
immunoassays. 
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5.4 Biotinylation of the purified murine anti-fPSA scAb and assay development  
 
NHS-Biotin is a 244 Da water soluble vitamin which can bind primarily to lysine 
residues of proteins. The murine anti-fPSA scAb was biotinylated and employed in a 
lateral flow immunoassay. Naturally biotin has a high affinity for 
streptavidin/neutravidin so a sandwich assay was investigated. The sandwich assay 
format involved capturing the biotinylated murine anti-fPSA scAb on a neutravidin-
coated plate and using an avian anti-fPSA scFv as the detection antibody. Precision 
assays were performed to determine the limit of detection of the assay with 95% 
confidence. Female serum samples were spiked and assay sensitivity investigated and 
serum samples from patients presenting with PCa analysed. PCa tissue samples were 
analysed using the generated recombinant antibody fragments to confirm specific 
binding to the secreted protein. 
 
5.4.1 Biotinylated of the murine anti-fPSA scAb 
 
The purified murine anti-fPSA scAb was successfully biotinylated using the Pierce EZ-
link biotinylation kit. During the biotinylation procedure biotin is covalently attached to 
the primary amines (lysines) of the recombinant antibody. The degree of biotinylation 
was determined using the HABA/Avidin test, as described in section 2.16. A sandwich 
assay format was investigated with the aim of improving assay sensitivity. 
 
5.4.2 Sandwich ELISA-based assay 
 
After confirming by ELISA the anti-fPSA secondary antibodies bound different 
epitopes of the captured fPSA molecule  as described in Section 2.17 (Figure 5.1), the 
optimal coating concentration of neutravidin was determined (5 µg/mL) and the TMB 
substrate incubation time was investigated to compare assay sensitivity between 10 and 
20 min incubation periods. A twenty minute incubation period was optimal with no 
increase in background signal observed. 
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Figure 5.1: Sandwich ELISA using the captured biotinylated murine anti-fPSA scAb and anti-
tPSA mAb, anti-fPSA mAb, anti-cPSA mAb and purified anti-fPSA scFv as detection antibodies. 
Each of the primary anti-PSA antibodies were detected using the appropriate enzyme-labelled 
secondary antibodies. 
 
Both commercial (anti-tPSA/fPSA mAbs) and the avian anti-fPSA scFv successfully 
recognised different epitopes on the fPSA molecule than the neutravidin captured 
biotinylated murine anti-fPSA scAb. The commercial anti-cPSA mAb did not bind to 
the captured fPSA molecule and no background signal was observed (Ao). 
 
5.4.3 Pre-study validation of sandwich ELISA assay 
 
To ensure an accurate, reliable working assay format the sandwich ELISA was repeated 
over three days (inter-day assay) as decribed in Section 2.23. The sample batches were 
made fresh on the day of analysis. The dilutions, incubation times and washing steps 
were performed accurately each day to guarantee a reproducible assay format (Figure 
5.2). The % CV and % accuracies were calculated for each concentration assessed 
(Table 5.1). An intra-day sandwich ELISA was performed 4 times using the same 
dilution batches over a period of one day to evaluate the overall precision of the assay. 
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The data was evaluated using a 4-parameter fit equation using BIAevaluation (Table 
5.2). 
 
 
Figure 5.2: Inter-day assay calibration curve for the determination of fPSA in PBST. A plate 
was coated with 5 g/mL neutravidin and blocked using 3% (w/v) BSA in PBS. The biotinylated 
murine anti-fPSA scAb was captured and a number of fPSA concentrations (25, 18.8, 14, 10.5, 
8.0, 6.0, 4.5, 3.3, 2.5, 1.8, 1.4, 1.0, 0.8 and 0.6 ng/mL) added to the plate. The purified avian 
anti-fPSA scFv was detected using an anti-HA-HRP-labelled antibody. The data is a result of 
three replicate measurements over a three day period. Using BIAevaluation 3.1 software the 
data was fitted with a 4 parameter equation and the original data points for each concentration 
added to the curve. The error bars represent the standard deviation for each concentration 
analysed in triplicate over a three day interval. 
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Table 5.1: Inter-day studies using a sandwich assay format with various fPSA concentrations 
and determination of the coefficient of variation. 
Concentration 
fPSA (ng/mL) 
Back-calculated 
concentrations 
(ng/mL) 
% CV’s % Accuracies  
25.0 25.6 6.3 97.5 
18.8 18.0 4.6 104.2 
14.0 14.5 5.1 96.5 
10.5 9.7 9.6 108.8 
8.0 7.8 2.2 102.0 
6.0 6.6 5.2 89.8 
4.5 4.6 3.7 97.5 
3.3 3.2 6.0 103.3 
2.5 2.5 9.9 99.9 
1.8 1.9 16.6 93.7 
1.4 1.2 33.7 115.7 
1.0 0.9 26.6 102.9 
0.8 0.7 50.6 106.1 
0.6 0.8 64.0 88.2 
 
The sandwich assay can detect low levels of fPSA (1.8 ng/mL) with acceptable % CV 
(16.6%) and % accuracy (93.7%) values. However, at the lower fPSA concentrations 
(1.4, 1.0, 0.8 and 0.6 ng/mL) the % CVs are outside the suggested 20% limit and the 
assay is unreliable at these concentrations. The range of assay sensitivity is between 25 
and 1.8 ng/mL fPSA. 
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Table 5.2: Intra-day studies using nine fPSA concentrations and determination of the coefficient 
of variation. 
Concentration 
fPSA (ng/mL) 
Back-calculated 
concentrations 
(ng/mL) 
% CV’s % Accuracies  
10.5 10.5 2.9 100.4 
8.0 7.9 2.6 99.6 
6.0 5.9 10.6 100.3 
4.5 4.5 4.7 98.5 
3.3 3.2 5.4 103.9 
2.5 2.6 4.5 98.0 
1.8 1.9 13.6 95.8 
1.4 1.5 6.5 94.4 
1.0 0.7 9.5 138.0 
 
The intra-day study suggested that the assay could detect 1.4 ng/mL as the values were 
well inside the acceptable limits. At 1.0 ng/mL the percentage accuracy of 138.02 
showed that the assay was unreliable at this concentration. The inter-day and intra-day 
studies show the proposed assay had good precision with CV‘s ranging from 16.61% to 
2.22% between 1.8 ng/mL and 25 ng/mL fPSA and 13.55% to 2.56% between 1 ng/mL 
and 10.5 ng/mL fPSA, respectively. The percentage accuracies determined in both assay 
formats provide an accurate assessment of the measured fPSA concentrations. Both 
assays had acceptable concentration values back-calculated from the curves. 
 
5.4.4 Determining the limit of detection (LOD) of the sandwich ELISA assay 
 
The LOD for any assay can be regarded as the lowest concentration which can be 
reliably differentiated with 95% confidence from the limit of the blank (LOB) (Section 
2.24). The LOB was determine using equation 2.3.2 and a precision assay performed 
with 20 positive and negative samples using the sandwich ELISA assay approach to 
investigate the accuracy of the test and to verify the LOD (Figure 5.3). 
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Figure 5.3: Twenty replicates of 2.5 ng/mL (blue diamonds) and 1.8 ng/mL (red square) fPSA 
were analysed with 20 blank samples to determine the lowest concentration of analyte that can 
be detected with 95 % confidence. The cut-off (LOB) was determined by getting the mean and 
adding 1.645 standard deviation of the 20 negative samples (red dotted line). The value 1.645 
is related to Gaussian curve where 90 % of the distribution falls between -1.645 and 1.645.  
 
The limit of detection determined using the precision assay (Figure 5.3) was 1.8 ng/mL 
fPSA with 95% confidence using 20 blanks and 20 sample replicates. After successfully 
determining the limit of detection of the sandwich assay spiked female serum samples 
were analysed. The serum was spiked with fPSA and a sandwich ELISA performed to 
investigate assay sensitivity (Figure 5.4). 
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5.4.5 Spiked female serum samples 
 
An inter-day study using serum samples spiked with different concentrations of fPSA 
was performed to evaluate assay sensitivity (Figure 5.4) over a 3 day period (Section 
2.25). 
 
 
Figure 5.4: An inter-day calibration curve using female spiked serum using a 4-parameter 
equation fit. The decrease in assay sensitivity is due to serum matrix which interferes with assay 
sensitivity. Female serum was spiked with fPSA and analysed using a sandwich assay approach 
with the biotinylated murine anti-fPSA scAb as the capture antibody and the avian anti-fPSA 
scFv as the detection antibody.  
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Table 5.3: Inter-day studies using female serum spiked with different fPSA concentrations and 
determination of the coefficient of variation. 
Concentration 
fPSA (ng/mL) 
Back-calculated 
concentration 
(ng/mL) 
% CV’s % Accuracies  
25.0 25.3 8.5 99.0 
18.8 18.5 12.1 101.4 
14 13.5 4.2 103.6 
10.5 11.2 13.5 94.0 
7.9 7.7 11.4 103.0 
5.9 6.4 0.8 91.9 
4.5 3.8 4.5 115.8 
3.3 3.5 5.6 94.0 
2.5 2.9 10.9 87.1 
1.8 1.4 146.7 131.4 
1.4 1.0 284.8 138.7 
1.0 1.0 232.7 105.3 
0.8 0.9 290.2 89.4 
0.6 1.0 143.3 61.9 
 
The female serum spiked samples (Table 5.3) had range of CV‘s (0.80% to 12.08%) 
between 2.5 ng/mL and 25 ng/mL fPSA while the lower concentrations had values well 
outside the acceptable limit. The calculated % accuracies were 87.08% and 115.80% 
between 2.5 ng/mL and 25 ng/mL fPSA. Therefore, the LOD for the sandwich assay in 
spiked female serum samples is 2.5 ng/mL fPSA. At the lower fPSA concentrations 
(1.8, 1.4, 1.0, 0.79 and 0.59 ng/mL), the assay is very unreliable and does not display 
any accurate values. The next stage of assay validation involved determining levels of 
fPSA in clinical patient serum samples presenting with PCa symptoms. 
 
5.4.6 Real patient serum sample analysis by sandwich ELISA 
 
Serum samples from patients presenting with PCa were kindly donated by Professor 
William Watson, Conway Institute, UCD, Belfield, Dublin. These samples were stored 
184 
 
at -80
o
C and analysed using the sandwich assay format using the biotinylated murine 
anti-fPSA scAb as the capture antibody and the avian anti-fPSA scFv as the detection 
antibody. The serum samples were added in duplicate and absorbances recorded. The 
unknown fPSA concentrations were back-calculated from the curve and correlated to 
the known tPSA values obtained from each sample analysed (Table 5.4). 
 
Table 5.4: Serum samples analysed by sandwich ELISA. Five patients presenting with PCa 
were tested to determine the levels of fPSA in each sample and to correlate the levels of fPSA to 
the tPSA serum levels analysed using the commercially available Abbott Diagnostic AxSYM test 
at Beaumont Hospital. 
Sample ID Serum analysis Calculated fPSA 
concentration 
(ng/mL) 
tPSA 
concentration 
(ng/mL) 
MMH/05/0121 Yes 1.8 6.0 
MMH/04/0068 Yes 1.9 6.2 
MMH/04/0086 Yes 1.8 6.1 
MMH/05/0104 Yes 2.2 6.4 
MMH/05/0111 Yes 2.5 7.0 
 
The levels of tPSA in the patient serum samples were previously tested in Beaumont 
Hospital using the Abbott Diagnostic AxSYM tPSA test. The fPSA levels were 
analysed using the sandwich assay approach and the unknown concentrations evaluated 
from the calibration curve. The levels of fPSA in the sample contribute to 
approximately 25% of tPSA as detected by ELISA. 
 
5.4.7 Immunohistochemistry study using purified murine anti-fPSA scAb and avian anti-
fPSA scFv antibodies on prostate tissue samples 
 
This study was performed on normal and cancerous prostate tissue samples and 
involved detecting fPSA localised within the tissue microarrays (TMAs). The purified 
recombinant antibodies were sent to Beaumont Hospital and the assay performed by 
Gillian O‘Hurley on TMAs using a Bond Max Automated Machine with a standard 
diagnostic commercially available antibody as an internal positive control. Both normal 
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(BPH) and tumour (PCa) prostate tissue cells were investigated using the murine and 
avian recombinant antibodies and the staining intensity evaluated. Since normal 
epithelial cells express PSA it was not a surprise to observe a higher staining intensity 
than tumour cells as PSA is released in the bloodstream when the architecture of the 
gland is disrupted and normal function is altered. The cells were visualised under high 
magnification and overall both recombinant antibody fragments bound the PSA in 
prostate cells albeit with less intensity compared to the positive control polyclonal 
antibody (Section 2.27 Figures 5.5, 5.6 and 5.7). The polyclonal antibody is a mixture 
of antibodies that recognise many epitopes of the PSA molecule whereas the 
recombinant antibody fragments are monospecific and bind to a single epitope. 
Therefore, this would corroborate the stronger staining intensity observed. 
 
 
Figure 5.5: Normal prostate tissue cells were analysed with the purified avian anti-fPSA scFv 
using a positive control. The tissue sections were incubated with HRP-labelled secondary 
antibodies using DAB chromagen as substrate. The staining intensity was greater using the 
positive control antibody. However, no surrounding background stromal tissue binding was 
observed with the avian anti-fPSA scFv. 
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Figure 5.6: The tumour cells have a smaller lumen than normal prostate cells and are clustered 
together with little differentiation. The tissue section was screened  using the purified avian 
anti-fPSA scFv and incubated with HRP-labelled secondary antibodies using DAB chromagen 
as substrate. The staining pattern is similar to the positive control (polyclonal antibody) but 
with less intensity. 
 
 
Figure 5.7: The purified murine anti-fPSA scAb demonstrated excellent staining identifying 
both epithelium and secretary PSA levels in the prostate gland but is not as intensity as the 
positive control test antibody (polyclonal antibody). This could be attributed to the fact that the 
polyclonal antibody was raised against tPSA while the recombinant antibody fragments were 
against fPSA. The lumen and epithelium of the prostate gland are clearly defined and 
recognisable when stained. 
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Figure 5.8: BPH glands (non-cancerous growth of prostate) were analysed using the murine 
and avian anti-fPSA recombinant antibody fragments. PSA is expressed within the gland, 
however, no staining was observed. The primary antibody (murine scAb or avian scFv) was not 
incubated on the tissue sections and the secondary-labelled antibody did not bind non-
specifically to the tissue sample. The slight blue staining of the nuclei is due to the destaining 
solution (Haematoxylin) which causes the cells to stain brown when positive. 
 
Both primary and secondary antibodies are required for staining of the tissue samples. 
Figure 5.8 demonstrates no staining due to the fact that the primary antibody (murine or 
avian recombinant antibody) is omitted from the experiment. 
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5.5 Discussion  
 
The aim of this chapter was to assess the potential of employing SPR biosensor, ELISA-
based and immunohistochemical assays for the detection of fPSA. The purified 
recombinant antibody fragments described in Chapter 4 were involved in immunoassay 
development and patient sample analysis. 
 
Initial studies using a Biacore-based inhibition assay showed a working range of 31.1-
6.3 ng/mL. This result was mirrored by an ELISA-based inhibition assay with poor 
reliability at low fPSA concentrations. This was a major concern as the FDA approved 
range of detection for PSA is 2-4 ng/mL. Therefore, the detection levels of fPSA were 
not acceptable using the inhibition-based immunoassays. Huang et al. (2005) developed 
a novel commercial PSA SPR biosensor immunoassay with detection limits of 10 
ng/mL using camel antibodies. The assay involved covalently attaching the recombinant 
antibody onto a gold surface and injecting PSA over the surface. They noticed that the 
limit of detection could be further improved to sub ng/mL range by constructing a 
sandwich assay involving a biotinylated antibody. Saerens et al. (2005) reported a 
Biacore sandwich PSA assay involving capturing camel single-domain antibodies and 
detecting clinical levels of different PSA in 15 minutes. Acevedo et al. (2002) 
demonstrated a sandwich ELISA-based immunoassay with a limit of detection of 0.1 
ng/mL using mouse monoclonal antibodies. Their ELISA-based sandwich immunoassay 
incorporated highly sensitive mAbs with a detection range of 25–0.12 ng/mL which was 
comparable to commercially available immunoassays. This assay format was different 
to the inhibition-based immunoassays. Therefore, a sandwich assay approach was 
investigated. 
 
The underlying achievement was the development of a sandwich assay format with high 
levels of sensitivity. Sandwich-based immunoassays were investigated, however, no 
improvement in assay sensitivity was observed over the inhibition-based assays using a 
Biacore assay format. It involved capturing fPSA using a biotinylated scAb and 
detecting bound fPSA with the purified avian scFv. The fPSA capture levels by the 
biotinylated scAb especially at the lower fPSA concentrations were statistically 
unreliable for accurate data analysis on the Biacore. A sandwich ELISA-based assay 
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demonstrated acceptable levels of sensitivity. Inter-day and intra-day studies confirmed 
a reliable working assay with a limit of detect of 1.8 ng/mL (Figure 5.2). A precision 
assay confirmed the detection limit with 95% confidence (Figure 5.3). Butch et al. 
(2001) investigated the analytical performance of Roche total and free PSA sandwich 
assays. They reported linear ranges of 0.01–103 ng/mL and 0.02–25 ng/mL, 
respectively. The CV‘s for both assays were < 5% for intra-day studies with inter-day 
study values of < 13.6%. The sandwich inter-day study showed CV‘s between 2.2–
16.6% (Table 5.1) at a linear range of 25–1.8 ng/mL (Figure 5.2). The intra-day study 
reported CV‘s between 2.6–13.6% (Table 5.2) at a linear range of 10.5–1.4 ng/mL. The 
developed sandwich assay showed acceptable levels of detection. Commercially 
available immunoassays (e.g. Roche) require expensive large automated machines to 
analyse samples. These assays are performed at dedicated centres throughout the world 
with trained personnel with prolonged waiting times for results (Healy et al., 2007). The 
aim was to develop an economical sensitive sandwich ELISA-based immunoassay 
which could be executed in a diagnostic environment using standard laboratory 
equipment. To the author‘s best knowledge, this is the first reported fPSA sandwich 
immunoassay using murine and avian recombinant antibody fragments. 
 
Zundel et al. (1990) reported a sandwich-based immunoassay using 2 monoclonal 
antibodies with detection levels below 2 ng/mL. In their study they confirmed no PSA 
in female serum and evaluated 79 clinical male samples with known PSA 
concentrations. Acevedo et al. (2002) also confirmed no PSA levels in the serum of 
healthy females. Therefore, spiked female samples were evaluated using the sandwich 
assay format (Figure 5.4) and a shift in sensitivity to 2.5 ng/mL was observed. Serum 
matrix interference can affect the binding ability of the antibodies and impact the limit 
of detection. After confirming low detection levels in spiked female serum samples real 
patient samples were analysed using the sandwich ELISA format. The concentrations of 
the unknown samples were calculated from the generated calibration curve (Table 5.4). 
The back-calculated fPSA concentrations were approximately 25% of the tPSA 
concentrations as reported using the Abbott Diagnostic AxSYM tPSA test in Beaumont 
Hospital. This would suggest that the assay could potentially be used for the detection 
of fPSA in clinical samples. 
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Surface-enhanced Raman scattering (SERS), ‗real-time‘ Immuno-PCR and SPR 
sandwich-based assay have shown pg/mL detection levels (Healy et al., 2007). The 
format severely influences the performance of the assay and sensitivity can be improved 
considerably. Assays such as ‗real-time‘ immuno PCR require careful sample 
preparation to prevent sample contamination, dedicated equipment and data 
interpretation. Sensitivity is limited by background signal due to non-specific adsorption 
of assay reagents to the walls of the tube (Lind et al., 2005). There are a number of 
commercial tests available that use monoclonal antibodies for the detection of fPSA in 
serum. Abbott Diagnostics have 2 commercial assays available (Architect and 
AxSYM), with detection limits of 0.3 ng/mL and 0.1 ng/mL, respectively. Diagnostic 
Products Corporation have the Immulite assay with detection limits of 0.25 ng/mL. 
Roche supply the Elecsys assay with a detection limit of 0.5 ng/mL and Beckman 
Coulter assay has limits of 0.2 ng/mL. These commercially available immunoassays 
require large expensive equipment at dedicated centres. 
 
Many other novel PSA assay formats have been reported in the literature. (Grubisha et 
al., 2003; Soukka et al., 2001; Fernandez-Sanchez et al., 2005; Escamilla-Gomez et al., 
2009). Grubisha et al. (2003) reported sensitivity levels as low as 1 pg/mL using a 
sandwich assay on gold nanoparticles coated with a Raman scatterer. Soukka et al. 
(2001) reported sensitivity levels in the 0.04 pg/mL range using fluorescently-labelled 
nanoparticles. These assays are ultrasensitive and could be employed in detecting levels 
of PSA after radical prostatectomy but would not be suitable for early detection of PCa. 
Fernandez-Sanchez et al. (2005) reported sensitivities in the region of 1 ng/mL fPSA 
using a disposable one-step lateral flow assay but these immunoassays can have 
significant drawbacks such as sensitivity. Escamilla-Gomez et al. (2009) described a 
method for the detection of fPSA and tPSA using a voltammetric electrochemical 
sensor using screen-printed electrodes. The reported sandwich assay format had a range 
of detection between 1–10 ng/mL and required a level of expertise in electrochemical 
immunoassay development. A major disadvantage when designing electrochemical 
immunoassays is the diffusion of the electroactive indicator where the electrodes are in 
close proximity resulting in negative results (Escamilla-Gomez et al., 2009). These 
reported assays have better sensitivity levels than the sandwich ELISA-based 
immunoassay described here, however, there are certain disadvantages associated with 
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using these assays, as previously mentioned. Assay sensitivity could be improved by 
performing mutagenesis on the selected antibody fragments (murine and avian). This 
would involve site-directed or random mutagenesis improving the affinities and the 
assay performance of the antibodies. Assay sensitivity could be further improved by 
incorporating the recombinant antibody fragments into an immuno-PCR (Lind et al., 
2005) using a capture antibody with a DNA label for product amplification or 
nanoparticle-based immunoassays using a bio-barcode assay for ultrasensitive levels of 
detection (Thaxton et al., 2009). These would be suitable immunoassays for detecting 
very low levels of PSA after radical prostatectomy where commercial immunoassays 
fail to detect PSA levels. 
 
The murine and avian recombinant antibody fragments were analysed on both normal 
and tumour prostate cancer cells. BPH is a non-cancerous growth of the prostate gland. 
As men get older the prostate grows as a result of proliferation of epithelial cells within 
the basal cell layer. BPH is characterized histologically by the presence of discrete 
nodules in the periurethral zone of the prostate gland (Edwards, 2008). The 
immunohistochemical study showed that both murine and avian recombinant antibody 
fragments can be utilised in TMAs for detection of the secreted PSA protein within the 
tissue sample. Both antibody fragments bound with less intensity than a polyclonal 
positive control but this may be due to the fact that the polyclonal antibody binds many 
epitopes on the PSA molecule while the recombinant antibodies have one specific 
epitope for binding. This would confirm and support the TMAs results. Varma and co-
workers (2002) analysed PCa tissue sections using immunohistochemistry staining and 
noticed that polyclonal anti-PSA antibodies were more sensitive than monoclonal 
antibodies.  
 
It would also be possible to use a cocktail of recombinant antibodies to different 
discrete epitopes on PSA. Expression of recombinant antibody fragments in bacterial 
cells offer an unlimited supply of protein at low costs. These are seen as advantageous 
characteristics and could substitute polyclonal/monoclonal antibodies for analysing PCa 
tissue samples. 
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Overall Conclusions 
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6.1 Overall conclusions 
 
The aim of the work presented in this thesis was the development of immunoassays for 
the detection of PCa. The strategy used involved the generation and characterisation of 
recombinant antibody fragments (scFv, scAb and Fab) to fPSA. Individual fragments 
were selected by phage display and characterised by ELISA, SDS-PAGE and Western 
blotting. Biacore and ELISA-based immunoassays were developed after significant 
optimisation for the detection of fPSA. 
 
Chapter 3 describes the methodologies used for the generation of recombinant antibody 
fragment libraries. Three antibody libraries were constructed using systems described 
by Krebber et al. (1997) and Barbas et al. (2001) from the spleens of immunised mice 
and chickens, respectively. Two scFv libraries and one Fab library were constructed and 
individual antibody fragments selected by panning. After polyclonal and monoclonal 
phage ELISAs confirmed positively-binding antibody fragments individual colonies 
were screened by ELISA to determine expression levels of selected antibody fragments. 
Comparative analysis between a murine scAb and its scFv counterpart showed 
significant differences in expression levels between antibody formats. Avian 
recombinant antibody fragments (scFvs and Fabs) were expressed and individual 
colonies screened for protein expression by ELISA. The diversity of the original avian 
Fab library was clearly observed (Figure 3.21) and colonies selected from round three of 
the selection panning process showed that two out of the five analysed antibody 
fragments had similar DNA patterns suggesting they could be the same antibody 
fragment. 
 
After identification of positive antibody fragments binding to fPSA the next stage 
involved additional screening and characterisation of the generated antibody fragments. 
A Biacore capture assay was employed to rank 94 expressed scAbs on the basis of their 
percentage stability after 5 min dissociation. Eleven antibody fragments with high 
percentage stability (above 68%) were selected and subjected to further analysis. The 
affinities were calculated using BIAevaluation software and the values were extremely 
similar. The most suitable antibody for immunoassay development was selected on a 
basis of its competitiveness in an inhibition ELISA. The selected antibody fragment 
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(scAb B5) was expressed in large-scale, purified using IMAC resin and the purity 
verified by SDS-PAGE and Western blotting. The avian antibody fragments were 
evaluated using the same capture assay approach on the Biacore A100 which allows for 
rapid data analysis and interpretation.  
 
Chapter 5 describes the generation of Biacore and ELISA-based immunoassays using 
the recombinant antibody fragments selected from Chapter 4. The murine anti-fPSA 
scAb was used to develop a subtractive inhibition Biacore assay. The fPSA antigen was 
immobilised on the surface of a CM5 sensor chip and the scAb concentration optimised 
for assay development using an appropriate flow rate. Decreasing concentrations of 
fPSA were incubated with anti-fPSA scAb and passed over the sensor surface. A 
decrease in binding was observed with increasing fPSA concentration. Regeneration 
studies proved the sensor surface to be stable for over 40 binding cycles with the assay 
format demonstrating reproducible and accurate inter-day coefficients of variation 
values of less than 20%. Overall, the assay showed good sensitivity and the sensor chip 
surface was very stable.  
 
A solid phase inhibition-based ELISA assay was also developed with similar sensitivity 
to the Biacore-based assay. The sensitivity was investigated using a sandwich assay 
approach to determine whether or not it could be improved. The purified scAb was 
biotinylated with the biotin covalently attached to the primary lysine residues of the 
antibody. This was captured on the chip using a neutravidin-coated surface and different 
concentrations of fPSA captured. The avian anti-fPSA recombinant antibody fragments 
(scFv/Fab) were injected over the captured fPSA and binding levels recorded. Suitable 
antibody pairs were selected for immunoassay development. A Biacore sandwich assay 
proved unsuccessful with no binding observed at low fPSA concentrations (15 ng/mL). 
The ELISA-based immunoassay showed a significant improvement in the limit of 
detection (1.8 ng/mL). Spiked female serum samples were analysed to investigate any 
change in sensitivity using a serum matrix. A slight shift is sensitivity was observed (2.5 
ng/mL) but this was expected as the performance of the antibody fragment may be 
altered in a complex serum matrix. Samples from individuals presenting with PCa were 
analysed by sandwich ELISA and the unknown concentrations determined using a 
calibration curve and compared to the values obtained in Beaumont Hospital. The levels 
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of fPSA in each of the samples were in line with reported levels of fPSA. This would 
suggest that the generated sandwich immunoassay could potentially be used to detect 
fPSA levels in serum. Improvements in assay sensitivity could be achieved using 
mutagenesis or employing a novel assay platform as described in Section 5.5. The 
immunohistochemistry studies proved that the generated recombinant antibody 
fragments (murine scAb and avian scFv) recognised secreted PSA in PCa tissue 
samples. This proves that the selected recombinant antibody fragments can be 
successfully utilised in TMAs and demonstrates clearly the possibility of using 
recombinant antibody fragments to detect markers of disease in tissue samples. 
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